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“People ask me often: « was the Nobel Prize the thing you were 
aiming for all your life? ». And I say that would be crazy.  
Nobody would aim for a Nobel Prize because, if you didn’t get it, 
your whole life would be wasted.  
What we were aiming at was getting people well, and the 
satisfaction of that is much greater than any prize you can get.” 
 
Gertrude Belle Elion 
Nobel laureate in  








Cover picture: Looking Forward, by Dhruba Deb 
“In Looking Forward, Dhruba Deb depicts two cancer cells that 
sustain themselves by communicating with healthy cells and 
receiving nourishment via expanding networks of blood vessels—
all while trying to escape detection by roving immune cells.”   
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1.1 Inflammation and cancer 
The earliest mention of a link between cancer and inflammation was found in 
the Ebers Papyrus (c. 1500 BC). The ancient Egyptian physician Imhotep (c. 
2600 BC) reported regression of tumors after infections induced by an incision 
in the tumor site1,2,3. Similar observations were noticed along the first 
millennium, albeit remained isolated and not investigated until the late 19th 
century. Two German physicians, Busch and Fehleisen, were the firsts to 
intentionally infect cancer patients with the erysipelas causative agent (S. 
pyogenes) and observe a tumor regression4,5. In 1891, the American physician 
William Coley accidentally experienced in a sarcoma patient the shrinkage of 
tumor mass partially excised by surgery. The extensive wound could not be 
successfully closed and became severely infected with erysipelas followed by 
a high fever and the complete disappearance of tumor6. From this evidence, 
Coley developed a series of experiments treating cancer patients with live or 
heat-inactivated Streptococcus pyogenes and Serratia marcescens bacteria – 
the so called Coley’s toxin or vaccine – with pioneering results for that era7. 
In the meanwhile, alongside the first evidences of interaction and balance 
between cancer and inflammation in infective status, in 1863 the brilliant 
German pathologist Rudolf Virchow noted the presence of the so-called 
“lymphoreticular” cells infiltrate into malignant tissue8,9. Despite these 
discoveries, the elucidation of mechanism of immune control of neoplastic 
disease was neglected for decades. An important turning point arrived in the 
mid-1900s, when Macfarlane Burnet and Lewis Thomas elaborated the 
hypothesis of ‘cancer immunosurveillance’ according to which lymphocytes 
supervise homeostatic tissues identifying and eliminating nascent somatic 
cells transformed by spontaneous mutations10.  
In 1980s and 1990s a series of fundamental immunological discoveries (Table 
1) provided the basis of the modern cancer immunology and immunotherapy. 
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Basically, inflammation consists of genetic programs acted by immune cells 
in response to harmful stimuli such as infections and tissue injury. The acute 
inflammatory response to infection or tissue injury requires a well-
orchestrated delivery of blood components (leukocytes and their products) to 
the site of infection or injury11. 
 
Table 1. Timeline of some of the key events in cancer-related  
immunology starting from 1980s 
Year Event Researcher Ref.
1982 Cytotoxic T-Lymphocytes (CTLs) recognized new antigens of immunogenic cancerous cells Boon T
12
1982 Identification of Interleukin-4 Paul W Howard M
13
1983 Interferon gamma (IFNg) activates macrophages Schreiber RD Katz DH
14
1983 Identification of T cell antigen Receptor (TCR) Kappler J Allison JP
15
1985
Cloning of Transforming growth factor-beta 
(TGFb) Derynck R
16
1985 MHC role in the antigen processing and presentation Unanue E
17
1985 Effective treatment with IL-2 and LAK of melanoma and renal cancer patients Rosenberg SA
18
1986
Anti-CD3 monoclonal antibody (muromonab-





1987 Identification of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) Golstein P
20
1989 Role of CD28 as co-stimulator of T cell activation June CThompson CB
21
1990 Low and chronic levels of Tumor Necrosis Factor (TNF) as pro-tumoral agent Balkwill F
22
1990 Highlights on pro-tumoral activity of Tumor-associated macrophages (TAM)
Mantovani A 23
1992
Identification of Programmed cell death protein 1 








1996 NF-kB pathway as regulator of macrophage inflammatory activity Gerondakis S
26
1996 Enhancement of Antitumor Immunity by CTLA-4 Blockade Allison JP
27
1998 PD-1 as negative regulator of immune response Honjo T 28
2003 Tumor regressions in patients treated with the CTLA-4-inhibiting antibody Dranoff G
29





PD-1-specific monoclonal antibody treatment 














This response has been characterized best for microbial infections 
(particularly bacteria), in which innate immune cells –including macrophages, 
mast cells, and dendritic and natural killer cells– interact and recognize the 
invading agent through specialized receptors, such as Toll-like receptors 
(TLRs) and NOD-like receptors (NLRs), and thus leading to the release of 
chemical inflammatory mediators, including chemokines, cytokines, and 
reactive oxygen species (ROS)35. The main and most immediate effect of these 
mediators is to allow recruitment of leukocytes to the area of injury or 
infection and lead to the elimination of pathogens and/or tissue repair, mainly 
mediated by neutrophils, tissue-resident and recruited macrophages, with 
dendritic and natural killer cells initiating the adaptive immune response and 
T cell recruitment. If the acute inflammatory response fails to eliminate the 
pathogen, a chronic inflammatory state persists and produces the formation of 
granulomas and tertiary lymphoid tissues.11  
The characteristics of this inflammatory state can differ depending on the 
effector class of the T cells that are present. In addition to persistent pathogens, 
chronic inflammation can result from other causes of tissue damage such as 
autoimmune responses (owing to the persistence of self-antigens) or 
undegradable foreign bodies11. 
The mechanisms of systemic chronic inflammatory process are not clearly 
understood, and the fact that these cells and mediators are present in the 
microenvironment of most tumors consistently corroborates the link between 
cancer and inflammation. 
This relationship has a ‘two-way’ connection. Chronic inflammation can 
represent the triggering event or at least a co-factor causing neoplastic 
transformation of cells36,37. Mantovani A. defined this process as the 
‘extrinsic’ pathway of the cancer-related inflammation37. Indeed, about 15-
20% of cancer deaths are attributable to infections (both viruses and bacteria) 
and to the related chronic inflammation9,38.  Examples of this process are 
human papillomaviruses, hepatitis C virus (HCV) and Helicobacter pylori, 
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which are important risk factors for cervical cancer, hepatocellular carcinoma 
(HCC) and gastric cancer, respectively. Moreover, increased risk of 
malignancy is associated with other sources of chronic inflammation such as 
biochemical agents (i.e. smoke, asbestos) or autoimmune disease (i.e. 
inflammatory bowel disease, IBD)36,38,39. Generally, it is thought that chronic 
inflammation results in DNA damage which increases the risk of malignant 
transformation40,41. 
 
Contrarily, the ‘intrinsic’ pathway of cancer-related inflammation is guided 
by genetic events, such as activation of oncogenes by mutation (e.g. myc, ras, 
ret), chromosomal rearrangement or amplification, and inactivation of tumor-
suppressor genes (e.g. pVHL), that trigger both carcinogenesis and 
inflammatory programs. 37,42–44 
Mechanistically, both ‘extrinsic’ and ‘intrinsic’ pathways converge, resulting 
in the activation of transcription factors, among which nuclear factor-κB (NF-
κB), signal transducer and activator of transcription 3 (STAT3) and hypoxia-
inducible factor 1α (HIF1α) play a central role in neoplastic cells. The 
activation of these molecular pathways in cancerous cells induces the 
production of inflammatory mediators, including cytokines, chemokines as 
well as the production of cyclooxygenase 2 (COX-2) (which, in turn, results 
in the production of prostaglandins). This inflammatory milieu promotes the 
recruitment and infiltration into the tumor microenvironment (TME) of 
leukocytes, most notably cells of myelomonocytic lineage. In some cancers, 
inflammatory conditions precede development of malignancy; in others, 
oncogenic changes generate a tumor-promoting “smouldering” inflammation, 
which aids proliferation and survival of malignant cells, angiogenesis, and 




Generally, this cancer-promoting inflammation precedes a process named 
immunoediting and proposed to consist of three phases (the three ‘Es’ of 
immunoediting’)46. In the early phase, the immune surveillance is able to 
continuously recognize and destroy nascent tumor cells (elimination phase); 
due to the intrinsic genetic, epigenetic and metabolic instability of neoplastic 
cells, the arising of new cell clone variants with a non-immunogenic 
phenotype are selected for growth, concurrently, the host immune system 
exerts a selective pressure on the genetically unstable and rapidly mutating 
tumor cells, that is enough to contain, but not fully extinguish, the tumor bed 
(equilibrium phase). At this point, tumor cell variants selected in the 
equilibrium phase have acquired resistance to immune detection and/or 
elimination, and thus can grow in an immunosuppressed environment (escape 
phase)10,46. Generally, during this phase, tumors expand and become clinically 
detectable, increase the immunological request, and boost the inflammatory 
shaping involving both innate and adaptive immune cells (Fig. 1).  
Several studies have emphasized that the “smouldering” inflammation 
associated with tumors is mainly oriented to tune the adaptive immune 
response. Thus, functional modulations of tumor-infiltrating lymphocytes 
have key roles in promoting tumor immune escape. Cancers also produce 
alterations of the myelopoietic output (‘emergency’ myelopoiesis) leading to 




Figure 1. Innate and Adaptative immunity to cancer. Overview of key innate and adaptive 
immune cells that are present in the tumor microenvironment. Both myeloid and lymphoid 
cells can function as a double-edge sword by promoting or inhibiting tumor progression. 
Abbreviations: PMN-, polymorphonuclear; M-, monocytic; MDSC, myeloid-derived 
suppressor cells; Th1, CD4 T helper 1; Th2, CD4 T helper 2; T-reg, CD4 T regulatory 
cells.51(adapted) 
 
Hence, the immune system plays a dual role in cancer: a) to suppress tumor 
progression by destroying cancer cells; b) to induce a disarmament of its 
anticancer capability, driven by the growing tumor. The driving mechanisms 
of this transition are not yet fully understood. In the last decade, cancer-related 
inflammation and immune-editing have attracted a lot of interest in cancer 
research, acquiring relevance in clinical practice. In 2011, Hanahan and 
Weinberg revised their “hallmarks of cancer” and have included the concept 
of ‘immune escape’ and ‘tumor-promoting inflammation’ as new cancer 




























Figure 2. Hallmarks of Cancer: The Next Generation. In 2000, in the first characterization 
of the cancer hallmarks, Hanahan and Weinberg highlighted six biological features, 
constituting an organizing principle for rationalizing the complexities of neoplastic disease. 
They included: sustained proliferative signalling, evading growth suppressors, resisting cell 
death, enabling replicative immortality, inducing angiogenesis, and activating invasion and 
metastasis. Conceptual progress in the last decade has added new emerging hallmarks and 
characteristics to this list: the capability to modify, or reprogram, cellular metabolism in order 
to most effectively support neoplastic proliferation; the ability of cancer cells to evade 
immunological destruction, in particular by T and B lymphocytes, macrophages, and natural 
killer cells; ‘smouldering’ inflammation supporting multiple cancer hallmark capabilities; 
genomic instability and thus mutability endowing cancer cells with genetic alterations that 














1.2    Tumor-associated Myeloid Cells 
 
In mammals, myeloid cells represent the most abundant hematopoietic cells 
in the human body and the first line of host defence against pathogens. These 
cells also play an essential role in tissue homeostasis and immune responses.54 
At the top of the hematopoietic hierarchy there are the hematopoietic stem 
cells (HSCs) which are quiescent cells with multipotent and extensive self-
renewal potential, and reside in the bone-marrow (BM) niche. HSC 
differentiation into multipotent progenitor (MPP) cells is the initial step in a 
cascade of events resulting in terminal differentiation of mature hematopoietic 
cells, including cells of innate immunity, although tissue-resident 
macrophages may also derive from embryonic progenitors. MPPs 
subsequently give rise to progenitor cells with myeloid lineage commitment 
(common myeloid progenitors; CMPs) or lymphoid lineage commitment 
(common lymphoid progenitors; CLPs). Further steps of differentiation lead 
CMPs toward more restricted progenitors, e.g., granulocyte-macrophage 
progenitors (GMPs), erythrocyte-megakaryocyte progenitors, and monocyte-
dendritic cell progenitors (Fig. 3). However, the commitments of myeloid 
progenitors do not form a hierarchical system, but can instead be considered 
as a network of cells that can differentiate into various more specialized 
myeloid cell subsets55,56. 
Generally, steady-state myelopoiesis is a continuous homeostatic process, 
occurring in the bone marrow, for replacing hematopoietic cells that are lost 
to normal programmed cell death. In contrast, in the presence of 
immunological stress, such as severe systemic infection or cancer disease, 
hematopoiesis sustains modifications of the magnitude and composition of the 
hematopoietic output to ensure proper supply of immune cells to increased 




In the course of tumor development, cancerous cells are able to produce 
factors (tumor-derived factors, TDFs), which acts in a paracrine or systemic 
fashion to 'reprogram' non-cancerous host cells exacerbating rather than 
ameliorating disease progression.  Many of these TDFs are myelopoietic 
stimulating factors, making the myeloid compartment a major target of this 
‘tumor reconditioning’ not only to create a widespread tolerogenic 
environment by blocking T cell functions and proliferation, but also to drive 
tumor growth by promoting cancer stemness, angiogenesis, stroma deposition 
and metastasis formation54,55. 
Moreover, the continuous exposure to uncontrolled myelopoietic-like growth 
factors corrupts the normal process of myeloid cell development and 
differentiation. This phenomenon drives the increase of circulating myeloid 
cells, which are partially restrained in their differentiation, with a consequent 
accumulation of highly immunosuppressive, immature myeloid cells 
(iMCs)55. 
 
Fig. 3. Myeloid cells in cancer. Soluble mediators produced in the tumor microenvironment 
promote the aberrant differentiation of myeloid lineage cells. Dashed lines indicate the normal 
developmental pathway of immature myeloid precursor cells, which differentiate into DCs, 
monocytes-macrophages and granulocytes (basophils, eosinophils and neutrophils) in non-tumor-
bearing hosts. Solid lines indicate the aberrant pathways of myeloid cell development.61 
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Indeed, different tumor-derived factors including VEGF, GM-CSF, IL-10, IL-
6, TGFb, prostaglandins and gangliosides have been implicated in this 
phenomenon and can affect myeloid cells at various stages of 
differentiation62,63. 
Myeloid alterations can occur at different level of development and 
functionality in all myeloid lineages. Generally, to distinguish the ‘normal’ 
myeloid cells, the dysfunctional population counterparts have been variously 
renamed myeloid-derived suppressor cells (MDSCs), tumor-associated 
macrophages (TAMs), tumor-associated neutrophils (TANs), immature DCs 
or tolerogenic DCs. Among these, TAMs and MDSCs represent the major 




















1.3    Myeloid-derived suppressor cells 
 
The term “myeloid-derived suppressor cells” (MDSCs) was coined in 2007 to 
describe a non-lymphoid immune suppressor cell population of myeloid origin 
which expand in pathological conditions, such as infection, autoimmune 
diseases, trauma, and graft-versus-host disease. Cancer is the predominant 
condition where MDSCs have been described.64–67. 
MDSCs constitute a population of myeloid cells with heterogeneous 
morphology, surface phenotype, functions, and immune-suppressive 
properties. They generate in the bone marrow (BM) from common myeloid 
progenitor cells and accumulate during cancer progression. MDSCs migrate 
to peripheral lymphoid organs and tumor tissues, where they inhibit T-cell 
responses, contributing to the formation of a pro-tumor microenvironment68. 
In addition, MDSCs are able to promote cancer development inducing tumor 
angiogenesis and matrix remodelling. Indeed, MDSCs have been implicated 
in the formation of pre-metastatic niches, tumor cell migration and invasion, 
tumor angiogenesis and growth and survival of metastatic tumor69,70. 
 
1.3.1   Phenotypical features of MDSCs 
MDSCs consist of a heterogeneous population conventionally divided into 
two major subsets based on their phenotypic and morphological features: 
polymorphonuclear (PMN)-MDSC, with some phenotypic feature similar to 
neutrophils, and monocytic (M)-MDSC, more similar to monocytes71. In 
mice, MDSCs historically were defined as cells expressing both CD11b and 
Gr-1 markers, the latter used to distinguish the two major subsets of MDSCs 
according to its level of expression (Gr1high cells are mostly PMN-MDSCs and 
Gr1low cells are mostly M-MDSC)72. Since the Gr-1 marker is a combination 
of the Ly6C and Ly6G markers, these subsets can be now more accurately 
identified based on Ly6C and Ly6G expression: PMN-MDSC (CD11b+ 
Ly6G+ Ly6Clo) and M-MDSC (CD11b+ Ly6G- Ly6Chi)66,69. 
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MDSC subset Mouse Phenotype Human Phenotype 
PMN-MDSC CD11b+ Ly6G+ Ly6Clo CD11b+ CD14- CD15+ (CD66+) 
M-MDSC CD11b+ Ly6G- Ly6Chi CD11b+ CD14+ HLA-DR-/lo CD15-. 
eMDSC Not defined Lin- (CD3/14/15/19/56-) HLA-DR- CD33+ 
Table 2. Minimal surface markers identifying MDSC subset in mouse and human. 
 
In human, the equivalent to PMN-MDSC are defined as CD11b+ CD14- 
CD15+ or CD11b+ CD14- CD66b+, and M-MDSC as CD11b+ CD14+ HLA-
DR-/lo CD15-. Prior to CD11b, CD33 was used as myeloid marker. CD33 
myeloid marker can be used instead of CD11b since very few CD15+ cells are 
CD11b-. While M-MDSC express the myeloid marker CD33, PMN-MDSC 
display CD33dim expression73. In humans, but not yet in mice, it has been 
identified a mixed group and more immature subset of MDSCs, named ‘early-
stage MDSC’ (eMDSC) identified as Lin- (CD3-, CD14-, CD15-, CD19-, 
CD56-) HLA-DR- CD33+ (Table 2)66. 
 
1.3.2   MDSCs immunosuppressive functions in cancer 
Immune suppression by MDSCs is exerted through several direct or indirect, 
antigen-specific or -non-specific mechanisms that could be recapitulated in 
four main groups: 1) depletion of essential extracellular metabolites; 2) 
production of immunosuppressive molecules; 3) interference with T cell 
migration and viability; 4) induction of immunoregulatory cells (Fig.4)70,74,75. 
Depletion of essential extracellular metabolites  (Fig.4.1) 
- Cysteine. T cells strictly need L-cysteine to sustain their proliferation and 
activation. Unlike other cells, T cells cannot produce cysteine either by the 
intracellular conversion of methionine (lack of cystathionase enzyme) or by 
import of extracellular oxidized cysteine (lack of xc- transporter). The only 
way to collect cysteine is during the immunologic synapse occurring between 
antigen-presenting cell (APC) and T cell. During this process, APCs cells, 
through the ASC transporter, couple the import of extracellular oxidized 
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cysteine with the export of reduced cysteine, which can be taken up by T cells. 
By contrast, MDSCs lack the ASC transporter and do not export cysteine, thus 
limiting the supplying of this amino-acid required for T cell fitness.76 
- Tryptophan. MDSCs express high levels of the isoenzyme indoleamine 2,3-
dioxygenase 1 (IDO1) that catabolize the L-Tryptophan into kynurenines, the 
degradation products. These metabolites have immune-modulatory and 
tolerogenic properties: inhibit CD8 T-cell proliferation by causing cell cycle 
arrest and inducing anergy; direct CD4 T-cell differentiation toward the Treg 
phenotype by Foxp3 upregulation; reprogram DCs toward a tolerogenic 
phenotype by binding the aryl hydrocarbon receptor; and concomitantly 
depriving T cells of an essential nutrient.77 
- Arginine. Metabolic conversion of L-arginine (L-Arg) through either iNOS 
or Arg1 is the first and the main mechanism associated with the 
immunosuppressive activities of MDSCs78. iNOS generates nitric oxide (NO) 
which is able to inhibit T-cells signalling pathways responsible of their 
activation and to induce T-cell apoptosis78,79. Arg1 activity, converting L-
arginine to urea, L-ornithine and polyamines, causes the depletion of this 
amino-acid, which induces the translational blockade of the ζ chain of CD3, 
preventing T cells from responding to various stimuli80. Moreover, ornithine 
and polyamines can support directly tumor cell proliferation81.  
- NAD. CD38 is an ectoenzyme belonging to the ADP-ribosyl cyclase family 
and, consuming extracellular nicotinamide adenine dinucleotide (NAD), leads 
to mitochondrial dysfunction of surrounding cells, as observed in metabolic 
diseases and cancer82. CD38 was found up-regulated in MDSCs from various 
preclinical tumor models and cancer patients83. Along with the detrimental 
effects associated with depletion of microenvironmental NAD, CD38 
generates second messengers associated with calcium signalling, resulting in 
an increased amount of NO that favours tumor growth83. NAD is the substrate 
for numerous NAD-consuming enzymes that participate in cell signalling, 
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including sirtuin 1 (SIRT1) whose lack in MDSCs fuels the glycolytic mTOR-
HIF1α pathway associated with a functional switch toward a pro-
inflammatory (NO, TNFα, IL-12) and anti-tumor phenotype84. The expression 
of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting 
enzyme in the NAD salvage pathway converting nicotinamide into 
nicotinamide mononucleotide (NMN), precursor of NAD, is elevated in 
MDSCs. Inactivation of NAMPT causing reduced NAD availability showed 
reactivation of specific antitumor activity of T cells.85 
- Fatty acids. In both tumor bearing mice and humans, tumor-derived 
cytokines induce expression of cell surface lipid transport receptors by 
MDSCs. This results in increased fatty acid uptake and oxidative metabolism 
in association with activation of MDSCs’ immunosuppressive mechanisms. 
Therefore, hampering the intracellular accumulation of lipids as well as 
pharmacological inhibition of fatty acid oxidation (FAO) blocks the 
immunosuppressive functions of MDSCs, improving the efficacy of either 















Production of Immunosuppressive Molecules   (Fig.4.2) 
- Adenosine. MDSCs express high levels of Ectonucleoside triphosphate 
diphosphohydrolase 1 (E-NTPDase1, CD39) and the ecto-5’- nucleotidase, 
which convert the extracellular ATP released by dying cells in adenosine. 
Extracellular adenosine is a powerful immunosuppressive factor that impairs 
differentiation of naïve CD8+ T cells in effector cells, inhibits cytolytic 
activity of NK and T cells, and it promotes the immunosuppressive functions 
of tumor-associated macrophages (TAM) and expansion of PMN-MDSCs.88 
- Cytokines. MDSCs also produce copious amounts of immunosuppressive 
cytokines, such as TGFβ and IL-10, which induce the generation of Treg cells, 
differentiation of pro-tumoral TAMs and direct suppressive effects on T 
effector cells. Mechanistically, it was confirmed that tumor-derived TGFβ 
triggers CD39 expression on circulating and tumor-infiltrating MDSCs via 
activation of mTOR/HIF1α-signaling.89  
- ROS. High arginase activity and NO production by MDSCs leads to 
augmented reactive oxygen species (ROS) and reactive nitrogen species 
(RNS), such as the free radical peroxynitrite (ONOO−). These radical species, 
interacting with macromolecules (DNA, lipids, proteins), disrupt their 
structure and biological processes, including immune responses. NADPH 
oxidase 2 (NOX2), the main actor in ROS production in leukocytes is induced 
by cytokines (i.e., TNFα and IFNγ) and growth factors (VEGF). NOX2-
dependent ROS production supports MDSCs expansion and recruitment in 
tumors through the up-regulation of VEGF receptors90; its lack impaired both 
generation of ROS by MDSCs and their ability to suppress CD8+ T cells91. 
Myeloperoxidase is another ROS-producing enzyme contributing to the 
suppression of antigen-specific T cell responses in tumor bearers75. Tumor-
infiltrating MDSCs produce large amounts of H2O2, which affect T-cell fitness 
by downregulating CD3 ζ-chain expression and reducing cytokine secretion, 




Fig. 4. MDSCs immunosuppressive mechanisms. (1) MDSCs deplete essential extracellular 
metabolites for T cells. Through the up-regulation of metabolic enzymes (e.g. ARG1, iNOS, IDO1, 
NAMPT, CD38) MDSCs consume L-Arg, L-Trp and NAD, and concomitantly produce 
immunomodulatory agents (NO, polyamines and kynurenines). Further, MDSCs internalize 
cysteine without releasing the oxidized form, and up-take and oxidize fatty acids (FA/FAO) 
inducing immunosuppressive activities. (2) MDSCs release a range of immunosuppressive 
molecules. They produce ROS and RNS through NOX-2, iNOS and MPO, adenosine via CD39, 
anti-inflammatory cytokines (IL-10, TGFβ) and growth factors (VEGF). TGFβ induces CD39 via 
HIF1α, promoting expression of immunosuppressive molecules (IL-10, VEGF). (3) MDSCs 
interfere with T-cell migration and viability. MDSCs express the metalloproteinase 
TACE/ADAM17, able to cut the integrin CD62L on the T-cell membrane. RNS promote homing 
of Tregs by nitration of selective chemokines (like CCL2) and limit recruitment of effector T cells 
by down-regulation of CD162 and CD44. MDSCs up-regulate PD-L1 in response to multiple 
signals, including hypoxia-HIF1α, IFNγ via STAT1/IRF1, COX2/PGE2, M-CSF and VEGF. PD-
L1 can induce T-cell apoptosis by engaging PD-1. (4) MDSCs drive specific subsets of immune-
regulatory cells. MDSCs produce CCL3, CCL4, CCL5 which drive differentiation and recruitment 
of CCR5+ Treg cells. Tregs differentiation is also induced by direct interaction between CD40 and 
CD40L and by inhibition of effector T cells-driving transcription factors (Tbet, GATA3) through 
TGFb and IL-10. The latter inhibit the IL-12 production by macrophages which in turn acquire an 
M2 immunosuppressive phenotype and induce further IL-10 production by MDSCs. For 
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Interference with T cell migration and viability   (Fig.4.3) 
T-cell activation and effector functions require trafficking to lymph nodes and 
tumor sites dependent by the expression of L-Selectin (CD62L) homing 
marker of naïve T cells. MDSCs highly express the metalloproteinase TNFα-
converting enzyme (TACE/ADAM17) which directly mediates the CD62L 
cleavage and, thus, interfering with T cell recruitment93. In addition, MDSCs 
can hamper the recruitment of circulating effector T cells into tissues by 
inhibiting the expression of CD162, a ligand of P-selectin and CD44, the 
receptor for the extracellular matrix component, hyaluronic acid (HA)94. 
MDSCs and cytotoxic T lymphocytes (CTLs) trafficking to the tumor is 
regulated by the CCL2/CCR2 axis. Intra-tumoral production of RNS induces 
nitration/nitrosylation of CCL2 that no longer attract tumor-specific CTLs, but 
can still recruit MDSCs95. 
Beyond the recruitment into the tumor site, MDSCs can hamper the activation 
of effector T cells through the expression of immune checkpoint inhibitors 
(ICIs). Programmed death-ligand 1 (PD-L1) is an inhibitory ligand, 
abundantly expressed in MDSCs that binds to PD-1 and, thus, suppressing T 
cell activation96. Several mechanisms can trigger its expression through 
different pathways and stimuli, such as: hypoxia-HIF1α 97; IFNγ via STAT1-
IRF1 axis96; M-CSF and VEGFA98; cyclooxygenase-2 (COX2)/prostaglandin 
E2 (PGE2) axis99. 
Induction of immune regulatory cells   (Fig.4.4) 
The fourth group includes the diversion of immune functions toward 
immunosuppression. As described above, reprogramming of MDSCs produce 
large amounts of TGFβ and IL-10 in the tumor microenvironment89. TGFβ 
exerts direct anti-proliferative effects on T cells, arresting their cell cycle in 
the G1 phase or inhibiting the IL-2 secretion100. Notably, TGFβ was shown to 
inhibit the differentiation of CD4+ T cells into Th1/Th2 cells by suppressing 
the expression of T-bet and GATA-3, master regulators of Th1 and Th2 
conversion, respectively101. MDSCs also promote the clonal expansion and 
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differentiation of CD4+ T cells to Treg cells directly, via cell–cell interactions 
(including CD40–CD40L), or indirectly through production of soluble factors 
such as IFNγ and IL-10102, or CCL3, CCL4 and CCL5 which drive the 
recruitment of immune-modulatory CCR5+ Treg cells103. Further, through an 
IL-10- or cell contact-dependent mechanism, MDSCs skew macrophages 
toward an M2 phenotype, resulting in IL-12 downregulation104. Macrophages, 
in turn, promote the production of IL-10 by MDSCs, creating a self-
maintaining negative loop104. 
 
1.3.3   MDSCs expansion and activation in cancer  
Accumulating evidence from tumor-bearing mice and human cancers 
indicates that MDSCs occurrence is governed by a network of transcriptional 
regulators that could be combined into two partially overlapping groups of 
factors: a) promoting myelopoiesis and preventing differentiation of mature 
myeloid cells; b) promoting pathologic activation of MDSCs105,106. 
Regulation of MDSCs expansion 
STAT3 was the first transcription factor characterized in MDSCs expansion 
and accumulation in cancer107. In addition to the well-described myeloid-
specific growth factors GM-CSF and G-CSF, several other factors have been 
implicated in the activation of STAT3. Among these, high levels of IL-6 
produced by MDSCs showed a critical role in the activation of STAT3 not 
only in MDSCs108, but also in cancer cells, increasing tumor invasiveness and 
metastatic potential109. STAT3 activation in MDSCs was reported also in 
response to hepatocyte growth factor, tumor-derived exosomes, and IL-11.106 
Interestingly, Yan et al. recently reported that exposure to a diet rich in 
polyunsaturated fatty acids (PUFAs) significantly increased the accumulation 
of MDSCs in tumor-bearing mice in a STAT3-dependent manner.110 IRF8 is 
a transcription factor implicated in the terminal differentiation of 
monocytic/macrophage lineage, which, interacting with the transcription 
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factor C/EBPa, prevent its binding to DNA, and thus resulting in the inhibition 
of the granulocytic differentiation program in favour of monocytic 
differentiation.111 The absence of IRF8 in tumor-bearing mice results in 
increased accumulation of MDSCs, while its overexpression is correlated with 
a decreased accumulation of MDSCs.112 The molecular mechanisms of IRF8-
dependent expansion of MDSCs are not fully understood, but evidences 
indicate that the Irf8 gene is negatively regulated by tumor-derived G-CSF 
and GM-CSF, through STAT3/STAT5.112  
Interleukin-17A (IL-17A) promotes both granulocyte-colony stimulating 
factor (G-CSF)- and stem-cell-factor-mediated neutrophilia113 and supports 
G-CSF-driven “emergency” myelopoiesis114. Terminal macrophage 
differentiation is instead induced by macrophage-CSF (M-CSF) through 
activation of the transcription factors PU.1 and IRF8115. The C/EBPb 
transcription factor isoform is implicated in the regulation of emergency 
myelopoiesis, both in response to infection58 and cancer116. Recent evidences 
have shown that, whereas C/EBPα appears to be a major regulator of “steady-
state” granulopoiesis117, C/EBPβ118 promotes the expansion and maturation of 
neutrophils in emergency conditions.  
The retinoic acid-related orphan receptor (RORC1/RORγ) orchestrates 
emergency myelopoiesis in cancer-bearers by suppressing negative (Socs3 
and Bcl3) and promoting positive (C/EBPβ) regulators of granulopoiesis, as 
well as the key transcriptional mediators of myeloid progenitor commitment 
and differentiation to the monocytic/macrophage lineage (IRF8 and PU.1).119 
The retinoblastoma protein RB1 was recently implicated in MDSCs expansion 
in mice and humans through a process mediated by tumor-derived G-CSF.120 
NLRP3 inflammasome is an intracellular sensor which regulates the 
production of IL-1b and IL18. NLRP3 is up-regulated in MDSCs and its lack 




Regulation of MDSCs activation 
The NF-kB pathway (see below) is activated in MDSCs through various 
mechanisms which showed to increase their suppressive activity. Although  
controversial evidences, TLRs-mediated activation of NF-kB through 
MyD88/HSP70 pathway appear to contribute to the suppressive activities of 
MDSCs.122,123 The IL-1b overexpression by tumor cells increases production 
of peroxynitrite by MDSCs.124 TNFa, another well-known activator of the 
NF-kB pathway, up-regulates iNOS expression in an NF-kB- and p38 MAPK-
dependent manner.125 Several studies have linked the IFNg-STAT1 pathway 
in the increase of iNOS and ARG1 expression in M-MDSCs, inducing their 
immunosuppressive activity.94 The STAT6 pathway can be activated in 
MDSCs through engagement of CD124 (IL-4Ra) by IL-4 or IL-13; this leads 
to the up-regulation of ARG1126, as well as increased production of TGFb127.  
The COX2/PGE2 pathway is implicated in a positive-feedback loop 
regulating MDSCs suppressive functions. PGE2 increases the expression of 
COX2 in monocytes, converting them to M-MDSC, and further increases the 
production of PGE2.128,129 This induces to the up-regulation of ARG1 and 
iNOS suppressing T cell activity.130 PGE2 is also involved in the recruitment 
of MDSCs to the tumor site by inducing the expression of CXCL12.131 
 
1.3.4  Role of myeloid-derived suppressor cells in tumor metastasis 
Tumor metastasis remain the major cause of cancer-related mortality.132 
Accumulating evidence from preclinical and clinical studies highlight that 
MDSCs play an important role in all steps of metastasis formation (Fig. 5). 
Although the immunosuppressive activity of MDSCs is critically important 
for the formation of a metastatic niche, these cells employ a number of other 




MDSCs migration to pre-metastatic niche 
The pre-metastatic niche is the receptive tissue microenvironment undergoing 
a series of molecular and cellular changes to form the metastatic-designated 
sites, or the fertile ‘soil’ for metastatic tumor cell ‘seed’ colonization, thus 
supporting tumor settlement and metastasis at distant organs.132 
Several chemokines and chemokine receptors are involved in the recruitment 
of MDSCs to the pre-metastatic niche. Among these CXCL1, CXCL2, and 
CXCL5 have been shown to recruit MDSCs to the pre-metastatic niche 
through the interaction with the same receptor, CXCR2.134–136 
Pro-inflammatory proteins S100A8 and S100A9 are potent chemoattractants 
for MDSCs and have been implicated in the promotion of tumor growth and 
metastasis by MDSCs.137–139 Moreover, S100A8/A9 induces serum amyloid 
A (SAA) 3 which in turn directly attracts MDSCs to pre-metastatic lungs, 
stimulate NF-κB signalling in a TLR4-dependent manner, and facilitate 
metastasis140. Thus, it appears that MDSC recruitment to tumor sites generate 
a chain reaction: MDSCs initially recruited to the tumor site by tumor-derived 
chemokines can facilitate the recruitment of other MDSCs via release of 
S100A8/A9 proteins134. 
MDSCs effects on angiogenesis 
Rapid growth of solid tumors results in hypoxia, which induces upregulation 
of proangiogenic factors such as VEGF, PDGF, basic fibroblast growth factor 
(b-FGF), and angiopoietins141, and enhances MDSCs migration to the tumor 
site via HIF1α-mediated production of chemokines134. Inhibition of MDSC 
recruitment in the tumor sites prevents tumor angiogenesis.142 The myeloid 
CSFs-dependent up-regulation of STAT3 in MDSCs induces the secretion of 
pro-angiogenic factors, such as VEGF, bFGF, and Bv8.143 Bombina variegata 
peptide 8 (Bv8) production by PMN-MDSCs has been shown to promote lung 
metastasis and its blockade is correlated with the inhibition of angiogenesis 
and tumor growth.144 
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MDSCs can promote tumor neovascularization by secreting matrix 
metallopeptidase 9 (MMP-9), whose activity promotes the bioavailability of 
VEGF in the tumor microenvironment.145 MDSCs can potentially incorporate 
into the vascular endothelium by differentiating into endothelial-like cells 
expressing VE-cadherin and VEGF-R2.145 
 
Fig. 5. Role of MDSCs in the metastatic process. MDSCs promote angiogenesis, tumor cell 
invasion, and metastasis through a variety of different soluble factors. MDSCs play an 
important role in the formation of the pre-metastatic niche and in promoting tumor 
metastasis.146 
 
Influence of MDSCs on metastasis formation 
The current concept suggests that MDSCs reach the pre-metastatic site before 
the tumor cells. Once into the site, MDSCs promote tumor seeding and growth 
through various mechanisms. MDSCs’ role in the promotion of metastasis was 
extensively investigated in mouse models of breast cancer and melanoma. 
MDSCs in 4T1 model of breast cancer upregulated the expression of several 
MMPs, which was critical in mediating invasiveness of tumor cells.147 
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MDSCs also downregulates protease inhibitors such as the neutrophilic 
granule protein, an inhibitor of tumor invasiveness and metastasis.148  
TGFb showed a direct, although controversial, role in the MDSCs-mediated 
metastatic process. Inhibition of TGFβ receptor II signalling increased 
MDSCs recruitment and tumor invasion mediated by SDF-1, CXCL5 and 
CCL9.147,149  
In contrast, a specific deletion of TGFβ receptor II in myeloid cells 
significantly inhibits tumor metastasis.150 MDSCs recruited to pre-metastatic 
lungs stimulate the migration of tumor cells by secreting TNFα, CXCL2, 
TGFβ, IL-6, and monocyte chemotactic protein-1 (MCP-1).109,138,151   
To disseminate, invade tissues and metastasize, some tumor cells undergo 
epithelial-mesenchymal transition (EMT), in which polarized epithelial cells 
lose epithelial markers and differentiate into cells with mesenchymal 
features.152 Recently, several studies have shown the role of MDSCs in EMT. 
Indeed, MDSCs recruited to the tumor site can produce hepatocyte growth 
factor (HGF) and TGFβ inducing EMT of primary tumor cells.136 
Because most of the metastasis are represented by epithelial cells, similar in 
morphology to the primary tumor, but not mesenchymal cells, it is suggested 
that EMT is a temporary event and that after arriving at a metastatic site, tumor 
cells undergo reverse transition from mesenchymal to epithelial phenotype 
(mesenchymal-epithelial transition, MET) in order to colonize the niche. In 
one model, MDSCs accumulated in the pre-metastatic lung secrete versican, 
an extracellular matrix proteoglycan, which contribute to MET and the 
formation of macro-metastasis in the lungs.153 MDSCs also promote cancer 
metastasis by inducing stemness of cancer cells or by expanding the cancer 





1.3.5   MDSCs as target for cancer therapy 
The expansion of MDSCs has been demonstrated to be associated with tumor 
progression, metastasis, and recurrence of many types of human tumors.69,156 
In addition, the efficacy of immunotherapy was negatively correlated with an 
elevated MDSCs frequency and activity not only in solid tumors157,158 but also 
in blood of non-Hodgkin lymphoma and multiple myeloma patients.159 
Importantly, the frequency of circulating MDSCs was found to correlate with 
disease stage. It was reported that patients with stage III and IV of a variety of 
cancer types have higher frequencies of MDSCs in the peripheral blood, as 
compared to stage I and II patients.160,161 In addition, a negative association 
between MDSCs numbers and clinical response to radio-, chemo-, and 
immunotherapy was reported.162 Therefore, MDSCs could become not only 
promising biomarkers for the survival of patients and treatment efficacy, but 
could also serve as a valuable target in combined immunotherapy of cancer 
patients. 
Three main strategies to modulate MDSCs are under development in several 
preclinical and clinical studies: 1) inhibition of immunosuppressive functions; 
2) inhibition of MDSCs trafficking; 3) regulation of myelopoiesis and/or 
depletion of MDSCs (Fig.6).163 
Inhibition of MDSC-mediated immunosuppression 
Recent preclinical and clinical studies showed that treatment with tadalafil, an 
inhibitor of phosphodiesterase-5, significantly inhibited MDSC functions by 
the downregulation of iNOS and ARG1 activities, leading to an increased 
T cell reactivity and improved outcome of advanced cancer bearers.164–166 A 
class I histone deacetylase inhibitor, entinostat, in combination with anti-PD-
1 antibodies, reduces the expression of ARG1, iNOS, and COX2 in MDSC 
subsets, inducing a strong reduction of tumor-infiltrating macrophages and a 
significantly delayed tumor growth in mice.167,168 
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Inhibitors of the activation of STAT3, others than old detrimental small 
molecule inhibitors, are showing promising therapeutic possibilities. Indeed, 
interfering with STAT3 mRNA through STAT3 siRNA or decoy 
oligonucleotides is applied in the combination with immune checkpoint 
inhibitors in the frame of the phase I/II clinical trial.169 In another approach, 
selective delivery to MDSCs of STAT3 inhibitors, through their coupling to 
CpG oligonucleotides, which are well-known agonists of TLR9 (highly 
expressed by myeloid cells), showed decreased immunosuppressive 
activity.170 A further possibility to target MDSCs is the modulation their 
metabolic pathways. Pharmacological inhibition of the fatty acid oxidation 
(FAO) decreased the immunosuppressive capacity of MDSCs and, in 
combination with low-dose chemotherapy and adoptive cellular therapy, 
resulted in antitumor effect in different cancer models.171 
Inhibition of MDSCs trafficking 
Myeloid-derived suppressor cells exhibit their main immunosuppressive 
activity within the tumor microenvironment. Therefore, intensive 
investigations were performed to block the chemokine-dependent migration 
of MDSCs to the tumor site. The blockade of CXCR2-CCL2 interaction with 
a CXCR2 antagonist in combination with chemotherapeutic drugs showed 
significant therapeutic effect.172 Another chemokine receptor, CCR5, is 
expressed on a broad spectrum of immune cells.173 Many evidences suggest 
that targeting CCR5 on MDSCs could be applied not only to prevent their 
recruitment but also to reduce their immunosuppressive functions in cancer 
patients174,175. Patients with a mutated CCR5 variant were reported to be 
resistant to the prostate cancer development; blocking the CCR5–CCR5 
ligand interaction improved the survival of tumor-bearing mice; CCR5+ 
MDSCs from melanoma patients displayed an increased immunosuppressive 




Fig. 6. Strategies for MDSC targeting. The MDSC modulation could be achieved by the 
inhibition of their immunosuppressive activity (blue box), by blockade of MDSC recruitment 
to the tumor site (green box), and by the regulation of myelopoiesis and/or depletion of MDSC 
(red box). Examples of each therapeutic approach are shown.163 
 
Regulation of myelopoiesis and/or depletion of MDSCs 
The number of MDSCs in tumor-bearing hosts could be reduced by the 
normalization of myelopoiesis, the inhibition of the conversion of immature 
myeloid cells (IMC) into MDSCs, and the differentiation of MDSCs into 
mature myeloid cells like DC or macrophages. Supporting evidences were 
shown by all-trans retinoic acid (ATRA), a vitamin A derivative binding to 
the retinoic acid receptor. ATRA alone, or in combination with other agents 
(i.e. IL-2, p53-DCs vaccine), decreased the frequency of MDSCs, induced 
their differentiation into dendritic cells or macrophage, downregulated ROS 
production by MDSCs.177,178 
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Tumor-derived extracellular vesicles (EV) were reported to induce the 
conversion of non-immunosuppressive IMCs into MDSCs and further to 
activate their immunosuppressive functions.179,180 Dimethyl amiloride or 
omeprazole, inhibitors of the EV release, reduced MDSCs expansion and 
immunosuppressive activity.181 
Tyrosine kinase inhibitors (such as sunitinib), which can block VEGF and c-
kit signalling, decreases the number of circulating MDSCs, reducing STAT3 
activation and ARG1 expression, while increasing the activity and 
proliferation of CD8 T cells. However, no significant prolongation of the 
overall survival was observed.182,183 
Some chemotherapeutics showed positive effects. Gemcitabine and 5-
fluorouracil induces apoptosis of MDSCs in mouse cancer models and reduces 
the frequency MDSCs in patients, but with poor effect on T cells activity.163,184 
Administration of docetaxel induced a decrease of tumor burden accompanied 
by the conversion of MDSCs into M1-like cells. Further, doxorubicin led to 
the reduction of MDSCs frequency and immunosuppressive activity, with an 
enhancement of granzyme B and IFN-γ production by effector T and NK cells. 
Paclitaxel, administrated at ultra-low, non-cytotoxic doses, reduced MDSCs 
number, and increased their differentiation into DCs. Treatment of mice with 












1.4 Tumor-associated Macrophages 
 
Macrophages are an essential component of innate immunity and play a central 
role in inflammation and host defence, with decisive functions in both innate 
and adaptive responses. Resident macrophages provide immediate defence 
against foreign pathogens and coordinate leukocyte trafficking.185 They 
mediate the degradation of apoptotic cells, microbes and possibly neoplastic 
cells. Moreover, they collaborate with T and B cells in triggering, instructing 
and terminating the adaptive immune response.185 Further, they play a role in 
tissue remodelling and wound healing.186 
Macrophages have remarkable functional plasticity that allows them to 
differently set their functions in response to environmental signals, such as 
microbial products, damaged cells, activated lymphocytes.185,187 
Tumors are abundantly infiltrated by macrophages. Although macrophages 
were originally thought to be part of an anti-tumor response, clinical and 
experimental data indicate that, in the large majority of cancers, tumor-
associated macrophages (TAMs) support cancer initiation, progression and 
metastasis.187,188 
 
1.4.1 Macrophage polarization 
Macrophages can respond to endogenous stimuli that are rapidly generated 
following injury or infection. These early stimuli are typically produced by 
innate immune cells and can exert a marked effect on the physiology of 
macrophages. The current consensus identifies the opposite extremes of 
macrophages as: 1) M1-polarized or classical activated macrophages and 2) 
M2-polarized or alternatively activated macrophages (Fig. 7).186,189,190 
The terms M1 has been used to designate the classically activated effector 
macrophages that are produced in response to inflammatory signals. In 
particular, the combination of two signals, interferon-γ (IFNγ) and tumor-
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necrosis factor (TNFa), results in a macrophage population that has enhanced 
microbicidal or tumoricidal capacity and secretes high levels of pro-
inflammatory cytokines and mediators. Typically, a TLR ligand (e.g. LPS), 
acting in a MyD88-dependent manner, induces the transcription of TNFa 
gene, which can then cooperate with IFNγ to activate the M1 program, 
associated with production of pro-inflammatory cytokines (e.g IL-12, IL-23, 
TNFa), nitric oxide (via iNOS) and ROS. Generally, the activation of M1 
macrophages requires activation of the transcription factors STAT1 
(following IFNγ receptor ligation) and nuclear factor-κB (NF-κB), obtained 
in response to TLR or TNF receptor ligation.186 
 
 
Figure 7. Macrophage polarization. M1 stimuli (LPS, TNFα, IFNγ) trigger the activation of 
several transcription factors, including, STAT1 and NF-κB (p65–p50 heterodimer). M1-polarized 
macrophages produce specific cytokines (e.g. TNFα, IL-1β, IL-12, IL-23, IFNγ), chemokines 
(CXCL10), ROS and nitric oxide (NO). M1 phenotype plays key roles in inflammation, 
immunostimulation and in antibacterial and anti-tumoral responses. Other cytokines (e.g. IL-4, IL-
13, IL-10, and TGFβ) induce M2-like phenotype through the activation of several transcription 
factors, including STAT3/6 and NF-κB (p50–p50 homodimer). M2-polarized macrophages 
produce specific cytokines (IL-10), chemokines (CCL17, CCL18, CCL22), and other proteins 
(CD163, CD206, Arg1, etc), relevant in tissue repair, matrix remodelling, angiogenesis, 
immunosuppression, and favouring tumor growth.191 
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The M2 or alternative activated macrophage population is certainly more 
intricate and heterogeneous. Generally, this definition embraces both the 
regulatory and wound-healing patterns of activation, which partially 
overlaps.187 During tissue injury one of the first innate signals to be released 
is thought to be IL-4 which rapidly converts resident macrophages into a 
population of cells that promote wound healing; IL-4 stimulates ARG1 
activity in macrophages, allowing them to convert arginine to ornithine, a 
precursor of polyamines and collagen, thereby contributing to the production 
of extracellular matrix. Furthermore, the M2 activation is efficiently driven by 
Th2 cytokines, including IL-13, together with IL-4.186,187,192 
Other factors inducing an alternative and immune-regulatory activation are 
glucocorticoids, immune complexes and anti-inflammatory cytokines, such as 
TGFβ and IL-10. The latter two are released by macrophages themselves 
following phagocytosis of apoptotic cells with the intent to dampen the 
inflammatory response.186 
M1 vs M2 paradigm is challenged in vivo, where the co-expression of a large 
number of stimuli with different temporal patterns may induce mixed and 
opposing functional states. Therefore, M1/M2 polarization of macrophages is 
a simplistic, although useful, concept that emphasizes the extremes of a 




Figure 8. M1 and M2 macrophages, the extremes of a continuum.187 
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M1 and M2 extremes exhibit specific expression of metabolic enzymes (iNOS 
vs ARG1), cytokines (IL-12highIL-10low vs IL-12lowIL-10high), chemokines 
(CXCL9/CXCL10 vs CCL17/CCL22), as well as transcription factors (NF-
κB p65-p50 vs NF-κB p50-p50; STAT1 vs STAT3/6).189 
Generally, classically activated M1 macrophages support specific anti-tumor 
T cell-mediated activities. However, during tumor progression TAMs 
generally acquire an M2-like phenotype which dampens tumoricidal activity 
and promotes tissue remodelling and angiogenesis.190  
1.4.2 Origins and recruitment of TAMs 
For a long time, TAMs were considered to originate exclusively from bone 
marrow-derived monocytic precursors that undergoes differentiation upon 
tissue infiltration. However, new evidence suggests heterogeneity also in the 
autologous pathways.193–195 In most cancer models, TAMs originate from 
circulating Ly6Chigh CCR2+ monocytes. In fact, blocking the CCL2/CCR2 
axis of monocyte recruitment leads to a strong decrease in TAMs abundance, 
suggesting that TAMs originate from bone marrow-derived monocyte CCR2+ 
precursors.196,197 In an inducible lung carcinoma model, splenectomy resulted 
in a strong reduction in TAMs. These spleen-derived TAMs were shown to be 
also CCR2-dependent, suggesting the contribution of an extramedullary 
myelopoiesis in TAMs generation.198 However, deletion of Ccr2 did not result 
in full depletion of macrophages. Bone marrow transfer experiment in a model 
of pancreatic ductal adenocarcinoma, proved that TAMs are composed of both 
newly recruited bone marrow-derived macrophages (BMDM) and tissue-
resident macrophages (TRMs). Fate mapping models strongly support that a 
significant fraction of these TRMs have an embryonic origin and actively 
proliferate along with tumor growth.194  
In spontaneous models of breast carcinoma it has been identified that the 
major TAMs population (CD11bloF4/80hiMHCIIint) as well as the mammary 
 
 33 
tissue-resident macrophage population (CD11bhiF4/80loMHCIIhi) originates 
both from Ly6ChiCCR2+ monocytes. However, the role of local non-
monocytic population cannot be excluded, since TAMs also expand their 
population through in situ proliferation.199,200 
These findings suggest that TAMs can arise from tissue-resident 
macrophages, originating either from embryonic precursors (Ly6C-) or from 
circulating monocytes (Ly6C+) (Fig. 9). 
 
Figure 9. Heterogeneity of TAM origin. (Left panel) BMDMs develop from hematopoietic 
stem cells that generate common myeloid progenitors. These progenitors, then divide and 
mature into monocytes in the BM. Under appropriate stimuli, monocytes traffic to other sites 
where they can become macrophages. TRMs develop from macrophage progenitors that are 
seeded into tissues during embryonic development. (Right panel) Schemes represent different 
scenarios of TAM ontogeny. In some tissues, embryonic-derived resident macrophages self-
maintain over time. A) Other subsets are progressively replaced by monocyte-derived 
macrophages with turnover rates depending on tissue specificity; B). At tumor onset, classical 
monocytes are recruited to the tumor (mainly in a CCR2-dependent manner) and differentiate 
into inflammatory TAM. Depending on tumor localization and the inflammatory state TRMs 
proliferate (A and B) or not (scenario C) and contribute more or less to the pool of TAM. For 






In addition, a smaller subset of TAMs deriving from monocytes that express 
the angiopoietin-2 receptor TIE2, may arise from Ly6CloCCR2- monocytes. 
These pro-angiogenic TAMs, known as Tie2-expressing monocytes (TEMs), 
are recruited to the tumor by angiopoietin-2, localize preferentially in areas of 
angiogenesis, aligned along the abluminal surface of blood vessels, and play 
important non-redundant roles in tumor neovascularization.203,204 
The monocyte-to-macrophage differentiation is normally regulated by several 
soluble factors.205 Among these, M-CSF, also known as colony stimulating 
factor 1 (CSF1), is the major lineage regulator of macrophages, both 
embryonal- and bone marrow-derived, and plays as a chemotactic factor for 
macrophages.206 Many cancer models showed that M-CSF inactivation 
(genetic deletion or neutralizing antibody) results in a reduced number of 
TAMs and decreased disease progression.207,208 VEGFA is another factor 
recruiting macrophage progenitors that differentiate to TAMs under the 
influence of IL-4, and promoting tumor angiogenesis and invasion.209 These 
factors collaborate with locally produced tumor-derived factors (e.g. IL-4, IL-
10, IL-13, CCL2, TGFβ, PGE2, C5a) to drive macrophage differentiation and 
activation.210,222–224 
Interestingly, metabolic environmental signals associated with malignant 
neoplasms can influence macrophage activity. The ‘Warburg effect’, a 
metabolic shift to a glycolytic pathway, generally occurring in highly 
proliferative cancer cells results in copious production of lactic acid that shifts 
TAMs toward an M2-like activation state.213 Hypoxic regions of tumors are 
generally characterized by a high frequency of TAMs. Hypoxia shapes and 
induces specific macrophage phenotype that promotes immune evasion, 





1.4.3 Pro-tumoral functions of TAMs 
A pivotal hallmark of TAMs is the ability to directly influence cancer 
progression through several mechanisms (Fig. 10), such as promotion of 
tumor angiogenesis, invasion and metastasis of neoplastic cells, and immune 
suppression.216  
The M2-like phenotype of TAMs includes low production of NO and ROS, 
low function as antigen presenting cells, suppression of cytotoxic T 
lymphocytes and induction of immunomodulatory Tregs.217 In agreement with 
the M2 signature, TAMs were reported to express high levels of M2 markers 
like ARG1, YM1, FIZZ1, MSR1, MMR1, and low levels of inflammatory 
cytokines (e.g. IL-12, IL-1b, TNFα, IL-6).218 
Among other events, the activation of the transcriptional factor NF-kB has a 
key role in the modulation of the inflammatory response of macrophages. In 
acute inflammation activated by M1 stimuli (e.g. LPS, TNFa), NF-kB acts as 
heterodimer of subunits p65-p50.219 In advanced cancer stages, TAMs display 
a preferential M2 polarization, guided by the p50 NF-kB homodimer, that 
promotes transcriptional program with anti-inflammatory and pro-
tumorigenic effects.220,221 
 
TAMs recruitment into  tumor microenvironment induce the production of 
angiogenic factors including VEGF, platelet-derived endothelial cell growth 
factor (EC-PDGF), thymidine phosphorylase.222,223 TAMs also play an active 
role in promoting the spread of distal tumor cells, expressing extracellular 




Figure 10. Schematic representation of cells and mediators influencing the function of TAMs. 
On the left side, different cells belonging to the immunological network, as well as tumor cells and 
tumor-associated fibroblasts, influence the phenotype of TAMs by producing specific soluble 
mediators such as cytokines, chemokines, and growth factors. For instance, Th2 cytokines (IL-
4/IL-13) and other cytokines such as IL-10 and TGFb, metabolic products derived from tumor 
cells (lactic acid) and immune complexes, drive TAM polarization into tumor-promoting 
macrophages. On the right side are listed the major pro-tumor functions of TAMs. For instance, 
by producing survival factors TAMs protect cancer stem cells from the toxic effect of 
chemotherapy or directly stimulate tumor cell proliferation via the epidermal growth factor (EGF). 
TAM production of nitric oxide (NO) and reactive oxygen species (ROS) induces genetic 
instability. TAMs switch on neoangiogenesis by secreting VEGF and suppress immune responses 
through expression of inhibitory molecules (PD-L1 and B7-4) and production of 
immunosuppressive cytokines/mediators (IL-10 and ARG1). In the rectangle, selected 
transcription factors that orchestrate TAMs functions are highlighted.225 
 
TAMs can suppress the cytotoxic functions of T cells through several 
mechanisms: nitrosylation of T cell receptors via ARG1, iNOS and 
peroxynitrite, inducing T cell apoptosis; expression of PD-L1, interacting with 
PD-1 on T cells and inducing their apoptosis; high levels of IL-10, which 
negatively regulate the production of pro-inflammatory IL-12 and induce 
Tregs recruitment; induction of immunomodulatory Th2 cells which produce 
IL4 and IL-13 reinforcing TAMs pro-tumor phenotype.226 
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1.4.4 Targeting TAMs in cancer therapy 
In the last decade, the therapeutic power of immunotherapy has opened a new 
era in cancer medicine.227,228 The effectivness of immune checkpoint blockade 
therapies (ICBs), such as anti-PD-1/PD-L1, anti-CTLA4 antibodies, which 
impede the activity of inhibitory receptors, and the generation of chimeric 
antigen T cell receptor (CAR-T) therapy are novel treatments able to increase 
tumor-specific cytotoxic T cells (CTLs) activity in various tumors.227,228 
Nevertheless, there are a large number of patients resistant to 
immunotherapy.229 Recent evidences showed that, at least in part, this 
resistance can be mediated by abundant and/or immunosuppressive infiltrating 
myeloid cells, including tumor-associated macrophages.230,231 Therefore, 
novel strategies targeting and reprogramming TAMs properties (recrutiment, 
polarization, survival, phagocytosis, angiogenesis) are currently in clinical 
development (Fig.11).202 
As described above, CCL2/CCR2 axis is the most well characterized pathway 
promoting the recruitment of CCR2+ myeloid cells. In preclinical models, 
CCR2 blockade inhibited infiltration and immunosuppressive polarization of 
macrophages.232,233 A number of CCR2 inhibitors (CCX872-B, PF-04136309, 
MLN1202, and BMS-813160) are currently in clinical trials for the treatment 
of solid tumors, in combination with other therapeutic agents (i.e. 
FOLFIRINOX regimen), achieving at least partial response and local tumor 
control.202 
Another chemoattractant target for cancer therapy is IL-1b that promotes 
recruitment of myeloid cells into tumors.234,235 The IL-1 receptor antagonist 
antibody (anakinra) showed to suppress myeloid cell accumulation and tumor 
progression in mouse models, and, in combination with other agents, is 
currently under Phase Ib clinical investigation.202 
As already mentioned, TAM subsets derived from proliferation of tissue-
resident macrophages (TRM), that originally arise from CX3CR1+Kit+ 
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erythromyeloid progenitors, self-maintain independently of the bone 
marrow.195,199,202 TRMs have specific markers (e.g. CX3CR1hi, and F4/80hi) 
and tissue-specific transcription factors (e.g. Gata6 in peritoneal-resident 
macrophages), which do not appear in bone marrow-derived macrophages 
(BMDMs).236 Thus, with the goal of improving cancer immunotherapy, 
selective therapeutic approaches targeting BMDMs and TRMs may be needed 
to limit macrophage content in tumors. 
The M2-like immunosuppressive polarization of TAMs correlates with tumor 
progression. Strategies to dampen this immunosuppressive signature and 
acquisition of pro-inflammatory signatures in macrophages (repolarization or 
reprogramming) are acquiring increasingly beneficial impact in cancer 
therapy.230 In preclinical studies, PI3Kg inhibition (genetic or 
pharmacological) suppressed accumulation of immunosuppressive BMDMs 
(monocytes and granulocytes) but did not affect the accumulation of TAMs in 
tumors.230 However, PI3Kg inhibition increased expression of 
proinflammatory cytokines such as TNFa, IL-12, iNOS, and MHC-II, and 
inhibited the expression of immunosuppressive factors such as IL-10, TGFb, 
ARG1 and CCL2, resulting in significant reduction of tumor progression, and 
increased survival in different mouse models of cancer, mediated by 
increasing CD8+ T effector cell activity.230,231,237 The PI3Kg inhibitor IPI-549 
is currently in clinical testing in multicenter Phase 1b trials for several 
advanced solid tumors in combination with anti-PD-1 nivolumab.202 
Another strategy to repolarize macrophages include targeting Bruton's 
tyrosine kinase (BTK), a transcription factor acting downstream of PI3Kg 
activated in TAMs. Pharmacological inhibition of BTK, ibrutinib (PCI-
32765), stimulates M1 macrophage polarization, reduces myeloid cell 
infiltration, and increases CD8+ T cells in murine pancreatic adenocarcinoma 
(PDAC).238 Ibrutinib is in Phase II and III clinical trials for the treatment of 
different solid tumors in combination with other therapeutic agents.202 
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TMP195, a class IIa histone deacetylase (HDAC) inhibitor, has been reported 
to repolarize TAMs to express proinflammatory cytokines and to synergize 
with PD-1 inhibitors, reducing tumor burden and metastasis in an 
autochthonous mouse model of breast cancer.239  
Receptor-interacting serine/threonine protein kinase 1 (RIPK1) is upregulated 
in TAMs, and its inhibition with the small molecule GSK547 repolarizes 
TAMs towards a proinflammatory state with increased MHCII, TNFa, and 
IFNg expression, reducing tumor growth.240  
Another target for macrophage repolarization is STAT3 which induces 
immunosuppression in myeloid cells.155,241 The STAT3 inhibitor TTI-101 is 
now undergoing testing in a Phase I clinical trial in patients with advanced 
cancers.202 
Toll-like receptor (TLR) agonists represent alternative strategies to reprogram 
macrophage activation. TLRs activation stimulates polarization of 
macrophages towards a proinflammatory phenotype. Intratumoral injection of 
3M-052, a TLR7/TLR8 agonist, induced macrophage repolarization and 
tumor regression in a mouse model of subcutaneous melanoma. Although 
TLR agonists stimulate potent proinflammatory polarization in myeloid cells, 
their effects can be limited, as they develop, in continuous administration, a 
tolerogenic response and expression of PD-L1, dampening anti-tumor 
inflammation.202,221 
Activation of CD40, a member of the TNF receptor family, promotes 
macrophage production of proinflammatory factors such as IL-1, IL-12, 
TNFa, and NO.242 Agonistic antibodies anti-CD40 are reported to induce 
cytotoxic macrophage activation against tumor cells. Several anti-CD40 
antibodies and recombinant CD40 ligands are currently under investigation in 
several clinical trials for solid tumors as single agents, or in combination with 





Figure 11. Macrophage Targeting Strategies in Cancer Therapies. Critical pathways that 
regulate the recruitment, polarization, survival, phagocytosis, and proangiogenic properties of 
TAMs. CSF1R inhibitors can suppress the survival of TAMs. Inhibitors of PI3Kg/mTOR 
pathway (e.g. IPI-549, rapalogs-rapamycin homologs), as well as agonists of CD40, or 
TLR4,7,8, or 9 can repolarize TAMs towards a proinflammatory phenotype. Inhibitors of 
CCR2 can suppress monocyte recruitment, and thereby macrophage accumulation in tumors. 
Inhibition of CD47 on tumor cells together with antitumor antibodies can promote 
phagocytosis of tumor cells by macrophages. Additionally, inhibition of macrophage-derived 
VEGF can suppress tumor angiogenesis and progression. These molecular targets that are 
currently under clinical development to promote effective antitumor immune responses. For 
abbreviation and details, see the text.202 
 
Although complement activation is an effective innate immune response 
pathway, complement-induced inflammation can also paradoxically promote 
neoplastic progression.243 Indeed, TAMs upregulate the production of C5a 
which in turn activates its C5a receptor (C5aR) on macrophages, resulting in 
immunosuppressive macrophage polarization and inhibition of CD8+ T cell 
activation.243 Inhibiting C5aR with the peptide antagonist PMX-53 in 
combination with paclitaxel effectively inhibited tumor growth by 
repolarizing TAMs towards the proinflammatory phenotype.202 
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CSF1R plays a major role in regulating macrophage proliferation and survival. 
Inhibition of CSF1R reduces immunosuppressive macrophage polarization, 
decreases tumor cell proliferation and increases apoptosis, resulting in reduced 
tumor progression and prolonged survival.244,245 Indeed, an anti-CSF1R 
antibody, emactuzumab, depletes TAMs and reduces tumor growth in a mouse 
model of subcutaneous colon carcinoma.246 Moreover, inhibition of CSF1R in 
combination with paclitaxel decreases macrophage recruitment to tumors, 
increased CTL activation resulting in prolonged survival in a breast cancer 
mouse model.202 
CD47, the ‘don’t eat me’ signal, is a self-molecule that protects hosts and 
tumor cells from destruction by macrophages, binding to the SIRP1a present 
on the surface of macrophages.247 Antibody-mediated inhibition of human 
CD47 promotes macrophage-mediated phagocytosis of tumor cells and T cell 
activation.248 Targeting CD47 with TTI-621, a human recombinant protein 
that blocks binding of SIRPa to CD47, stimulates phagocytosis of tumor cells, 












1.5 The transcription factor NF-kB 
 
The nuclear factor-κB (NF-κB) family of transcription factors was first 
described as a B-cell-specific transcription factor that binds the kB site in the 
Ig κ light chain enhancer. Soon after, NF-κB activity was found to be inducible 
in all cell types.250 NF-κB is a key player in the regulation of many genes 
involved in various biological process, including cell growth and survival, 
development, and immune responses, both innate and adaptive.251–253 
Furthermore, several tumors have been shown to have a constitutive activation 
of NF-κB.254 
At present, more than 150 genes under control of NF-κB have been identified, 
as a demonstration of its vast spectrum of biological functions.255,256 In 
immune cells, NF-κB activation is triggered by the engagement of several 
receptors, such as B-cell receptor (BCR), T-cell receptor (TCR), Toll-like 
receptors (TLRs), TNF receptor and CD40, resulting in the expression of 
cytokines, growth factors and effector enzymes.250 
Due to its pleiotropic and central activity, dysfunction of NF-kB system can 
lead to various pathological immune-related conditions, such as rheumatoid 
arthritis, asthma, intestinal bowel diseases (IBDs), multiple sclerosis and 
cancer.257–259 Thus, exploring and defining the NF-κB pathways could provide 
the basis for the development of therapeutic strategies with a relevant impact 
on human diseases.  
1.5.1  NF-kB family and activation pathways 
NF-κB family is evolutionarily conserved and includes five members: NF-
kB1 (p105/p50), NF-κB2 (p100/p52), RELA (p65), RELB and c-REL (Fig. 
12). Each family member shares an N-terminal 300 amino acid conserved 
region known as the rel homology domain (RHD) through which they can 
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form homo- and hetero-dimers. RHD region is also responsible for the nuclear 
localization, binding to DNA, and interaction with IκB family members.250,260 
The RELA, RELB and c-REL proteins also have a C-terminal non-
homologous transactivation domain (TD), which strongly activates 
transcription of target genes once the NF-κB dimers bound to specific DNA 
consensus sites named κB.260 p50 and p52 are generated by proteolytic 
degradation of p105 and p100 precursors, respectively, and they lack TDs; 
therefore, p50 and p52 can activate transcription by forming heterodimers with 
p65, RELB and c-Rel, which contains TDs. If they form homodimers (e.g. 
p50/p50 homodimer) they can still bind the DNA consensus sites, but they do 
not activate transcription.261,262 The main activated form of NF-κB is the 
heterodimer containing p65 together with p50 or p52.253 
In most cells, NF-κB complexes are inactive, residing predominantly in the 
cytoplasm in a complex with inhibitory IκB proteins, and the intact NF-kB 
subunits p100 and 105. When signalling pathways are activated, the IκB 
protein, p100 and p105 are degraded and NF-κB dimers enter the nucleus to 
modulate target gene expression. Whereas p50 and p65 are expressed widely 
in various cell types, the expression of RELB is restricted to specific regions 
of the thymus, lymph nodes and Peyer’s patches. The expression of c-REL is 




Figure 12. NF-kB proteins and their activation pathways. A) NF-kB proteins contain a well-
conserved N-terminal rel-homology domain (RHD), which includes DNA-binding and 
dimerization domains, and a nuclear localization signal (NLS). Some proteins, such as RELA, 
RELB and c-Rel contain transactivation domains (TD) in addition to the RHD. B) Canonical 
pathway is triggered by numerous signals, including those mediated by innate and adaptive 
immune receptors. It involves the activation of IKK complex by TAK1, IKK-mediated IκBα 
phosphorylation, and subsequent degradation, resulting in rapid and transient nuclear translocation 
of the prototypical NF-κB heterodimer RELA p65/p50. Non-canonical NF-κB pathway relies on 
phosphorylation-induced p100 processing, which is triggered by signalling from a subset of TNFR 
members. This pathway is dependent on NIK and IKKα, but not on the trimeric IKK complex, and 
mediates the persistent activation of RELB/p52 complex.253,260 
 
In resting conditions, IκBs exert regulatory functions binding and masking the 
Nuclear Localization Sequence (NLS) on NF-κB proteins, thus impeding the 
nuclear translocation of IκBs-NF-κB complexes, retained into the cytoplasm 
in inactive forms. Activation of several receptors can induce NF-κB signalling 
that starts upon phosphorylation of IκB proteins by IκB Kinases (IKK). IKK 
is a complex of three subunits: two kinases IKKα and IKKβ, and the regulatory 
IKKγ (or NEMO, NF-κB Essencial Modifier). Hence, upon activation of 
IKKβ, IκB is phosphorylated and degraded by the proteasome; the released 
NF-κB dimers translocate into nucleus and activate gene transcription.250,263 
The activation of NF-κB involves two major signalling pathways, the 




important for regulating inflammatory responses despite their differences in 
signalling mechanism.250,252,260 
The canonical NF-κB pathway is mainly mediated by Toll like receptors 
(TLRs), TNF receptor (TNFR) superfamily members, as well as T-cell 
receptor (TCR) and B-cell receptor.264 The primary mechanism for canonical 
NF-κB activation is the inducible degradation of IκBα triggered through its 
site-specific phosphorylation by a multi-subunit IκB kinase (IKK) complex.265 
IKK is composed of two catalytic subunits, IKKα and IKKβ, and a regulatory 
subunit named NF-κB essential modulator (NEMO) or IKKγ.252 IKK can be 
activated by different stimuli, including cytokines, growth factors, mitogens, 
microbial components and stress agents.265 Upon activation, IKK 
phosphorylates IκBα triggering ubiquitin-dependent IκBα degradation in the 
proteasome, thus resulting in rapid and transient nuclear translocation of 
canonical NF-κB members predominantly the p50/p65 and p50/c-Rel 
dimers.251,265 
On the other side, the non-canonical NF-κB pathway selectively responds to 
a specific group of stimuli, including ligands of a subset of TNFR superfamily 
members, such as LTβR, CD40 and RANK.260,266 In addition, the alternative 
NF-κB activation does not involve IκBα degradation but rather relies on 
processing of the NF-κB2 precursor protein p100.265 A central signalling 
molecule for this pathway is NF-κB-inducing kinase (NIK), which activates 
and functionally cooperates with IKKα to mediate p100 phosphorylation, 
which in turn induces p100 ubiquitination, and degradation in mature NF-κB2 
p52 subunit. This translocate into nucleus as p52/RELB dimer.265 
Functionally, canonical NF-κB is involved in almost all aspects of immune 
responses, whereas the non-canonical NF-κB pathway appears to be evolved 
as a supplementary signalling axis that cooperates with canonical NF-κB 




1.5.2  NF-kB in cancer-related inflammation  
Accumulating evidences are profiling a key role of NF-kB pathway in cancer 
progression beyond the inflammatory-related activity.267 Indeed, NF-kB 
signalling in malignant cells can modulate the transcription of genes encoding 
for proteins important for cell proliferation (e.g. cyclin D1, c-Myc) survival 
(BCL-2, c-FLIP), angiogenesis (e.g. VEGF, MMP-9), and adhesion (e.g. 
MMPs, VCAM1).267–269 Nevertheless, the major role of NF-kB in tumor 
diseases is focused on the modulation of  a wide variety of genes that control 
cancer-related inflammation.254 
Indeed, NF-kB represent a master regulator of inflammation triggering the 
transcription of several pro-inflammatory factors, such as IL-1β, TNFα, IL-6 
and IL-8, which in turn upregulate the NF-kB activation, thus generating a 
positive feedback pathway into the inflammatory microenvironment. This is 
directly involved in both early stages of the disease, when inflammation acts 
predominantly as anti-tumoral, and advanced disease, characterized by 
immunosuppressive and anti-inflammatory microenvironment favouring cell 
proliferation, transformation and survival, and consequently cancer 
development (Fig.13).220,256,270 Moreover, the pro-inflammatory stimuli, such 
as bacterial products or inflammatory cytokines (e.g. TNFα and IL1β), 
through the respective receptors, activate NF-κB that translocates into the 
nucleus inducing the expression of cytokines (such as TNFα and IL6) and 
chemokines, which contribute to inflammation-related tissue damage. 
Elevated IKK/NF-κB activity may also lead to aberrant upregulation of certain 
tumorigenic adhesion proteins, chemokines, and inhibitors of apoptosis that 
promote cell survival.271 In particular, in a breast cancer model, the potent 
induction of epithelial-mesenchymal transition by TNFa has been shown to 
be mediated by the activation of the NF-κB pathway.272  
NF-κB was also found to promote the metastatic process in a genetic mouse 
model of prostate cancer, in which inactivation of IKKα was found to reduce 
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metastatic spread.273 Moreover, it has been demonstrated in many cancers that 
NF-κB signalling is constitutively active. Although with many unclear 
aspects, several mechanisms regulating this activation have been proposed, 
such as IL-1β and TNFα production, shorter IκBα half-life or IκBα 
mutations.274,275 For these reasons, NF-κB represents an ideal therapeutic 
target for the development of new anti-tumor therapies. 
1.5.3  NF-kB1 (p105/p50) in tumor-associated myeloid cells  
As described above, the NF-κB1 gene encodes for the p105 protein, which, 
once cleaved, gives rise to the functional form p50. The p50 subunit could 
generate dimers with another p50 subunit or with other NF-κB family 
members.261 The role of p50 and its precursor in cell physiology and function 
is very complex and not fully defined. Indeed, although originally it was 
considered a repressor of transcription, p50 could also be a transcriptional 
activator, and the balance between pro- and anti- inflammatory activity of p50 
depends on cell type and environmental conditions.276,277 
The nuclear translocation of the homodimeric p50/p50 complexes deeply 
controls functions of myeloid cells in cancer.270 In macrophages, under 
prolonged stimulation with LPS, the TLR4-mediated massive production of 
TNFa results down-regulated via overexpression of p50 protein, inducing a 
tolerant, M2-like, immunosuppressive phenotype. Genetic deletion of p50 in 
macrophages unable the induction of tolerance by long-term pre-treatment 
with LPS.48,221,278 Moreover, our group has demonstrated that TAMs display 
a defective NF-κB activation in response to the M1 polarizing signals (LPS 
and TNFα) and that this phenotype is due to the overexpression of nuclear p50 
NF-κB homodimers which inhibits the transcription of pro-inflammatory 
genes.221 By contrast, LPS treatment of TAMs genetic deleted for p50 recover 
an M1 phenotype with increased expression of IL-12, TNFα, and decreased 
IL-10, restoring antitumor immunity.279 Further, a detailed analysis of the role 
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of p50 NF-κB homodimer in macrophage functions revealed that its nuclear 
accumulation, both in TAMs and LPS-tolerant macrophages, not only 
mediates a status of unresponsiveness (tolerance) toward pro-inflammatory 
signals, but actually plays a role as key regulator of M2-driven inflammatory 
responses.221 In contrast, other studies showed that inhibition of NF-kB 
activation in TAM correlates with impaired expression of inflammatory 
functions, such as expression of cytotoxic mediators (NO) and cytokines 
(TNFa, IL-1 and IL-12).280  Possible explanations for this discrepancy are 
based on the functional feature of macrophages, which are considered plastic 
cells able to finely modulate their programs in response to different 
microenvironmental conditions.280 It has been speculated that dynamic 
changes of the tumor microenvironment may occur during the transition from 
early neoplastic events toward advanced tumor stages.281 These events would 
drive an M1 toward M2 switch of TAMs functions (Fig. 13) and are probably 
connected to the profound changes occurring in the tumor 
microenvironment.280 
 
Figure 13. NF-kB role in TAMs reprogramming during tumor progression. It is proposed that a 
gradual switching of TAMs polarization, from M1 to M2, is paralleled by the gradual inhibition of NF-
kB, during different stages of tumor progression. Early in the carcinogenesis, T cell driven M1 activated 
macrophages may contribute to elimination. Regulatory mechanisms result in M2 polarized TAMs that 
orchestrate smouldering, non-resolving tumor-promoting inflammation.282 
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Further, nuclear accumulation of p50 NF-κB promotes a tolerogenic 
phenotype in dendritic cells (DCs), affecting both their survival and capacity 
to drive activation of effector T cells. Lack of p50 subunit in murine DCs 
promoted increased lifespan, increased maturation and expression of the pro-
inflammatory cytokines IL-1, IL-18 and IFNβ, enhanced capacity of 
activating and expanding effector T cells and decreased ability to induce 
differentiation of regulatory T cells.283 In colorectal cancer models the p50-
dependent inhibition of M1-polarized gut inflammation supported colorectal 
cancer development. Indeed, lack of p50 showed an enhanced activation of 
Th1/M1 cytokine pathway (e.g. IL-12, CXCL10), reduced frequency of 
TAMs at the tumor site, and increased recruitment of NK, NK-T and CD8 T 
cells, resulting in a marked dampening of disease progression.284 Therefore, a 
profound investigation of the molecular mechanisms associated with NF-κB 
activation, with particular attention to p50 protein activity, represents a novel 
fascinating approach to identify strategies that revert the immunosuppressive 

















1.6 The transcription factor RORg(t) 
 
The retinoic acid-related orphan receptor (ROR) gamma (t) is a member of 
RORs subfamily of nuclear receptors, that, by definition, function as ligand-
dependent transcription factors.285 Recent studies have demonstrated that 
RORs, including the other two members RORa and RORb, have been 
implicated in several physiopathological processes.286–288 Therefore,  RORs 
represent an active area of research and are emerging as important drug targets 
for the treatment of various diseases, such as multiple sclerosis, rheumatoid 
arthritis, psoriasis, cancer and metabolic syndrome.286,289,290 
 
1.6.1    RORg(t) structure, activation and functions 
The RORg(t) encoding gene (RORC) was initially discovered in Jetten’s lab 
from human pancreas poly(A)+ RNA.291 Murine Rorc gene and the human 
form (RORC) share an 88% sequence homology.292 Both murine and human 
RORC genes encode for two different mRNA splicing variants, which 
produce two different protein isoform: 1) RORg (or RORC1, RORg1) and 
RORgt (or RORC2, RORg2) (Fig.14).293 Structurally, the RORgt isoform 
lacks the 24 N-terminal amino-acidic residues present in RORg form, which 
are encoded by the first two exons (1g and 2g). These latter are replaced by a 
unique exon (1gt) specific for RORgt isoform, which result in 3 amino-acidic 
residues (Fig.14).294 
RORg(t) exhibits a domain structure that is typical of nuclear receptors and 
contain an N-terminal domain, a highly conserved DNA-binding domain 
(DBD) consisting of two zinc finger motifs, a ligand-binding domain (LBD), 
and a hinge domain spacing the DBD and LBD (Fig.14).290 As opposed to the 
majority of other nuclear receptors, which act as dimers (e.g. LXRs, RXRs), 
RORg(t) regulates gene transcription recognizing and binding as monomer to 
specific ROR response elements (ROREs) consisting of the RGGTCA 
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consensus preceded by an A/T-rich sequence in the regulatory regions of 
target genes (Fig.15).285,295 
Another peculiarity of RORs, as compared to the other nuclear receptors, is 
their intrinsic constitutive capacity to activate transcription in a ligand-
independent manner. Indeed, the positive and negative transcriptional 
regulation of the RORs occurs through the recruitment of nuclear receptor co-
activators and co-repressors, proteins with intrinsic chromatin remodeling or 
integration activity (e.g corepressors NCoR, RIP140, SMRT, and coactivators 
GRIP, SRC-1/2, PGC1α).285 
 
Figure 14. RORg(t) structure and functions. (A) Organization of the RORC locus. The usage of 
exons 1g and 2g produces the RORg protein. These are replaced by a unique exon (exon 1gt) to 
produce the immune-specific isoform RORgt. As a result, the 24 first amino-acids of RORg are 
replaced by 3 residues from exon 1gt. (B) Schematic representation of the domain structure of 
RORγ isoforms: RORγ and RORγt. Amino-terminal domain (A/B or AF1), DNA- binding domain 
(DBD), hinge region, ligand-binding domain (LBD), and the activation function helix-2 (AF2). 
(C) Biological functions of RORgt. 1. Development of secondary/tertiary lymphoid organs. RORgt 
induce the expression of lymphotoxin a/b on lymphoid tissue inducer (LTi) cells, which interact 
with mesenchymal organizer cells, driving tissue formation. 2. During thymocyte development, 
RORgt is expressed in DP cells and is required for the survival of these cells by controlling the 
expression of the survival factor Bcl- XL. 3. RORgt is the master transcription factor of Th17 cells, 
sources of IL-17. RORgt is induced in naïve CD4+ T cells upon their activation by an antigen-
presenting cell, in the presence of a cocktail of cytokines (IL-6, IL-21, IL-23, IL-1b, TGFb). Th17 
cells have been shown to be required for immunity against infective agents. Excessive IL-17 










Conversely, the ligand-dependent transcriptional activity of RORg remains 
controversial for two main issues. The first issue is –as the definition of 
‘orphan’ receptors claims– the little-known molecular source of endogenous 
ligands for RORg. Although until ten years ago the natural RORg ligands were 
almost unknown or merely supposed, many recent evidences indicate 
cholesterol and cholesterol derivatives as endogenous molecules with high 
affinity for the LBD or RORg protein.286,296,297 
The second issue concerns the functional role of endogenous ligands. Indeed, 
as mentioned above, RORs can result constitutively active and retain the 
ability to interact with several co-activators also in the absence of binding any 
ligand.298 It appears that some ligands induce trivial conformational changes 
in protein structure, but with unclear capacity to alter their functions.298 It has 
been proposed that they are important to maintain the constitutive 
transcriptional output level of the receptor and to prevent hyperactivation via 
agonist or inadvertent repression by endogenous inverse agonists.298 
 
Figure 15. RORg(t) activation. The nuclear receptor RORg(t) acts its transcriptional activity through 
the DNA-binding domain (DBD) inducing expression of target genes. These are related to immune 
response (e.g. IL17, IL23, C/EBPb) circadian rhythms (BMAL1, CLOCK), and lipid and glucose 
metabolism (e.g. INSIG2A, CYP7B1). Conversely to other NRs, RORg(t) can function as monomer, 
and translocate into the nucleus exerting its transcriptional function in a ligand-independent manner. 
Ligands modulate the entity of RORg activity which is strictly dependent by co-activator factors. LBD, 





























The tissue expression levels and functional effects of the two RORg isoforms 
are quite varied. RORgt isoform is well-known for its involvement in 
immunological processes. Indeed, it is highly expressed in lymphoid tissues, 
such as thymus, gut-associated lymphoid tissue (GALT), lymph-nodes (LNs) 
where it plays a fundamental role during organogenesis. Mice genetic deleted 
for RORgt do not develop Peyer’s patches, peripheral lymph node and 
generally develop thymic lymphoma.287 Moreover, RORgt is expressed in 
various T cell subsets, including innate lymphoid cells (ILCs) (Fig.14). 
RORg, instead, is more known for its metabolic predominance. It is expressed 
in many tissues including skeletal muscle, kidneys, adipose tissue, and liver.290 
Indeed, it has been emerged an important involvement of RORg in the 
metabolic regulation of adipogenesis and insulin sensitivity, with direct effect 
in the development of metabolic syndrome.285,287,299  
In addition, RORg isoform is involved in the regulation of circadian rhythms. 
Indeed, in the liver and kidneys, it can bind and activate the promoter of the 
ARNTL (BMAL1) gene, a transcription factor which, dimerizing with 
CLOCK protein, has a central role in the generation of physiological circadian 
rhythms, inducing or repressing the transcription of genes mainly involved in 
the metabolic pathway.293 
Although RORg isoform it has been considered for a long time not involved 
and/or expressed in immune cells, our group has recently identified that 
tumor-derived factors (e.g. CSFs) induce an overexpression of RORg in 
myeloid progenitor cells, driving the cancer-associated emergency 
myelopoiesis.119 Furthermore, RORg(t) is emerging to be involved in various 
mechanisms of tumorigenesis. These include both immunological and 





1.6.2   RORgt in lymphoid cells and cancer 
RORgt isoform has a T cell specific expression. In the thymus, RORg is 
transiently expressed to induce the transition from CD4-CD8- double-negative 
(DN) immature cells to CD4+CD8+ double-positive (DP) cells, which 
subsequently differentiate into single-positive CD4+ or CD8+ T cells 
(Fig.14).293 The absence of RORgt results in a dramatic decrease in the number 
of DP and mature CD4+ and CD8+ cells, due to a reduced expression of anti-
apoptotic factor Bcl-XL thus resulting in the apoptosis of DP cells.293 
Mature, but naïve CD4+T (Th0) cells can be differently polarized to produce 
the cytokines characteristic of Th1, Th2 and Th17 cells. RORgt is required for 
the development of Th17 cells whose name reflects their ability to produce the 
cytokines IL-17A and IL-17F, as well as IL-21 and IL-22.285 Th17 cells 
protect against extracellular pathogens, but are also associated with various 
autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel 
disease, multiple sclerosis and asthma.300 RORgt is recruited to ROREs in 
several Th17 marker genes, including Il17a, Il17f, and Irf4. The latter is a 
transcription factor which in turn can induce the expression of Rorc gene. IL-
6 and low levels of TGFb can also induce the expression of Rorc in a STAT3-
dependent manner.301 
Th0 cells can also differentiate in Tregs. Specific signals, such as high levels 
TGFb, IL-2 and retinoic acid, upregulate the expression of FOXP3 which 
interacts with and inhibits RORgt, thus promoting Treg differentiation.302 
RORgt also plays a critical role in the generation of innate lymphoid cells 
(ILCs). ILCs are a heterogeneous population of cells with the typical lymphoid 
cell morphology, but lacking cell surface molecules typical of lymphocytes, 
and thus, impeding ILCs to recognize specific antigens and to respond to 
cytokines produced during innate immune responses.303 ILCs have been 
classified into three groups, based on their cytokine production profiles and 
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mirroring the corresponding T helper (Th) cell types: ILC1 (Th1) producing 
IFNg; ILC2 (Th2) producing IL-5 and IL-13; and ILC3 (Th17) producing IL-
17. As a consequence, RORgt is required for the development of ILC3s, a 
heterogeneous population of cells, including lymphoid tissue inducer (LTi) 
cells (CD4+CD3-) required for the development of secondary lymphoid organs 
and Peyer’s patches.304  
In cancer, RORgt showed controversial activities (Fig.16).288 In a study 
exploring the function of Th17 cells in a mouse B16 melanoma model, RORgt 
was found to be expressed by tumor-infiltrating Th17 cells. Th17 cells did not 
exhibit in vitro tumor cell killing activity, although CD8+ cytotoxic T cells 
stimulated by Th17 cells could activate the tumor killing response.305 
The expression of RORgt mRNA and protein was found to be downregulated 
in PBMCs from non-small cell lung cancer (NSCLC) patients compared with 
controls, suggesting a possible pro-tumor activity of RORgt.306 Other evidence 
showed that RORgt is overexpressed in neoplastic cells, contributes to their 
proliferation and is negatively correlated NSCLC prognosis.307 Other studies 
confirmed that RORgt mRNA is upregulated in the peripheral blood of 
patients with NSCLC compared with that of healthy controls.308–310 
Conflicting evidence in hepatic cancers showed that RORgt mRNA expression 
was found both increased and decreased in tumor tissues.311,312 In colorectal 
cancer, Foxp3+IL-17+ cells were found to express RORgt313, and directly 
correlated with the capacity of regulatory T cells to suppress anti-tumoral 
inflammation and with the stage of human colon cancer.314 Another study 
showed that RORgt was not expressed within colorectal cancer tissues or by 
infiltrating CD4+ T cells.315  
The expression and regulation of RORgt in various cancers remain 





Figure 16. Expression and function of RORg(t) in tumor microenvironment. The upregulation 
of RORγt in ILC3 leads to protumor effect. The downregulation of RORγt in Th17 cells indicates 
the antitumor effect of IL-17 in colon cancer. The upregulation of RORγt in Treg shows protumor 
effect in colon cancer. The expression of RORγ in myeloid cells has protumor effects via Socs3, 
Bcl3, and C/EBPb. The expression of RORγ in tumor cell is either increased or decreased 
depending on the cancer type. Increased expression of RORγ(t) in lung cancer, prostate cancer, 
and gastric cancer results in protumor effects, while decreasing expression of RORγ(t) in breast 
cancer and melanoma induces antitumor responses via TGFβ/epithelial–mesenchymal transition 
(EMT) or vitamin D3 derivatives. The question mark refers to unknown mechanisms. There are 
indicated the expression of RORa and RORb, other members of RORs family, whose 
downregulation induces antitumor effect in hepatoma, breast cancer, melanoma, and colon cancer. 
The up or down black arrow refers to upregulation or downregulation.288 
 
1.6.3   RORg in tumor-associated myeloid cells 
Controversial evidences are described also for the RORγ isoform. Indeed, in 
castration-resistant prostate cancer (CRPC), RORγ was found to be 
overexpressed and to directly drive androgen receptor (AR) hyperactivity 
through binding to an exonic RORE, exacerbating tumor proliferation and 
growth.316 Therefore, inhibition of RORγ may represent a possible treatment 
option for CRPC. In breast cancer, high expression of RORγ in cancer cells 
was both inversely correlated with reduced expression of PRMT2, suppressor 
of cell migration, and positively associated with a longer metastasis-free 




Figure 17. RORC1 drives tumor-promoting emergency myelopoiesis. Tumor-derived 
colony-stimulating factors (CSFs) up-regulate RORg in myeloid progenitors, driving the 
expansion of MDSCs, the inhibition of neutrophils maturation, and the induction of M2 
phenotype in TAM, and, thus, promoting tumor growth.119 
 
Accordingly, the different functions of RORγ in cancers could be due to 
distinct cell origins as well as isotypes. For instance, when expressed by 
immune cells, RORγ acts as an immune suppressor, although when produced 
by cancer cells, it acts as a potential survival factor. Indeed, in a recent work 
published by our group it has been demonstrated that RORγ expression is 
upregulated in myeloid progenitors by tumor-derived CSFs and drives tumor-
promoting “emergency” granulo-monocytopoiesis by suppressing negative 
(Socs3 and Bcl3) and promoting positive (C/EBPb) regulators of 
myelopoiesis. These lead to RORγ-dependent expansion of 
immunosuppressive MDSCs and TAMs, with marked pro-tumor functions 
(Fig.17).119 Moreover, PBMCs from cervical cancer patients showed a high 
expression of RORγ.318  
Additional observations are needed to elucidate the regulating mechanisms 





1.6.4   RORg in regulation of metabolism 
RORγ, together with RORa, have been implicated in the control of energy 
homeostasis and the regulation of several lipid and glucose metabolic genes.285 
Regulation of energy homeostasis is a complex process that involves multiple 
interrelated glucose and lipid metabolic pathways in many organs and is 
controlled by the circadian clock, gut microbiota, and by the endocrine, 
immune and nervous systems.319 This has made it difficult to determine 
whether the metabolic changes observed in RORγ deficiency are cause or 
effect. In this context, most of the studies and evidences in metabolic 
regulation by RORs focused on the RORa protein, which is structurally and 
functionally similar to RORg, and in certain cases it exerts the same 
transcriptional activities in alternative and/or synergistic manner.285 
For instance, both RORα and RORγ have been shown to be induced during 
adipocyte differentiation.320 RORγ plays a role in the regulation of glucose 
metabolism and insulin sensitivity.285,299,321 RORγ-deficient mice were 
significantly more insulin sensitive and glucose tolerant than wild-type mice; 
instead, the overexpression of RORg in hepatocytes led to an increase in 
glucose production starting from pyruvate.299,321 It was also identified the 
recruitment of RORg in the regulatory region of a number of metabolic genes 
involved in glycolysis and gluconeogenesis, including G6Pase, PPARd, 
Glut2, which result decreased in RORg deficient mice.299 Together, these 
observations indicated that RORγ is an important modulator of hepatic 
gluconeogenesis and glycolysis, and, thus of insulin sensitivity. This is 
supported by studies showing that the level of RORγ expression positively 
correlates with adiposity and insulin resistance in human obese patients.321,322  
In addition to gluconeogenesis, RORγ regulates hepatic lipid metabolism. 
Several studies showed that RORγ deficiency significantly decreased the 
expression of genes involved in lipid regulation and in fatty acids and 
cholesterol metabolism, including the insulin-induced gene 2a (Insig2a), 
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elongation of very long chain fatty acids-like (Elovl3), Cyp7b1, Cyp8b1, 
Sult1e1.285 These data indicated that RORγ positively regulates the 
transcription of these metabolic genes by directly binding ROREs in their 
regulatory regions. Moreover, the dysregulated expression of these genes in 
RORγ-deficient mice fed with high-fat diet (HFD) were associated with 
reduced levels of triglycerides, cholesterol, and bile acids in liver and blood.285 
These observations suggest that RORγ antagonists might be beneficial in 
controlling glucose homeostasis and in the management of metabolic diseases. 
 
1.6.5 The dual relationship between RORg and cholesterol metabolism 
Cholesterol and its metabolites are bioactive lipids that interact with and 
regulate the activity of various proteins and signalling pathways implicated in 
the control of several physiological and pathological processes. 
A clear connection has been established between cholesterol 
intermediates/metabolites and their regulation of RORs activity. Several 
studies demonstrated that various intermediates of the cholesterol biosynthesis 
pathway, downstream to lanosterol, bind RORγ and enhance its activity, 
suggesting their potential function as endogenous ligands for RORγ (Fig.18). 
Zymosterol, 7-dehydrodesmosterol and desmosterol were among the most 
effective sterols activating RORγ. 297,323 
Cholesterol and other sterols can be metabolized by a number of cytochrome 
P450 enzymes and lead to the formation of a wide range of oxysterols 
(Fig.18).324 CYP7A1 catalyzes the formation of 7-ketocholesterol (7-KC) and 
7α-hydroxysterols (7a-OHC), while CYP27A1 generates 27-
hydroxycholesterol (27-OHC), and CYP46A1 produces various 
hydroxysterols, such as 24(S)-hydroxycholesterol (24-OHC). Many of these 
cholesterol modifications appear concomitantly, generating ‘combined’ 
oxysterols (e.g.  7α-,27α-dihydroxystolesterol). Many of these cholesterol 
modifications can occur in a non-enzymatic manner, through oxidation by 
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reactive species (e.g. ROS) aberrantly expressed in several pathological 
conditions like cancers (Fig.18).325   
A number of these oxysterols can act as ligands for RORγ, with both agonistic 
or antagonistic activity.298,326 For instance, 7-ketocholesterol (7-KC) and 
24(S)-hydroxycholesterol (24-OHC) function as inverse agonists for RORγ, 
while 25-hydroxycholesterol (25-OHC), 27-hydroxycholesterol (27-OHC), 
7α,27- and 7β,27-dihydroxycholesterol act as agonists for RORγ.326 In 
addition to being hydroxylated, sterols can be sulfo-conjugated by 
sulfotransferase SULT2A1 and SULT2B1, and generating sulfated sterols, 
such as cholesterol- and desmosterol sulfate, which function as RORγ 
agonists.323 Therefore, alterations in sterol homeostasis and, thus, 
modification of the intracellular pool of RORs ligands affect RORg 
transcriptional activity and, consequently, the physiological and pathological 
processes in which RORg is implicated.  
This hypothesis was strongly supported by studies examining the effect of 
disruption of cholesterol biosynthesis on RORγt-dependent regulation of Th17 
differentiation and gene expression. Interestingly, during Th17 differentiation, 
the expression of several cholesterol biosynthetic genes (e.g., SQS, DHCR24) 
are enhanced, whereas genes involved in cholesterol metabolism (e.g., 
CYP7A1, CYP27A1) and efflux (e.g., ABCA1, ABCG1) are decreased.323 In 
addition, Th17 differentiation is accompanied by an increase in the expression 
of the sulfotransferase SULT2B1.323 Together, these findings are consistent 
with the concept that increased expression of genes involved in cholesterol 
biosynthesis would enhance the availability of RORγt agonists and 
subsequently stimulate RORγt activity. Indeed, several studies have 
demonstrated that disruption of the cholesterol biosynthesis pathway has a 
negative effect on RORγt activation and Th17 differentiation. 
Statins, which inhibit HMGCR, the key enzyme in the initiation of cholesterol 
biosynthesis (Fig.18), and thus, lower the generation of RORγ sterol agonists, 
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have been shown to dampen Th17 differentiation and the expression of 
inflammatory cytokines.327 Moreover, other studies of either pharmacological 
or genetic inactivation of sterol synthesis (e.g. azoles, CYP51A deletion), 
showed similar effects in inhibiting RORγ activity.326 
Cytochrome P450 enzymes play a key role in the regulation of various aspects 
of cholesterol homeostasis and formation of oxysterols, several of which act 
as agonists of RORγ(t). CYP27A1 catalyzes the formation of 27-
hydroxycholesterol, 7α,27- and 7β,27-dihydroxycholesterol. These 
oxysterols, which were reported to be preferentially produced by mouse Th17 
cells, act as RORγt agonists and stimulate Th17 differentiation.296 Moreover, 
oxysterols production and accumulation in various cells and tissues are 
increased in dyslipidemic conditions such as obesity and 
hypercholesterolemia.324,328 Accordingly, hypercholesterolemic mice (ApoE 
deficient) spontaneously develop atherosclerosis and are susceptible to 
arthritis, pathological conditions in which Th17 pro-inflammatory cells play a 
key role in pathogenesis.329 The lack of conclusive evidences correlating 
elevated blood levels of cholesterol, Th17- or myeloid cells-driven 
inflammation, and RORγ activation suggests to explore these patterns as 






Figure 18. RORg and cholesterol metabolism relationship. (A) Representation of cholesterol 
biosynthesis pathway. Acetyl-CoA molecules are joined and modified through several enzymatic steps 
in mevalonic acid, first, and then in squalene (mevalonate pathway). The linear structure of squalene is 
cyclized to give rise to lanosterol, the first molecule with the ‘four ring’ sterol backbone. The 
intermediates downstream to lanosterol (lanosterol pathway) have a certain affinity for the RORg ligand-
binding pocket. In red, cholesterol precursors with the highest affinity for RORg. Statins inhibits 
HMGCR, the key enzyme of cholesterol biosynthetis. (B) Representation of oxysterols with the highest 
affinity for RORg. Cholesterol is highly predisposed to enzymatic or non-enzymatic oxidation to 
produce oxysterols, biologically active molecules and precursors of bile acids. Cholesterol is also 
modified by enzymatic sulfonation, increasing its affinity for RORg. Red arrows indicate the enzyme 
which expression is regulated by RORg.296 (adapted) 
 
In addition to being regulated by sterols, RORγ itself regulates the expression 
of a number of genes involved in cholesterol transport and sterol metabolism. 
The hepatic expression of sterol-12α-hydroxylase, CYP8B1, and 7b-
hydroxylase, CYP7B1, which are involved in the conversion of cholesterol 
into bile acids, and in the regulation of hepatic and serum cholesterol levels, 
have been reported to be directly regulated by RORγ.326 Moreover, RORγ has 
been implicated in the circadian regulation of sterol sulfotransferases 
SULT2A1 and SULT2B1.330 Regulation of sterol metabolic genes by RORγ 
may enhance or reduce the synthesis of agonists, thereby modulating RORγ 
activity and creating a positive or negative feedback loop. Whether the 
regulation of sterol metabolic genes by RORγ affects the availability of RORγ 

























































1.7 Obesity, cholesterol metabolism and cancer-related 
inflammation 
 
Obesity incidence is continuously growing and reaching pandemic 
proportions; population data link obesity to the increased incidence of 
cancers.331–333 Cancer is predicted to overtake heart disease as the leading 
cause of death across all age groups in the U.S. by 2030, and moreover it is 
expected an epidemiologic shift from previously known modifiable risk 
factors, such as smoking and alcohol consumption, toward obesity as the main 
risk factor for malignancies.334,335 Obesity also portends worse cancer-specific 
outcomes after diagnosis in several tumor types including those of the breast, 
esophagus, colon, prostate, kidney, ovary, uterus, liver, tongue, and others.332 
Additionally, obesity is a poor prognostic factor for both adenocarcinoma and 
squamous cell carcinoma histologies.335 
Obesity is defined conventionally as a body mass index (BMI) ≥ 30 kg/m2 
[(weight in kg)/(height in m)2], typically as a consequence of excess adipose 
tissue.335 The primary function of white adipose tissue (WAT) is to store 
energy as lipid and to maintain energy homeostasis. Uncontrolled 
hyperadiposity as a result of excess caloric intake or reduced caloric 
expenditure leads to expansion of adipose compartments via hyperplasia 
and/or adipocyte hypertrophy. These conditions commonly lead to a number 
of pathophysiologic effects that have been associated with tumor development 
and progression.336  
Moreover, in the most recent review of the cancer hallmarks, the alteration of 
energy metabolism into tumor microenvironment has been highlighted to fuel 
neoplastic cell growth and division, as well as cancer-related inflammation 
and immune escape (Fig. 2).337,338 In this scenario, obesity-associated 
metabolic syndrome, inducing a systemic deregulation of energy metabolism, 
could play a fundamental role in cancer development.  
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Currently, the mechanisms by which obesity is postulated to promote cancer 
include: (1) increased levels and bioavailability of growth factors, such as 
insulin and insulin-like growth factor (IGF-1); (2) increased sex steroid 
hormones such as estrogen and factors affecting their metabolism; (3) altered 
adipokine levels such as leptin, adiponectin, and visfatin, all originally thought 
to primarily affect energy balance, but known to have growth, immune, and 
tumor-regulatory functions; (4) low-grade inflammation and oxidative stress 
affecting growth-promoting cytokines and immune-modulation; and more 
recently, (5) altered microbiomes, especially in the intestinal flora.332 
Obesity is associated with a form of non-resolving inflammation, referred to 
as chronic low-grade sterile inflammation or “metaflammation” 
(inflammation in metabolic tissues) and characterized by a modest increase in 
circulating proinflammatory factors and the absence of clinical signs of 
inflammation (hence the term ‘subclinical inflammation’).11,339  
Obesity-related inflammation is usually simplified by elevated levels of IL-6 
and TNFa but a number of evidences highlighted the role of different 
molecular mechanisms associated with alterations of the immune system, 
especially of myeloid compartment, and predisposing to cancer devolpment 
and progression.335 For instance, elevated circulating levels of TNFα and IL-
6 occur in obese women and have been associated with the development and 
progression of breast tumors.336 Additionally, systemic inflammation 
characterized by elevated levels of prostaglandin E2 (PGE2) metabolite in the 
urine is associated with increased risk of developing postmenopausal breast 
cancer.340,341 Free fatty acids (FFAs) released from the entrapped adipocyte 
and from other sources can activate toll-like receptor (TLR)-4 on the 
macrophage plasma membrane, leading to increased NF-kB-dependent 




Circulating chemokines, including monocyte chemoattractant protein-1 
(MCP-1), promote the recruitment of monocytes to adipose tissue, where the 
cells differentiate and become the so-called adipose tissue macrophages 
(ATMs). In addition to playing a role in recruitment, MCP-1 was recently 
found to stimulate ATMs proliferation in situ.343 Moreover, adipose tissue 
produces alarmins S100A8/A9, which in turn stimulate ATMs to express high 
levels of IL-1b via NLRP3 inflammasome. The elevated levels of IL-1b in 
circulation are able to reach bone marrow niche and to stimulate 
myelopoiesis.344,345 
A recent study shows that obesity induces an increase of IL-5 and GM-CSF 
production by adipose tissue, which in turn promotes the expansion and 
recruitment of granulocytic subsets that increase breast cancer metastasis.346 
The increase of adipose tissue associated with obesity correlates with 
enhanced leptin levels and reductions in adiponectin levels. Leptin regulates 
appetite and energy balance through activation of a negative feedback loop 
between the adipose tissue and the CNS. Leptin has been shown to activate 
cell proliferation and survival in cancer cell lines, including those of the 
prostate, breast, endometrium, and colon. Leptin can also induce IL-6 
production, suggesting that changes in leptin levels may contribute to the 
systemic inflammation observed in the obese conditions.347 Further, leptin 
overexpression can drive the accumulation of immune suppressive MDSCs 
that promote tumor progression but also provide some protection against the 
metabolic dysfunction that accompanies obesity.348 Adiponectin balances 
many of the pro-tumorigenic effects of leptin; it inhibits cell growth in models 
of breast, endometrial, prostate, and colon cancers.347 
Steroid hormones, in particular sex hormones androgens and estrogens, have 
been shown to be directly linked to obesity, inflammation and cancer 
development. Androgens are converted in estrogens by aromatase 
CYP19A1.349 The rate of conversion of androgens to estrogens is elevated in 
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postmenopausal women with obesity, and increased levels of estrogens in 
these women are associated with increased risk of breast cancer.350 Other 
evidences indicate that several proinflammatory mediators associated with 
WAT inflammation, including TNFa, IL-1b, and COX-2–derived 
prostaglandin E2, can induce aromatase expression in breast adipose 
tissues.351 Moreover, steroid hormones are biosynthetic products which derive 
from cholesterol and oxysterol molecules by several enzymatic steps.349 The 
availability of adequate cholesterol substrate is a critical requirement for the 
optimal steroid hormone production.349 
Obesity is a condition generally characterized by dyslipidemias, namely 
abnormal amount in blood triglycerides and cholesterol.352 The recent growing 
interest on the comprehension of the mechanisms connecting and balancing 
obesity, cholesterol, hormones, inflammation, and cancer is opening new and 
hopeful perspectives for the treatment of both metabolic syndrome and cancer. 
 
1.7.1    Cholesterol metabolism and cancer development 
 
Cholesterol metabolism 
Cholesterol is an essential lipid constituent of cell membranes, and is a 
precursor of steroid hormones, bile acids and Vitamin D.353 Cholesterol 
sources are both endogenous and exogenous; in both cases, liver plays a 
central role in the regulation of cholesterol management (Fig.19).354 
Exogenous cholesterol is obtained directly from the diet (significant amounts 
of cholesterol only occur in meat, eggs, and milk products). Free cholesterol, 
triglycerides and free fatty acids arriving in the intestine in emulsified form, 
are mixed with bile salts released by the liver and/or gallbladder to form 
micelles. These particles are able to mediate the absorption of cholesterol and 
fatty acids across brush border membranes and into enterocytes of the small 
intestine. While details of the mechanism are still unclear, recent studies have 
identified NPC1L1 as a putative transporter of cholesterol expressed on the 
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brush border membranes of enterocytes. In addition to NPC1L1, the ATP 
binding cassette G5 and G8 proteins (ABCG5/8) appear to negatively regulate 
cholesterol transport into enterocytes.355 
Once into the enterocytes, cholesterol and triglycerides are complexed with 
ApoB48 and a series of other apolipoproteins to form chylomicrons.356 
Chylomicrons are drained by lymphatic vessels (lacteals), reach the blood 
circulation and, interacting trough lipoprotein lipase on the surface of 
endothelium, release triglycerides and relatively small quantities of 
cholesterol to peripheral tissue. Chylomicrons remnants arrive to the liver 
where they are absorbed via several LDL receptor-related proteins (LRPs).356 
Cholesterol esters and remnant triglycerides are now catabolized, excreted or 
re-used to form VLDL lipoproteins.353 
The endogenous cholesterol is synthetized starting from Acetyl-CoA, derived 
from glycolysis, and from beta-oxidation of fatty acids, through several 
enzymatic steps and transformation (see Fig.18).353 The key enzyme of 
cholesterol metabolism HMGCR (target of statins) is subjected to feedback 
inhibition by cholesterol itself, directly on the enzymatic activity or at the 
transcriptional level, through a sophisticated mechanism.357 
The sterol response element (SRE)-binding proteins (SREBPs) are the 
downstream inducer of transcription of HMGCR gene. SREBP in the 
endoplasmic reticulum is bound to a second protein, namely SREBP cleavage 
activating protein (SCAP). This protein is the cholesterol sensor, adopting two 




Figure 19. Schematic representation of the critical step of cholesterol metabolism. (A) Dietary 
cholesterol is absorbed by enterocytes, complexed in chylomicrons, drained by lacteals. Once 
arrived in blood chylomicrons release via endothelial lipase triacylglycerol, and then reach the liver 
to re-use or excrete cholesterol. (B) Remnant cholesterol from chylomicrons or endogenous 
cholesterol synthesized in the liver are complexed with ApoB100 and other apolipoproteins to form 
VLDL that are secreted into circulation distributing triacylglycerol and cholesterol to peripheral 
tissue, and thus becoming LDL, rich in cholesterol. Remnants LDL cholesterol is either picked up 
by the liver and excreted into the intestine in the form of bile acids and eliminated by fecis, or, in 
case of hypercholesterolemia, captured by macrophages via LDL receptors or in case of modified-
LDL by other scavenger receptors (e.g. LOX-1, SR-A1). For abbreviations and more details, see 


























































At high cholesterol levels SCAP bind to a third protein, INSIG. When this 
ternary complex form, it is rapidly targeted toward proteolytic degradation. At 
lower cholesterol concentrations, SCAP binds to COPII, another membrane 
protein, creating vesicles which reach Golgi apparatus. Once SREBP reaches 
the Golgi, it is cleaved realising the DNA-binding domain of the protein that 
enters into the nucleus and binds to sterol response elements (SRE) sequence, 
increasing the expression of HMGCR and also of various other enzymes from 
cholesterol metabolism (e.g. LDLR).357 
Like other lipids, cholesterol has low water solubility and therefore requires 
special mechanisms and vehicles for transport. In the bloodstream, both 
cholesterol and triacylglycerol are transported within lipoproteins. These 
contain diverse apolipoproteins which mainly mediate the interaction with 
target molecules and cells, such as lipoprotein lipase on endothelial cells 
(ApoC2) or the LDL receptor (ApoE).354,358 
The cholesterol pool in liver cells derived from endogenous biosynthesis 
and/or chylomicron remnants, is esterified and packaged together with 
triacylglycerol and apolipoproteins into particles of very low-density 
lipoprotein (VLDL), released into the blood circulation to distribute lipid to 
peripheral tissues. Like chylomicrons, VLDL interacts with lipoprotein lipase 
and thereby turns into intermediate (IDL) and then low-density lipoprotein 
(LDL). LDL is taken up by cells in the periphery through endocytosis 
mediated by the LDL receptor.358 
Excess cholesterol is sensed into cells through several mechanisms such as 
LXR nuclear receptors, which are activated by cholesterol precursors and 
oxysterols, and then induce the transcription of genes involved in reverse 
cholesterol transport (RCT). Among these, membrane cells efflux transporters 
ABCA1 and ABCG1 mediate the efflux of cholesterol delivering it to high 
density lipoprotein (HDL), which then carries it back to the liver via scavenger 
receptor B1 (SR-BI) to be excreted through bile acids.353,354,359 Bile acids are 
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the quantitatively most important derivatives of cholesterol. Aside from their 
essential role in fat digestion, they are also required to keep hydrophobic 
constituents of the bile in solution, such as unconjugated bilirubin and 
cholesterol itself.360 
Cholesterol in the liver is catabolized through a series of cytochrome P450 
enzymes and pathways into oxysterols which are then transformed and 
conjugated with other molecules (e.g. taurine, glycine) in bile acids. Cholic 
acid, taurocholate, glycocholate are some examples of bile acids produced 
through conjugation with glycine.360 
In macrophages, as for other cell types, uptake of native LDL via the LDL-
receptor is regulated by negative feedback, which avoids intracellular 
cholesterol overload. In contrast to other cells, however, macrophages also 
have a number of so-called scavenger receptors, through which they bind and 
ingest various kinds of debris. Scavenger receptors do not take up native LDL 
and are not subject to cholesterol-dependent regulation. Oxidized or otherwise 
modified LDL, however, does enter via the scavenger receptors, which 
induces cholesterol overload and transforms the macrophages to foam cells. 
This is a crucial step in the pathogenesis of atherosclerosis.361 
The role of cholesterol in cancer cells 
Generally, for hypercholesterolemia is intended an imbalance of serum 
cholesterol counterparts with high levels of total and LDL cholesterol (the 
‘bad’ cholesterol), often accompanied by decreased levels of HDL cholesterol 
(the ‘good’ cholesterol).362  
In absence of genetic predisposition (e.g. LDL receptor deficiency)363, the 
most common cause of hypercholesterolemia in industrialized societies is the 
consumption of high-fat, high-cholesterol diets, known as Western-type diets 
(WDs).359 In addition to cardiovascular diseases (CVDs), increased serum 
cholesterol levels have been reported to be positively correlated with higher 
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risk of developing cancers, such as colon, rectal, prostate, testicular and breast 
cancer.364–366 
Elevated serum LDL levels and an opposed decrease of HDL were associated 
with increased development of metastasis and with a poor prognosis in 
initially metastatic colorectal cancer patients and in esophageal squamous cell 
carcinoma patients.367–369 Further, two meta-analysis demonstrated that high 
serum HDL cholesterol levels are associated with increased overall survival 
and disease-free survival in patients with different solid tumors, proposing 
HDL levels as a prognostic factor for the outcome of patients.366,370 
Observations based on cancer models further support the positive correlation 
between hypercholesterolemia and carcinogenesis. Using the murine MMTV-
PyMT breast cancer model, it was found that a high cholesterol diet enhanced 
the growth and metastasis of tumors.371 Statins treatment, the gold standard 
for lowering high cholesterol levels, is associated with reduced cancer-related 
mortality.372 
Despite these positive correlations between hypercholesterolemia and 
carcinogenesis, some epidemiologic observations suggest that no association 
exists. A recent meta-analysis found that five years of statins treatment had no 
effect on the risk of cancer-related death.373 More surprisingly, a clinical study 
involving patients with bladder cancer found that the tumors became more 
aggressive in more than half of patients treated with statins.374 Further, nine 
cohort studies involving healthy individuals performed in 1980s showed that 
low cholesterol was associated with colon and lung cancer, yielding the 
opposite conclusion.375  
While the contradictory epidemiologic studies fuel the controversy regarding 
a role for cholesterol in cancer, preclinical studies more consistently suggest 
involvement. The clearest evidences arise from deregulation of intracellular 




A gene expression profiling study identified 7 cholesterol synthesis’ genes 
upregulated in different cancers (sarcoma, acute myeloid leukemia, 
melanoma). The increased activity of these genes was directly correlated with 
decreased patient survival.376 A direct involvement in the regulation of 
cholesterol biosynthesis in cancer cells was shown by PI3K/AKT/mTOR 
signalling, also responsible of intracellular oncogenic signals.376,377 Further, in 
several cancer types, elevated mitochondrial cholesterol levels induced 
resistance to apoptotic signals.378 
Another example of cholesterol homeostasis’ gene deregulated in cancer cells 
is ABCA1 transporter which mediates cholesterol efflux. Decreased activity 
of ABCA1 promoted cancer cell survival by increasing mitochondrial 
cholesterol levels. ABCA1 activity is reduced in colorectal cancer cells, either 
through loss-of-function mutations or gene downregulation.379 
Cholesterol metabolites (steroids and oxysterols) have also been associated 
with the development of various cancers.376,380 Oxysterols play an essential 
role in cholesterol homeostasis, inhibiting cholesterol synthesis and enhancing 
its export by activating LXRs.381 Certain oxysterols have shown anti-
proliferative effects on various cancer types.376 However, 27-
hydroxycholesterol (27-OHC) has recently been shown to act as an estrogen 
receptor agonist in breast cancer, inducing tumor growth and metastasis.380 In 
breast cancer, decreased expression of CYP7B1 triggers accumulation of 27-
OHC.382 
As an important component of the cell membrane, cholesterol may be closely 
related to membrane receptors through which cholesterol could directly 
activate oncogenic signalling, such as the Hedgehog pathway and Wnt/β-
catenin pathway.383 Cholesterol is a vital structure of lipid rafts, necessary 
platforms for cellular transduction and cancer signalling. Changes in 
membrane cholesterol and cholesterol-rich membranes have been shown to 
affect cancer progression and invasion, also providing a signal transduction 
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platform for oncogenic signalling pathways. AKT is the major example of 
intracellular transducer interacting with membrane lipid components.384 
Overall, hypercholesterolemia may be an important factor in some types of 
cancer, such as breast and prostate cancer, which is supported by clinical and 
preclinical studies. However, because of the discrepant observations, another 
level of interaction should be considered, such as the tissue of origin of cancer 
and/or the immune response influence. 
1.7.2   Cholesterol metabolism and tumor-associated myeloid cells 
The association and interaction of hypercholesterolemia, inflammation and 
myeloid cells is widely characterized in the context of cardiovascular diseases 
and atherosclerosis.359,385,386 Indeed, the accumulation of absorbed LDL 
cholesterol into the intima of arterial wall generates inflammatory signals (e.g. 
IL-6, TNFa, IL-1b) inducing the increase in the hematopoietic output and the 
recruitment of myeloid cells, especially monocytes which infiltrate the artery 
wall and differentiate into macrophages. Herein, macrophages up-take 
massive quantities of LDL and oxidized LDL (ox-LDL) through several 
scavenger receptors and, thus, transforming in foam cells and contributing to 
atherosclerotic plaque formation and to subsequent pathological processes 
(Fig.20).359,387 
It has been well described that hypercholesterolemia is associated with a 
prominent expansion of immature monocytes, marked as Ly6Chi monocytes, 
which share some phenotypical features of monocytic Ly6Chi myeloid-
derived suppressor cells.388 Once infiltrated into tissue, monocytes 
differentiate into macrophages, which, beyond their activity of ‘LDL 
scavenging’ cells, exert dynamic inflammatory patterns, ranging between M1 





Moreover, it was demonstrated that hypercholesterolemia, specifically 
elevated LDL cholesterol, promotes hematopoietic stem cells (HSCs) 
proliferation, leading to increased production of GMP in the blood, as well as 
myelomonocytic differentiation, resulting in increased frequency of 
monocytes and neutrophils in the bone marrow and blood. In addition, 
elevated LDL cholesterol generates an increase of plasma levels of CXCL12 
which elevates the mobilization of CXCR4+ bone marrow progenitor cells. 
These effects of LDL appear to be counteracted by HDL.390,391 
 
Figure 20. Schematic representation of how hypercholesterolemia influences the functions of 
myeloid cells in cancer and atherosclerosis. Increased levels of serum LDL cholesterol and 
decreased HDL, contribute to: 1) hyperplasia and hypertrophy of adipose tissue, resulting in 
recruitment of macrophages and production of inflammatory factors (e.g. TNFa, IL-1b, IL-6); 2) 
activation of endothelial cells with the production of nitric oxide (NO) and cytokines; 3) 
proliferation, mobilization and differentiation of hematopoietic/myelopoietic progenitor cells; 4) 
fuel tumor microenvironment and cancerous cells to proliferate. The results is a chronic 
inflammatory state with an expansion of myeloid cells, which: A) differentiating in macrophages 
and scavenging LDL and ox-LDL contribute to formation (M1-like) and stabilization (M2-like) of 
atherosclerotic lesions; B) skewing to immunosuppressive phenotype (MDSCs), that inhibits 
cytotoxic T cells and promote tumor growth and metastasis.  
 
Recent evidences demonstrated that obesity in both mice and human increases 
the frequency of MDSCs.348,392 In particular, obese mice, both genetic (leptin 
deficient mice, ob/ob) and high-fat diet-induced models, together with higher 










































metastasis in different cancer models (breast, kidney, melanoma, prostate). 
Although some molecular mechanisms have been defined to drive 
obesity/MDSCs regulation (e.g. IL5, GM-CSF, CCL2/MCP-1, leptin), the role 
of metabolic components influencing this scenario remain still poor 
clarified.346,348,393–395 
In a recent characterization of granulocytic subsets in cancer patients, it has 
been unravelled that LOX-1, scavenger receptor for oxidized LDL, is a 
specific marker which distinguish the immunosuppressive PMN-MDSC 
subset from mature and pro-inflammatory neutrophils.396 
Oxysterols, biological active cholesterol derivatives, are highly represented in 
obesity and hypercholesterolemia.324,328 In the most common estrogen 
receptor-positive breast cancer, CYP27A1 enzyme converts cholesterol in 27-
hydroxycholesterol (27-OHC), which in turn, promotes primary tumor growth 
through the binding of estrogen receptor and increases metastatic process via 
liver X receptor (LXR).382,397 Recently, it has been shown that 27-OHC acts 
directly on HSC via ERα, leading to increased cell mobilization.398 
25-hydroxycholesterol (25-OHC) is generated directly from cholesterol by 
CH25H, and it is further converted into 7α,25-dihydroxycholesterol (7α,25-
OHC) by CYP7B1. Expression of Ch25h is upregulated in macrophages and 
dendritic cells after stimulation with various inflammatory mediators and, its 
product 25-OHC, in turn, augments the production of inflammatory cytokines 
in macrophages.399 Moreover, human monocytes treated in vitro with constant 
levels of oxysterols (i.e. 27-hydroxycholesterol) showed a prominent 
macrophage differentiation and polarization toward an M2 
immunomodulatory functional phenotype.400 
As already mentioned, 25-, 27-OHC as well as cholesterol precursors and 
other oxysterols interact with LXR nuclear receptors. LXRα and LXRβ are 
two isoforms involved in cholesterol homeostasis, regulating synthesis, uptake 
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and efflux of cholesterol. LXRs and their ligands exert an anti-inflammatory 
role in macrophages and dendritic cells (DCs).401  
LXRs/oxysterols signalling affects also tumor-associated immune cells. 
Indeed, oxysterols produced by tumor cells impair antigen presentation by 
inhibiting chemokine receptor 7 (CCR7) expression on DCs.402 Oxysterols 
promote tumor immunosuppression also by recruiting pro-tumor neutrophils 
in a LXRs-independent, C-C motif chemokine receptor 2 (CXCR2)-dependent 
manner.403 
The epigenetic reprogramming of innate immune cells induces a long-lasting 
pro-inflammatory phenotype, a phenomenon known as ‘innate immune 
memory’ or ‘trained immunity’. Emerging evidences indicate that not only 
pathogens, but also hypercholesterolemia and ox-LDL are capable to induce 
‘trained immunity’ via epigenetic modification of monocytes, and that this 
imprinting persists after treatment with statins despite normalization of 
circulating cholesterol.404,405 
Mice deficient in ABC transporters (ABCA1/ABCG1) show hyper-
proliferation of hematopoietic progenitor cells, resulting in monocytosis and 
neutrophilia and activation of inflammatory gene expression.406 The anti-
inflammatory capacities of ABCA1 and ABCG1 are probably because of their 
role in cholesterol efflux.407 
Hitherto, the role of reverse cholesterol transport in cancer-related immune 
response is controversial. ApoA1 and HDL were reported to exert an 
antitumor role in B16 melanoma mouse model, by skewing TAMs toward an 
M1 phenotype.408 
In contrast, the genetic absence of ABCG1, which, together with ABCA1, 
mediated cholesterol efflux and complexing it with ApoA1 in HDL –thus 
reducing reverse cholesterol transport–, is  associated with an anti-tumor M1 
phenotype of macrophages, increased NF-κB activation and inhibition of 
tumor growth in high-cholesterol diet-fed mice.409 
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These findings have been recently confirmed by another study where the block 
of cholesterol efflux in myeloid cells, by deletion of ABCA1 gene or ABCA1 
and ABCG1 genes, resulted in a significant reduction of tumor growth, 
associated with a reduction of MDSCs.410 More recently, in line with these 
evidences, it has been identified that membrane cholesterol efflux of 
macrophages via ABCA1/G1 enhances their pro-tumoral activation in 
response to the M2 polarizing IL-4 stimulus.411 
Characterizing the obese state by systemic and tissue-specific measures could 
provide more reliable identification of high-risk populations and a 
mechanistically informed approach for the development of effective 
prevention and treatment strategies that target cancers. This thesis aims to 
discuss the mechanisms through which adipose tissue inflammation fosters a 
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2.   Outline of the thesis 
 
During the last decade cancer immunotherapy has witnessed remarkable 
advances in the treatment of a number of malignancies. However, in some 
cancers and some patients, the success of cancer immunotherapy has been 
limited to partial or modest clinical responses, as well as to severe adverse 
effects. One of the great challenges to improve the efficacy of 
immunotherapy is deciphering the molecular network controlling cancer-
related immune alterations. 
Cancer growth provides an immunological stress perceived by hematopietic 
progenitors and resulting in modifications over the magnitude and 
composition of hematopoietic output (“emergency” hematopoiesis). Myeloid 
cells, in particular, abundantly expand in tumor bearers and infiltrate solid 
cancers where they are exposed to microenvironmental signals (e.g. 
cytokines, growth factors) and micro-pathophysiological conditions (e.g. 
hypoxia, pH, glucose levels) that reprogram their genetic programs towards a 
tumor-promoting phenotype. 
New evidence indicates that the metabolic instruction of immune response 
(immunometabolism) relates to the influence of metabolic pathways, 
expressed either by immune cells or systemically, on the differentiation and 
functions of immune cells. This metabolic/immune interplay is strongly 
affected by nutrition, microbioma metabolites as well as cancer-driven 
metabolic alterations.  
Although dynamic changes in myeloid cell heterogeneity and functions have 
been reported to parallel tumor progression, a large gap remains in our 
understanding of the molecular inflammatory, epigenetic and metabolic 
pathways guiding this cancer-driven “emergency” myelopoiesis. 
Tumor-associated macrophages (TAMs) and myeloid-derived suppressor 
cells (MDSCs) are two major myeloid populations associated with cancer 
development and are considered to have a major impact on the orchestration 
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of cancer-related inflammation, promoting the construction of a pro-tumor 
microenvironment that unleashes tumor growth and metastasis formation.  
Tumor-associated myeloid cells result from pathological expansions, 
differentiation and mobilization of bone marrow hematopoietic progenitors 
in response to inflammatory cytokines and growth factors (e.g. TGF-β, 
VEGF, IL-1b, IL-6, CSFs) secreted by growing cancers. Myeloid cell 
plasticity is exemplified in the M1 vs. M2 extremes of macrophage 
polarization, which respectively express pro- vs. anti- inflammatory 
functions and whose balance is a main determinant of cancer growth. 
Epigenetic reprogramming of regions encoding for receptors and 
transcription factors involved in myelopoiesis represents a key event in the 
pathological myelopoiesis of cancer bearers. While in last years, several 
advances have been achieved in the understanding of the molecular players 
regulating this pathologic process, several open questions remain. Hence, the 
common thread of our works is to decipher the driving mechanisms of 
differentiation and recruitment of myeloid cells in cancer disease. 
We previously reported that, during cancer progression, massive nuclear 
accumulation of p50 NF-κB drives the M2 polarization of tumor-associated 
macrophages (TAM), which share common gene signature with monocytic-
MDSC (Biswas KS et al Blood 2006). p50 NF-κB is a key intracellular 
transcription factor regulating positively (heterodimer p50/p65) or negatively 
(homodimer p50/p50) the expression of a multitude of genes involved in 
immunity and inflammation. However, little is still known about the 
involvement of p50 NF-κB in MDSCs expansion and functions. Hence, we 
investigated the role of p50 NF-κB in differentiation, recruitment and 
immunosuppressive functions of M-MDSCs. 
Another intriguing aspect we investigated is the interplay between immunity 
and metabolism (immunometabolism) in cancer berarers, pointing to 
obesity-related metabolic events as potential inducers of inflammation and 
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myelopoietic alterations. Our lab has recently identified RORC1/RORg as a 
pivotal transcription factor driving cancer-associated emergency 
myelopoiesis (Strauss L. et al Cancer Cell 2015). RORg is a nuclear receptor 
whose activity has been recently described at the molecular level to be 
enhanced by binding of cholesterol derivatives. However, the relevance of 
this molecular interaction has not been yet investigated, neither in tumor 
biology nor in innate immunity. Furthermore, high circulating cholesterol 
levels are known to promote expansion of the myelomonocytic lineage. 
Given this premise, we determined the impact of cholesterol metabolism on 



























Tumor-derived prostaglandin E2 promotes p50 NF-kB-dependent 
differentiation of monocytic MDSCs  
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Tumor-derived PGE2 induces nuclear p50 NF-κB, that epigenetically 
reprograms the response of monocytic cells to IFNg towards an 
immunosuppressive (NOS2high/TNFαlow) phenotype. Inhibition of the 
PGE2/p50 axis in vivo prevents the differentiation of suppressive MDSCs, 
retrieving the anticancer properties of IFNg.  
Abstract 
Myeloid-derived suppressor cells (MDSCs) include immature monocytic (M-
MDSCs) and granulocytic (PMN-MDSCs) cells that share the ability to 
suppress adaptive immunity and hinder the effectiveness of anti-cancer 
treatments. Of note, in response to interferon-γ (IFNγ) M-MDSCs release the 
tumor-promoting and immunosuppressive molecule nitric oxide (NO) 
whereas, in contrast, macrophages largely express anti-tumor properties. 
Investigating these opposing activities, we found that tumor-derived 
prostaglandin E2 (PGE2) induces nuclear accumulation of p50 NF-κB in M-
MDSCs, diverting their response to IFNγ towards NO-mediated 
immunosuppression and reducing TNFα expression. At genome level, p50 
NF-κB promoted binding of STAT1 to regulatory regions of selected IFNγ-
dependent genes, including inducible nitric oxide synthase (Nos2). In 
agreement, ablation of p50, as well as the pharmacological inhibition of either 
the PGE2 receptor EP2 or NO production, reprogrammed M-MDSCs towards 
an NOS2high/TNFαlow phenotype, restoring the in vivo antitumor activity of 
IFNγ. Our results indicate that inhibition of the PGE2/p50/NO axis prevents 






Microenvironmental signals are sensed by myeloid cells through cytokine 
and/or innate immune receptors, whose differential engagement leads 
different polarized programs.1,2 This functional plasticity is exemplified in the 
M1 vs M2 extremes of macrophage polarization1–3 and has major impacts in 
the orchestration of cancer-related inflammation, immunosuppression4–6 and 
clinical responses.2,7 Of note, a time-dependent M1 to M2 transcriptional 
reprogramming of myeloid cells was reported in response to prolonged 
exposure to Toll-like receptors (TLR) ligands (e.g. lipopolisaccharide) (i.e. 
LPS tolerance)8,9, which requires the nuclear accumulation of p50 NF-kB and 
results in altered responsiveness to polarizing cytokines, such as IFNg and IL-
4.8 Cancer fuels myeloid cells heterogeneity also by sustaining altered 
myelopoiesis10–13 that supports resistance to anticancer immunotherapy.14 Of 
relevance, divergent outcomes have been reported in response to 
immunotherapy, either with cytokines15–17 or checkpoint inhibitors.18,19 In 
particular, IFNg, originally termed “macrophage activating factor” 20, was 
paradoxically shown to be equally necessary for melanoma development and 
rejection.17 Indeed, IFNg has pleiotropic and contrasting effects in the tumor 
microenvironment. On one hand it exerts anti-angiogenic activities, 
suppression of pro-tumorigenic properties, enhancement of tumoricidal 
activity of macrophages and of processing and presentation of tumor antigens 
to T lymphocytes.15,21 On the other hand, IFNg promotes immunosuppressive 
functions in myeloid cells22 inducing expression of the immunosuppressive 
enzymes indoleamine 2,3 dioxygenase (Ido) and inducible nitric oxide 
synthase (Nos2), involved in the catabolism of L-tryptophan23 and L-
arginine12, as well as the ligand programmed-death receptor-ligand 1 (PD-L1, 
B7-H1)24, whose interaction with the co-inhibitory receptor Programmed 
Death-1 (PD-1) can be blocked to restore antitumor immunity.25 Mixed 
responses to IFNg were also reported in different human malignancies.15,16,26 
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We have previously reported that accumulation of nuclear p50 NF-kB plays 
an essential role in the M2 orientation of tumor-associated macrophages 
(TAM)8,10, which share common myeloid precursors and a similar M2-like 
gene signature with M-MDSC.10 Here, we investigated how tumor-derived 
signals affect transcriptional activities and myeloid cell functions in response 
to immune stimulatory cytokines and the impact of these events on cytokine-
mediated cancer immunotherapy.  
Results 
p50 NF-kB controls both M-MDSC suppressive functions and 
differentiation of myeloid precursors. 
Nuclear accumulation of p50 NF-kB, as occurring in TAMs and LPS-tolerant 
macrophages, impairs both M1 polarization and antitumor activities.8,10 
Similar to TAMs, confocal microscopy analysis showed selective nuclear 
accumulation of p50 NF-kB in splenic and tumor-infiltrating monocytic (M)–
MDSCs (CD11b+Ly6G-Ly6C+ cells) from fibrosarcoma (MN/MCA1) bearing 
mice, at advanced stages of tumor development (day 21; Fig.1A, 
Supplementary Fig.1A). As inhibition of T cells proliferation validated their 
suppressive activity (Supplementary Fig.1B), we explored whether p50 NF-
kB could be actually involved in accumulation of suppressive M-MDSC 
occurring during tumor development. According to our previous findings10,27, 
C57BL/6 p50-/- mice displayed both reduced tumor growth and metastasis 
formation, as compared to WT mice (Fig.1B), but, paradoxically, displayed 
increased accumulation of splenic myeloid cells expressing the M-MDSCs 
phenotype CD11b+Ly6G-Ly6C+ (Fig.1C and Supplementary Fig.1C), which 
coincided temporally with the nuclear accumulation of p50 (21 days) 
(Fig.1A). Hence, we analyzed whether these cells expressed genes encoding 
for immunosuppressive activities.28,29 Noteworthy, in the absence of p50, 
magnetically sorted splenic CD11b+Ly6G-Ly6C+ cells (Supplementary 
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Fig.1D) showed a drastic reduction of both Nos2 gene expression (Fig.1D) 
and NO production (Fig.1E), in response to IFNg treatment. Accordingly, p50 
depletion impaired in vivo NO production in tumor tissues (Supplementary 
Fig.1E). In contrast, expression of both arginase I (Arg1)22 and indoleamine-
2,3-dioxygenase (Ido1), Programmed Cell Death 1 Ligand 1 (Pd- l1) were 
poorly affected (data not shown) and not further investigated. To establish the 
actual role of p50 NF-kB in the suppressive activity of M- MDSCs, splenic 
CD11b+Ly6G-Ly6C+ cells isolated from tumor bearing mice were activated 
with IFNg and tested for antigen-specific suppressive activity. In keeping with 
the data above, p50-/- M-MDSC displayed reduced suppressive activity 
(Fig.1F, left), and NO levels in the co-culture supernatants (Fig.1F, right). The 
M-MDSC suppressive activity was NO-dependent, as addition of the NOS 
inhibitor L-NMMA to the co-culture abolished both T cell suppression 
(Fig.1F, left) and NO production (Fig.1F, right) and by the similar death rate 
of T cells observed in the presence or absence of MDSCs (data not shown). 
These data suggested that the NO-dependent suppressive capacity of M-
MDSCs in response to IFNg, relies on p50 nuclear accumulation. 
We next determined whether the nuclear accumulation of p50 was also 
observable in blood M-MDSCs22,30 from colorectal carcinoma patients (CRC). 
Compared to healthy donors, the frequency of M-MDSC (CD33+CD14+HLA-
DRlow/-) was increased (Fig.1G, left) and these cells showed higher nuclear 
levels of p50 (Fig.1G, center and right), along with increased NOS2 (Fig.1H, 
Supplementary Fig.2A). To confirm the role of p50 in human myeloid cells, 
circulating CD14+HLA-DR+ mononuclear cells from healthy donors were 
transfected with a small interfering RNA against p50 (p50 siRNA). Silencing 
of p50 (Supplementary Fig.2B), significantly inhibited NOS2 mRNA 




Figure 1. Role of p50 NF-kB in IFNg-induced NO-dependent suppressive activity of M-MDSC. (A) 
Confocal microscopy showing selective up-regulation of nuclear p50 NF-kB in the splenic M-MDSC 
subset during tumor growth (day 21). (B) Inhibition of both tumor growth (MN/MCA1) (data shown are 
mean±SD *p<0.01 by two-tailed two-way ANOVA, n=9 WT and n= 8 p50-/-
 
mice) and metastasis 
formation in p50 NF-kB–deficient mice (data shown are mean±SEM ***p<0.001 by two-tailed t-test, 
n=9 WT and n= 8 p50-/-
 
mice). (C) Increased number of M-MDSC (CD11b+Ly6G-Ly6C+
 
cells) in the 
spleen of p50-/-
 
tumor-bearing mice (data shown are mean±SEM *p<0.05 by two-tailed two-way 
ANOVA, n=5 WT and n= 5 p50-/-
 
mice). (D) Lack of p50 in M-MDSC impairs Nos2 mRNA expression 
in response to IFNg data shown are mean±SEM ***p<0.001, by two-tailed t-test n=4 WT and n=4 p50-
/-
 
biological replicates each run in triplicate). (E) Reduced IFNg-mediated NO production in p50-/-
 
M-
MDSC (data shown are from a representative experiment *p<0.05 by two-tailed t-test, n=3 WT and n=3 
p50-/-
 
technical replicates). (F) Left, decreased antigen-specific suppressive activity of p50-/-
 
M-MDSC 
in response to IFNg, at different MDSC:OT1 splenocytes ratio (data shown are from a representative 
experiment *p<0.05, ***p<0.001 by two-tailed t-test, n=3 WT and n=3 p50-/-
 
technical replicates). 
Right, decreased NO production in the co-culture supernatants of IFNg-treated p50-/-
 
M-MDSC, as 
compared to WT M-MDSC. L-NMMA, nitric oxide synthase inhibitor. (data shown are from a 
representative experiment *p<0.05, ***p<0.001 by two-tailed t-test, n=2 technical replicates). (G), Left, 
Increased number of CD33+CD14+HLA-DRlow/-
 
cells in blood from CRC patients (*p<0.05 two-tailed 
t-test; n=3 healthy donors n=6 CRC patients). Center, Representative confocal microscopy on nuclear 
p50 in peripheral blood CD14+HLA-DRlow/-
 
cells from CRC patients, as compared to peripheral blood 
mononuclear CD14+
 
cells from healthy donors (scale bars are 10μm). Right, MFI of nuclear and nuclear 
vs cytoplasmic ratio of p50 in CD14+HLA-DRlow/-
 
cells from CRC patients (**p<0.01; ***p<0.001 by 





cells in blood from healthy donors and CRC patients (*p<0.05 by two-tailed 
t-test n=3 healthy donors n=6 CRC patients).  
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The predominant increase in the M-MDSCs subset within the spleen of tumor-
bearing mice might result from its accelerated proliferation rate or preferential 
skewing of precursors. To study the implication of p50 in normal 
hematopoiesis, we evaluated the BM for composition in hematopoietic stem 
cells (HSC), along with their proliferation and differentiation potential. HSCs 
are immunophenotypically defined as cells lacking lineage specific markers 
(Lin-) but expressing Sca-1 and c-Kit (Lin-Sca-1+c-kit+, LSK), while the 
methylcellulose-based colony-forming unit (CFU) assay allows to quantify 
their derived progeny in vitro. We observed a significant enrichment of LSK 
progenitors (Lin-Sca-1+c-kit+) in BM of p50-/- mice (Fig.2A-B), associated 
with higher clonogenic potential of p50-/- HSCs in both GM-CFU and M-CFU 
progenitors, but not in G-CFU (Fig.2C). These results indicate that lack of p50 
results in a preferential skewing of HSC towards the monocytic branch at the 
myeloid/granulocytic bifurcation. Accordingly, histopathological analysis 
showed a severe impairment of terminal granulopoiesis in the BM of p50-/- 
mice, which was associated with an increased number of immature myeloid 
precursors (Fig.2D). Consistently, the hematopoietic parenchyma of p50-/- 
mice was characterized by the marked reduction of mature segmented 
granulocytes and by the expansion of myeloid blasts showing abnormal 
interstitial localization and aggregation in clusters (Fig.2D). Monocytic 
differentiation (Fig.2E), as well as erythropoiesis and megakaryocitopoiesis 
(data not shown) was preserved in the BM of p50-/- mice. Consistent with BM 
histopathology, flow cytometry revealed a neat decrease in the Gr1+c-Kit- 
granulocytic population and a paralleled increase in Gr1+c-kit+ myeloblasts in 
p50-/-, as compared to control WT BM (Fig.2F). Accordingly, blood 
granulocytes from p50-/- mice were enriched in immature and blast-like forms 
compared with circulating granulocytes from WT controls (Fig.2G). 
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Figure 2. p50 deficiency in the BM stroma associates with enhanced myelopoiesis. BM cells from WT 
and p50-/-
 
mice were stained with mAb to c- Kit, Sca-1 and lineage-specific markers (CD3, CD11b, 
CD11c, Gr-1, B220, ter119). LSK progenitors were defined as Sca1+
 
cells within the gate of lin-c Kit+
 
cells. (A) Representative FACS analysis of LSK progenitors in WT and p50-/-
 
BM. (B) Collective data 
showing that the fraction of LSK progenitors is increased in p50-/-
 
mice (*p<0.05 by two-tailed t-test 
n=6 WT and n=6 p50-/-
 
mice). (C) Hematopoiesis was analyzed using a clonogenic colony culture assay. 
The relative number of total BM-CFU, GM-CFU and M-CFU myeloid colonies was significantly 
increased in p50-/-
 
mice compared to the WT counterpart. (**p<0.01,***p<0.001 by two-tailed t-test 
n=6 WT and n=6 p50-/-
 
mice). (D) Histopathological analysis (H&E) of the BM of p50-/- and control 
WT mice. The BM hematopoietic parenchyma of p50-/- mice is characterized by the marked impairment 
of terminal granulopoiesis and by the increase in the density of immature myeloid precursors and blasts 
that show aggregation in clusters. Red arrows indicate myeloid blasts. Original magnifications: upper 
panels, scale bars are 100μm; lower panels, scale bars are 50μm. (E) Monocytic differentiation is 
preserved in the BM of p50-/-
 
mice, as testified by the presence of cells with mature monocytic 
morphology and by the normal density of hemosiderin-laden macrophages. scale bars are 50μm. (F) 




granulocytes in BM from WT and p50-/-
 
mice. 
The fraction of immature granulocytes is increased in the absence of p50 in comparison to the WT 
counterpart (***p<0.001 by two- tailed t-test n=6 WT and n=6 p50-/-
 
mice). (G) Morphologic analysis 
(left) and quantification (right) of Giemsa-stained peripheral blood smears from 12 weeks-old p50-/-
 
and 
WT mice showing that circulating granulocytes from p50-/-
 
mice are enriched in immature and blast-like 
forms (*p<0.05 by two-tailed t- test n=6 WT and n=6 p50-/-
 
mice). (H) Cytofluorimetric analysis of IRF8 
in M- (CD11b+Ly6G-Ly6C+
 
cells) and PMN-MDSC (CD11b+Ly6G+Ly6Clow/-
 
cells). (*p<0.05 by two-





Overall, these results confirm previous observations31 and demonstrate that 
p50 NF-kB deficiency is associated with defective granulocytic differentiation 
in favor of the monocytic lineage. Of relevance cytofluorimetric analysis of 
tumor infiltrating MDSC revealed a significant increase of the negative 
regulator of MDSC expansion IRF832 expression by the p50-deficient PMN-
MDSC subset (CD11b+Ly6G+ cells) (Fig.2H), which also acts as promoter of 
terminal monocytic maturation.33 This result is in agreement with the 
preferential expansion of non-suppressive Ly6C+ monocytic cells (M-MDSC-
like) observed in tumor bearing p50-deficient mice.  
Hematopoietic deletion of p50 NF-kB abolishes NO production by  
M-MDSCs and impairs metastasis formation  
 
To establish whether the expression of p50 NF-kB in the hematopoietic 
compartment was uniquely responsible for the suppressive activity of M-
MDSCs, we generated chimeric mice by transplanting WT or p50-/- BM cells 
into sub-lethally irradiated WT and p50-/- mice, which were subsequently 
implanted with the MN/MCA1 fibrosarcoma. Splenic CD11b+Ly6G-Ly6C+ 
cells isolated from mice receiving p50-/- BM cells, and subsequently activated 
with IFNg, were strongly impaired in their capacity to suppress both T cell 
proliferation and NO production (Fig.3A). To investigate further the in vivo 
importance of p50 in the hematopoietic compartment, we used the deleter 
strain B6.Cg-Tg(Tek-Cre)1Ywa to ablate p50 in all hematopoietic lineage 
cells (p50Tie2 mice).34 In agreement with Figure 1A and B, we observed 
inhibition of lung metastasis formation in tumor bearing p50Tie2 mice, which 
was paralleled by an increased number of splenic and tumor-infiltrating 
CD11b+Ly6G-Ly6Chigh cells, while an increase of CD11b+Ly6Clow/-Ly6G+ 
cells was observed at the tumor site (Fig.3B and Supplementary Fig.3A). 
Further, splenic and tumor-associated CD11b+Ly6G-Ly6C+ cells from p50Tie2 
mice (Fig.3C) showed decreased NOS2 but higher TNFa expression, 
associated with increased number of both splenic and tumor-infiltrating IFNg 
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expressing CD4+ and CD8+ T cells (Fig.3D), these latter also expressing high 
levels of the cytotoxic molecule Granzyme B (GZMB). Of note, 
transplantation of B16 melanoma cells35 in p50Tie2 mice fully recapitulated the 
phenotype of the MN-MCA1 fibrosarcoma, both in terms of tumor growth 
(Supplementary Fig.3B) and accumulation of splenic and tumor-infiltrating 
immune cells (Supplementary Fig.3C-E).  
 
Figure 3. Myeloid-specific p50 NF-kB reprograms innate ad adaptive immune functions. (A) Splenic 
M-MDSC from p50-/-
 
BM-transplanted mice display reduced suppressive activity (left) and NO 
production (right) in response to IFNg. Proliferation was assessed by 3H-thymidine incorporation 
(*p<0.05; **p<0.01; ***p<0.001 by two-tailed one-way ANOVA n=6 technical replicates of T cells 
only, n=3 technical replicates of pooled WT mice with WT BM, n=3 technical replicates of pooled WT 
mice with p50-/-
 
BM, n=3 technical replicates of pooled p50-/-
 
mice with WT BM, n=2 technical 




BM). NO production by a technical triplicate (n=3) for each 








n=5). Center and right, increased 
number of splenic and tumor infiltrating M-MDSC (CD11b+Ly6G-Ly6C+) and PMN-MDSC 
(CD11b+Ly6G+Ly6Clow/-) respectively in p50Tie2
 



















tumor- bearing mice 
(**p<0.01 by two-tailed t-test; n=5 p50flox
 
and n=5 p50Tie2 mice). Bottom, flow cytometry analysis of 
TNFa in tumor-infiltrating M- and PMN-MDSC from p50flox and p50Tie2 tumor-bearing mice (**p<0.01 













mice (*p<0.05, **p<0.01 









mice; GZMB tumor n=5 p50flox
 
and n=5 p50Tie2 mice).  
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p50 influences IFNg-induced Stat1 recruitment to a subset of p50-
dependent genes  
Since the absence of p50 has strongly altered the response of CD11b+Ly6G-
Ly6C+ cells to IFNg, we further investigated this aspect. IFNg-induced Stat1 
phosphorylation36 was not reduced in the absence of p50 (Fig.4A) suggesting 
that downstream events occurring in p50-/- cells could be responsible for 
defective IFNg-mediated gene expression. To directly assess this hypothesis, 
we generated mRNA sequencing (mRNA-Seq) data sets of wt and p50-/- 
CD11b+Ly6G-Ly6C+ cells, 
isolated from the spleen of tumor bearing mice, treated or not with IFNg. p50-
/- CD11b+Ly6G-Ly6C+ cells showed selective gene expression defects in 
response to IFNγ stimulation as compared to WT controls (Fig.4B and 
Supplementary Table 1). Using as cut-offs a log2(fold change) ≥ 1 and a FDR 
≤ 0.05, 15 (2.4%, cluster 2) of the 628 genes induced by IFNg in WT 
CD11b+Ly6G-Ly6C+ cells 15 (2.38%) were down-regulated in p50-/- cells, 
whereas 16 (2.5%) were up-regulated. Analysis of the generated gene profiles 
confirmed that p50 deficiency results in a significant impaired induction of 
Nos2 (Fig.4C) along with an increased induction of some interferon inducible 
genes, such as Oas1g and Pyhin1/Ifix, (Supplementary Table 1). Collectively, 
our data highlight a specific function of p50 in controlling a subset of 
functionally relevant genes in response to IFNg stimulation. Since 
transcriptional responses to IFNg predominantly rely on the Stat1 transcription 
factor, we evaluated the recruitment of Stat1 on the Nos2 gene using 
Chromatin Immunoprecipitation (ChIP) with a validated antibody directed 
against Stat1.37 Lack of p50 reduced binding of Stat1 on the Nos2 gene in 
CD11b+Ly6Chigh cells under both steady state and IFNg-treatment (Fig.4D), 
therefore indicating that p50 controls IFNg-dependent responses at epigenetic 
level. 
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Along with MDSCs, macrophages produce NO in response to IFNg, which 
mediate either their immunosuppressive5,22 or tumoricidal capacity38. Similar 
to M-MDSCs, in thioglycollate elicited macrophages (PECs) lack of p50 
decreased Nos2 mRNA expression and NO production in response to IFNg 
(Supplementary Fig.4A), without reducing Stat1 phosphorylation 
(Supplementary Fig.4B). In further analogy with MDSCs, PECs primed with 
the tumor supernatant (TSN) produced higher level of NO in response to IFNg, 
in a p50-dependent manner (Supplementary Fig.4C). Moreover, 
transcriptional analysis (mRNA-Seq) of WT and p50-/- PECs, confirmed that 
 
Figure 4. Effects of p50 deficiency on gene expression and STAT1 binding in splenic M-MDSC, from 
tumor bearing mice, treated with IFNg. (A) M-MDSC from WT and p50-/-
 
tumor-bearing mice were 
isolated from spleen and stimulated with IFNg for 15’. Cells were stained with an anti-P- Stat1 antibody 
and analyzed by FACS (*p<0.05 by two-tailed t-test n=2 WT and n=2 p50-/-
 
biological replicates) (B) 
Heatmap showing selective gene expression alterations in p50-/-
 
M-MDSC stimulated with IFNg for 4 
hours (n=2 WT and n=2 p50-/-
 
biological replicates). Data obtained with two biological replicates were 
highly correlated (R2>0.97) indicating high reproducibility between samples. For each transcript, the 
expression level (log2-transformed FPKM) is z-score scaled (red: highly expressed; blue: lowly 
expressed). In the vertical bar, colors indicate six groups of genes (Red: IFNg-induced genes up-
regulated in p50-/-
 
M-MDSC; orange: IFNg induced genes down-regulated in p50-/-
 
M-MDSC; light 
grey: IFNg induced genes not affected by p50 ablation; blue: IFNg repressed genes down-regulated in 
p50-/- M-MDSC; light blue: IFNg repressed genes up-regulated in p50-/-
 
M-MDSC; grey: IFNg repressed 
genes not affected by p50 ablation. The number of genes belonging to each group is indicated on the 
left. (C) A representative snapshot of RNAseq expression data for the Nos2 and Tnf genes. (D) 
Chromatin immunoprecipitation showing impaired recruitment of STAT1 on regulatory regions of the 
NOS2 promoter, in splenic M-MDSC from p50-/-
 
tumor bearing mice mice treated with IFNg 
(***p<0.001 by two-tailed one-way ANOVA n=3 WT and n=3 p50-/-
 
technical replicates).  
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p50-/- PECs showed selective gene expression defects in response to IFNg 
(Supplementary Fig.4D and Supplementary Table 2), including Nos2. On the 
other hand, in agreement with Figure 2H, p50 deficiency resulted in an 
increased induction of the monopoiesis-inducing transcription factor Irf8 
33(Supplementary Table 2). We then performed ChIP coupled to next-
generation sequencing (ChIP-Seq). Almost all DNA binding events occurred 
only after Stat1 activation (Supplementary Table 3) and positively correlated 
with IFNg-induced gene expression in a statistically significant manner 
(Supplementary Fig.4E), highlighting the prominent role of Stat1 as a 
transcriptional activator. A discrete fraction of the Stat1 cistrome was 
selectively affected by p50 deficiency, with an abrogation or reduction of 
Stat1 occupancy at 2571 sites (8.3% of all inducible peaks) in p50-/- PEC 
relative to WT controls. For instance, we confirmed that Stat1 was not 
efficiently recruited to either promoters or enhancers of Nos2 gene in p50-/- 
macrophages, and this was associated with its reduced induction in response 
to IFNg (Supplementary Fig.4F). These observations were then validated at a 
genomic scale by computationally integrating our ChIP-Seq and mRNA-Seq 
datasets (Supplementary Table 4). As shown in Supplemental Fig.4G, p50-
dependent genes were located at shorter distances from p50-dependent Stat1 
peaks than p50-independent genes. Conversely, p50-independent genes were 
closer to p50-independent Stat1 peaks.  
These findings identify a role for p50 in controlling IFNg-induced Nos2 gene 
expression in myeloid cells, and are consistent with a model of p50- dependent 
assistance of Stat1 recruitment to selected p50-dependent genes in response to 




Ablation of p50 NF-kB in M-MDSCs restores the in vivo antitumor 
activity of IFNg  
We next investigated whether increased nuclear p50 NF-kB in M-MDSCs 
limits cytokine-mediated immunotherapy in vivo. While IFNg treatment of 
WT tumor-bearing mice was ineffective, the same treatment significantly 
reduced tumor development in p50-/- mice (Fig.5A). Noteworthy, in vivo 
depletion of CD4+ and CD8+ T cells in p50 NF-kB-deficient tumor bearing 
mice restored tumor growth (Fig.5A, center) and metastasis formation 
(Fig.5A, right), indicating that myeloid-specific p50 NF-kB is suppressing 
specific anti-tumor immunity. Hence, to test the specific contribution of p50 
to the immunosuppressive activity of M-MDSCs, p50-/- tumor-bearing mice 
were adoptively transferred with WT M-MDSCs (1x106) and treated daily 
with IFNg. Such M-MDSCs transfer restored tumor growth in p50-/- mice 
(Fig.5B) and decreased both IFNg production and GZMB expression by CD8+ 
T cells, both in the spleen and the primary tumor (Fig.5C-D). Of note, transfer 
of p50-/- CD11b+Ly6G-Ly6C+ cells did not affect tumor growth, as well as the 
phenotype of CD4+ and CD8+ T cells. These data demonstrate that 
accumulation of nuclear p50 in M-MDSCs promotes their suppressive 
functions in blunting the efficacy of cytokine-mediated immunotherapy (i.e. 
IFNg). This conclusion was further strengthened observing that ablation of 
p50 in tumor bearing mice improved the antitumor and anti-metastatic activity 
of the immunostimulatory cytokine IL-12 (Supplementary Fig.5).  
Tumor-derived PGE2 primes M-MDSCs for higher IFNg-induced NO-
mediated suppressive activity 
In the attempt to identify tumor-derived signals controlling nuclear p50 
accumulation, we used BM-MDSC39 to test molecules detected in the tumor 
supernatants (TSN) (Fig.6A) and reported to either induce nuclear 
accumulation of p50 NF-kB homodimers in macrophages (i.e. PGE2, IL-10, 
TGFb)10 or myeloid cell differentiation (GM- CSF, G-CSF and M-CSF). 
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Figure 5. Ablation of p50 NF-kB in M-MDSC restores IFNg-mediated antitumor activity in vivo. (A) 
Left, antitumor effects of IFNg in WT vs p50-/-
 





T cells in p50 NF-kB-deficient tumor bearing mice abolishes the antitumor activity of IFNg in 
terms of tumor growth (data shown are mean±SEM P value was calculated by two-tailed two-way 
ANOVA, n=5 WT vehicle treated mice, n=5 p50-/-
 
vehicle treated mice n=5 WT IFNg treated mice, n=6 
p50-/-
 
IFNg treated mice, n=6 p50-/-
 
anti-CD4/CD8 and IFNg-treated mice) and metastasis formation 
(***p<0.001 by two-tailed one-way ANOVA n=4 WT IFNg treated mice, n=4 p50-/-
 
IFNg treated mice, 
n=5 p50-/-
 
anti-CD4/CD8 and IFNg treated mice). (B) Adoptive transfer of WT M-MDSC in p50-/-
 
tumor-bearing mice abolishes the antitumor activity of IFNg in vivo, restoring tumor growth. (data 
shown are mean±SEM, P value was calculated by two-tailed two-way ANOVA n=8 WT mice, n=8 p50-
/-
 





T cells for IFNg and GZMB expression and effector memory phenotype (CD62L-
CD44+CD8+
 









M-MDSC mice) and (D) tumor (P<0.05, 




























Confocal microscopy analysis showed that neither M-, GM- nor G-CSF 
induced p50 accumulation (Supplementary Fig.6A). In contrast, PGE2 
efficiently induced nuclear p50, whereas the PGE2 receptor antagonists EP2 
(AH6809) and EP4 (AH23848)40 inhibited the TSN-induced nuclear 
accumulation of p50 (Fig.6B). Furthermore, BM-MDSCs primed with TSN 
showed higher levels of both Nos2 mRNA and NO production in response to 
IFNg (Fig.6C), which was prevented by AH6809 (Fig.6D). In agreement, pre-
treatment with Butaprost, a selective agonist of EP2, enhanced IFNg-mediated 
NO production in a p50-dependent manner (Fig.6D). Nuclear p50 
accumulation was also promoted by IL-10, however neutralization of TSN-
derived IL-10 only marginally reduced its priming activity (not shown).  
We next evaluated the capacity of AH6809 to interfere with the MN/MCA1 
fibrosarcoma in vivo. Daily treatment with AH6809 inhibited tumor growth in 
WT but not in p50-/- mice (Fig.6E, left) and reduced the number of lung 
metastasis in WT mice (Fig.6E, right). In agreement with the phenotype of 
p50-/- mice (Fig.3C-D), flow cytometry of tumor tissue (MN/MCA1) from 
tumor-bearing WT mice, showed that AH6809 treatment significantly reduced 
the expression of NOS2 (Fig.6F, left) by CD11b+Ly6G-Ly6C+ cells, while 
increasing the expression of TNFa (Fig.6F, center), as well as the IFNg+CD4+ 
and IFNg+CD8+ T cells (Fig.6F, right). Similar results were obtained in splenic 
M-MDSCs (Fig.6G). Further supporting the pro-tumoral activity of the PGE2-
p50-NO axis, in vivo treatment with AH6809 displayed an antitumor effects 
comparable with an antibody against the PD-1 immune checkpoint inhibitor 
(anti-PD-1), both in terms of primary tumor growth (MN/MCA1) and lung 
metastasis formation (Supplementary Fig.6B), while the expression of NOS2 
in CD11b+Ly6C+ WT M-MDSCs cells was reduced to levels comparable with 
p50-/- M-MDSC (Supplementary Fig.6C).  
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Figure 6. Tumor-derived PGE2 promotes p50 NF-kB mediated suppressive M-MDSC functions. (A) 
Levels of IL-10, TGFb, PGE2, GM-CSF, G-CSF and M-CSF in n=2 independent TSN, estimated by 
ELISA. (B) Right, confocal microscopy of p50 NF-kB in BM-derived M-MDSC conditioned with either 
TSN, PGE2 (10μM and 20 μM) or TSN plus the EP2 antagonist AH6809 or the EP4 antagonist 
AH23848 (scale bars: 10 μm). Post 48 hrs of in vitro activation, cells were stained with anti-p50 NF-kB 
antibody (green) and nuclei were counterstained with DAPI (blue). Left, quantification of p50 NF-kB 
nuclear fluorescence intensity (**p<0.01, ***p<0.001, by two tailed one-way ANOVA, medium n=34 
nuclei, PGE2 10 μM n=62 nuclei, PGE2 20 μM n=71 nuclei, TSN n=96 nuclei, TSN+AH6809 n=70 
nuclei, TSN+AH23848 n=61 nuclei). (C) TSN primes IFNg-treated MDSC for enhanced expression of 
NOS2 mRNA and NO production (***p<0.001 by two-tailed one-way ANOVA, n=3 technical 
replicates of a representative experiment). (D) Inhibition of NO production by the EP2 receptor 
antagonist AH6809, in TSN-primed and IFNg-treated WT and p50-deficient BM-MDSC (**p<0.01, 
***p<0.001 by two-tailed one-way ANOVA, n=3 technical replicates of a representative experiment). 
(E) Left, AH6809 inhibits fibrosarcoma growth (data shown are mean±SEM; *p<0.05 by two-tailed 
two-way ANOVA: n=6 WT vehicle mice, n=6 WT AH6809 treated mice, n=6 p50-/-
 
vehicle mice, n=6 
p50-/-
 
AH6809 treated mice) and lung metastasis formation in tumor-bearing WT mice (**p<0.01 by 
two-tailed t-test n=5 WT vehicle treated mice, n=6 WT AH6809 treated mice). (F-G) FACS analysis of 
infiltrating immune cells in tumor (F) and spleen (G) of fibrosarcoma (MN/MCA1) bearing WT mice 
treated with AH6809 or untreated (vehicle), and expression evaluation of NOS2 and TNFa in M-MDSC 




T cells. Data pooled from two different experiments (*p<0.05, **p<0.01 
by two-tailed t-test. Tumor, TNFa in M-MDSC n=6 WT vehicle and n=6 WT AH6809 treated mice, 
NOS2 in M-MDSC n=7 WT vehicle and n=7 WT AH6809 treated mice; IFNg in CD4+
 
T cells n=6 WT 
vehicle and n=6 WT AH6809 treated mice; IFNg in CD8+
 
T cells n=7 WT vehicle and n=7 WT AH6809 
treated mice. Spleen, NOS2 and TNFa in M-MDSC and IFNg in CD8+
 
T cells n=4 WT vehicle and n=4 
WT AH6809 treated mice, IFNg in CD4+
 
T cells n=3 WT vehicle and n=3 WT AH6809 treated mice). 
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In agreement, treatment of B16 bearing WT mice with AH6809 reduced tumor 
growth and NOS2 expression by CD11b+Ly6C+ M-MDSC, mimicking p50 
NF-kB ablation (Supplementary Fig.6D). 
 
Figure 7. Blocking NO production restores the anti-tumor activity of IFNg in vivo. (A) L-NMMA 
treatment reduces melanoma (B16) growth in WT mice and releases the antitumor activity of 
IFNγ (data shown are mean±SEM P value was calculated by two-tailed two-way ANOVA n=5 WT 
Vehicle treated mice, n=5 IFNγ treated mice, n=5 L-NMMA treated mice, n=5 IFNγ + L-NMMA treated 
mice). (B) L-NMMA reduces the expression of NOS2 (Top) and increases the expression of TNFa 
(Bottom), in tumor-infiltrating M-MDSC (*p<0.05 by two-tailed one-way ANOVA n=5 WT Vehicle 
treated mice, n=5 IFNγ treated mice, n=5 L-NMMA treated mice, n=5 IFNγ+L-NMMA treated mice). 
(C) L-NMMA enhances tumor infiltration of IFNγ-expressing CD8+
 
T cells (*p<0.05 by two-tailed one-
way ANOVA n=4 WT Vehicle treated mice, n=5 IFNγ treated mice, n=5 L-NMMA treated mice, n=4 
IFNγ+L-NMMA treated mice). (D) Representative flow cytometry of EP2 receptor and NOS2 
expression in peripheral blood M-MDSC from CRC patients (n=5 CRC patients). (E) Flow cytometry 
analysis of NOS2 in IFNγ-treated human peripheral blood monocytes primed with TSN from the human 





Finally, we investigated the effect of NO on the antitumor activity of IFNg in 
vivo. WT B16-bearing mice were then treated with IFNg and/or with L-
NMMA. While treatment with IFNg elicited poor effects on tumor growth, L-
NMMA alone displayed a significant antitumor effect, which was enhanced 
in combination with IFNg (Fig.7A). Moreover, L-NMMA, and even more its 
combination with IFNg, reduced the expression of NOS2 by tumor M-MDSC 
(Fig.7B, top) and enhanced the expression of TNFa (Fig.7B, bottom), while 
increasing the number of tumor-infiltrating IFNg+CD8+ T cells (Fig.7C). 
These results indicate NO as a terminal mediator of suppressive myeloid cell 
functions and suggest that blocking the PGE2-p50-NO axis either upstream 
(i.e. EP2 inhibitors) or downstream (i.e. NOS2 inhibitor L-NMMA) may 
restore antitumor immunity.  
To corroborate this finding in cancer patients, we analyzed the expression of 
both the PGE2 receptor EP2 and NOS2 in PBMCs from patients with 
advanced colorectal cancer (CRC; stage T2/T3; n=5). In agreement with 
mouse data, human M-MDSCs (HLA-DRlow/-CD14+CD33high) 
(Supplementary Fig.2A) expressed the PGE2 receptor EP2 (Fig.7D). 
Moreover, human peripheral blood monocytes primed with TSN from the 
human pancreatic carcinoma cell line PANC1, containing 923 μg/ml of PGE2, 
and subsequently treated with IFNg showed higher levels of intracellular 
NOS2 protein, that were reduced by treatment with AH6809 (Fig.7E). While 
confirming the suppressive activity of PGE2 in cancer bearers41, our results 
are the first to identify the PGE2-driven nuclear accumulation of p50 NF-kB 






Cancers support a pathological generation of immunosuppressive and tumor-
promoting MDSC populations22,29, that share phenotypic traits with TAMs, 
including the expression of anti-inflammatory M2 polarized genes.10 Here, we 
demonstrate that tumor-derived PGE2 drives the suppressive phenotype of M-
MDSCs through upregulation of nuclear p50 NF-kB, a key player in the 
resolution of the inflammatory response, that links unresolved cancer- 
inflammation with tolerance.8,42  
Accumulation of nuclear p50 NF-kB, in both mouse (CD11b+Ly6G-Ly6C+) 
and human (CRC patients) (CD14+HLA-DRlow/-) M-MDSCs, diverts their 
transcriptional responses to IFNg towards enhanced production of the 
immunosuppressive molecule NO. Consistently, ablation of p50 NF-kB 
reactivated specific antitumor immunity and reinstated the in vivo antitumor 
activity of IL-12 and IFNg, two immunostimulatory cytokines evaluated in 
clinical trials against various human tumors (e.g. CRC, soft tissue sarcoma, 
melanoma and plasma cell neoplasms).16 This observation provides new 
insights into the ambivalent action of IFNg 21,43,44, which in clinical protocols 
has shown either moderate or poor efficacy.15,17,45 This ambiguity is 
reminiscent of the bimodal immunological activities of IFNg, which promotes 
transcription of genes involved in the activation of immune responses (e.g. 
MHC class I and class II, IL-12)46 and simultaneously induces 
immunosuppressive pathways, including B7-H147,48 and the 
immunosuppressive enzymes IDO23 and iNOS/NOS222,29. The biological 
activity of IFNg requires the nuclear translocation and the DNA binding of the 
STAT1 homodimer to gamma activated sequence (GAS) sites on the 
promoters of downstream target genes49, including Nos250. Accumulation of 
p50 NF-kB in myeloid cells does not affect IFNg-dependent STAT1 
phosphorylation, but rather controls their chromatin landscape to promote 
binding of STAT1 onto specific gene regulatory elements of IFNg-responsive 
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genes, including Nos2. We also observed that lack of p50 results in increased 
CD11b+Ly6G-Ly6C+ cells in the spleen of tumor-bearing mice, with low NO 
production and suppressive activity, as well as in the preferential skewing of 
HSCs towards the monocytic branch in the bone marrow. This hematopoietic 
output is in agreement with the IRF8high feature we observed in p50-deficient 
PMN-MDSCs, since IRF8 is a cell fate switching factor driving terminal 
differentiation of the monocytic lineage33 and preventing MDSC expansion32. 
COX2-stimulated production of PGE2 enhances the expansion of MDSCs and 
promotes suppression of adaptive immunity51. We show that antagonists of 
the PGE2 receptors EP1/EP2 reprogram M-MDSC functions in response to 
IFNg towards an inflammatory phenotype (i.e. NOS2low/TNFhigh), associated 
with increased specific anti-tumor immunity. Of relevance, in analogy with 
the results obtained both with the inhibition of PGE2 receptors and with the 
ablation of the NF-kB p50 gene, the NOS L-NMMA inhibitor reprogrammed 
the M-MDSCs towards an NOS2low/TNFhigh phenotype, associated with an 
increased antitumoral effect of IFNg. This evidence indicates the 
gasotransmitter NO 52 as the final effector of the pro-tumoral reprogramming 
of myeloid cells, guided by the PGE2/p50 axis.  
COX inhibitors (e.g. aspirin) were suggested for prevention and treatment of 
cancer41. Nevertheless, due to their severe side effects, targeting specific 
prostanoid receptors endowed with immunosuppressive properties, such as 
EP2 53–55, might provide an alternative selective and safer approach to burst 
specific immunity in cancer patients. Our work indicates that p50 NF-kB 
accumulation diverts the differentiation and activation status of myeloid cells, 
leading to the resolution of immune and inflammatory responses. It further 
demonstrates that in cancer an accumulation of p50 NF-kB, induced by PGE2, 
acts as an epigenetic hacker of M-MDSC functions, which establishes their 
suppressive phenotype, suggesting the use of PGE2 receptor antagonists as 
potential adjuvants for anticancer immunotherapy.  
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Materials and Methods 
Mice and ethics statement. The study was designed in compliance with: Italian 
Governing Law (Legislative Decree 116 of Jan. 27, 1992); EU directives and 
guidelines (EEC Council Directive 86/609, OJ L 358, 12/12/1986); Legislative 
Decree September 19, 1994, n. 626 (89/391/CEE, 89/654/CEE, 89/655/CEE, 
89/656/CEE, 90/269/CEE, 90/270/CEE, 90/394/CEE, 90/679/CEE); the NIH Guide 
for the Care and Use of Laboratory Animals (1996 edition). All experiments 
involving animals described in this study were approved by the Ministry of Health 
(authorization numbers 160/2012-B and 25/2018-PR). The study was approved by 
the scientific board of Humanitas Clinical and Research Center. Mice have been 
monitored daily and euthanized when displaying excessive discomfort. p50 NF-kB 
deficient mice on the C57BL/6J background were available in the laboratory.27 The 
NFKB1flox/flox (p50flox) mice was recently generated.42 p50flox
 
mice were crossed 
with B6.Cg-Tg(Tek-Cre)1Ywa mice (Jackson Laboratories, Bar Harbor, Maine, 
USA) to generate p50flox; Tie2Cre mice (p50Tie2
 
mice). OT-I mice were obtained from 
Jackson Laboratories (Bar Harbor, Maine, USA).  
Tumor models. 8 weeks old mice were injected intramuscularly in the left leg with 
105
 
cells of murine fibrosarcoma (MN/MCA1) or subcutaneously with 5x105
 
cells of 
murine melanoma (B16). Tumor growth was monitored 3 times a week with a caliper.  
MDSC purification. MDSC were purified from the spleens of tumor-bearing mice 
by magnetic separation (MACS Miltenyi). In detail, CD11b+GR1+
 
cells were 
obtained by staining splenocytes with a purified rat anti-mouse GR1 antibody (BD 
pharmingen) followed by positive selection with anti-rat IgG microbeads (MACS, 
Miltenyi). M-MDSCs (CD11b+Ly6C+Ly6G-) and PMN-MDSC 
(CD11b+Ly6G+Ly6Clow) populations were first enriched by consequent serial 
negative selections with CD19 and CD11c microbeads, according to manufacturer’s 
instruction. Then Ly6G+
 
cells were positively selected with Ly6G microbeads kit. 
Remaining cells were positively selected with CD11b+
 
microbeads, which all stained 
positive for the Ly6C marker. Cell population purity was assessed by flow cytometry. 
Cell culture and reagents. Bone marrow MDSC (BM-MDSC) were derived from 
bone marrows (BM) cells isolated from C57BL/6 mice as previously described.39 
Mouse BM cells were obtained from the femurs and tibias. After blood cells lysis, 
BM cells were cultured for 4 days in RPMI- 1640 containing 10% FBS, 2 mmol/L 
glutamine, 100 units/mL penicillin- streptomycin, 10mM HEPES and 20 μM beta-
mercaptoethanol and supplemented with 40 ng/ml of murine recombinant IL6, GM-
CSF and G-CSF (Peprotech). If needed, cells were washed with PBS and detached 
with EDTA 2mM and plated for the experiments. Peritoneal Exudate Macrophages 
(PEC) were obtained as previously described.10 Human monocytes were isolated 
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from peripheral blood as previously described8 and cultured in RPMI-1640 
containing 10% FBS, 2 mmol/L glutamine, 100 units/mL penicillin-streptomycin. 
The concentration for the different treatments were as follows: MN/MCA1 tumor 
supernatant, dilution ratio 1:1 to medium, human pancreatic carcinoma cell line 
PANC1 supernatant (30%), PGE2 (Sigma) 10-5
 
mol/L, PGE2 receptor (EP2) agonist 
Butaprost (Sigma) 10-5
 
mol/L, PGE2 receptor (EP2/EP1) antagonist AH6809 (Tocris) 
10-5
 
mol/L, murine IFNγ (Peprotech) 200U/ml, M-CSF (Peprotech) 20ng/ml, GM-
CSF (Peprotech) 20ng/ml, GCSF (Peprotech) 20ng/ml, LPS (ALX-581-009, Enzo 
Life Sciences) 100ng/ml, human IFN (Peprotech) 20ng/ml.  
Real-time PCR. Real-time PCR was performed as previously described (Biswas et 
al., 2006). The sequences of the murine NOS2 gene-specific primers are: (Fw: 
gccaccaacaatggcaaca; Rev: cgtaccggatgagctgtgaatt).  
Nitrite production. 2*105
 
cells were plated and stimulated with IFNγ (Peprotech 
200U/ml) for indicated time points. Nitric oxide production was evaluated in culture 
supernatant using the Griess Reagent System (Promega). Equal volumes of 
supernatant (50 μl) and 1% sulfanilamide in 5% phosphoric acid were incubated at 
RT for 10 min, followed by addition of 0.1% N-1-naphthylethylenediamine 
dihydrochloride in water. After 10 min at RT, absorbance at 550 nm was measured. 
Nitrite concentrations were determined by comparing absorbance values to a standard 
curve generated by serial dilution of 0.1 mM sodium nitrite.  
Suppression assay. M-MDSCs (CD11b+Ly6C+Ly6G- cells) isolated from the spleen 
of WT MN-MCA1 tumor-bearing mice were plated in 96 wells at a final 
concentration of 24% and 12% of total cells and co-cultured with splenocytes from 
naive C57Bl6 mice, labelled with 1µM CFSE, in the presence of anti-CD3 (3µg/ml, 
2C11, Biolegend) and anti-CD28 (2µg/ml, 37.5, BD). After 3 days of co-colture, cells 
were stained and CFSE signal of gated lymphocytes was used to analyze cell 
proliferation. For antigen-specific suppression assay Mixed-lymphocyte reaction was 
performed as previously reported (Strauss et al., 2015) M-MDSC isolated from the 
spleen of tumor bearing mice were then stimulated with IFNg (200U/ml), in the 
presence or absence of 500μM of L- NG-monomethylarginine (L-NMMA, 
Calbiochem). At day 3, 50 μl of supernatant were tested for NO production (as 
control) and 2*105
 
splenocytes from OT-I mice were added for additional 72h in the 
presence of 250 μg/ml of ovalbumin peptide (OVA257–264) (Sigma). [3H]-
thymidine was added for the last 16 hours of culture and its incorporation was 
analyzed by MicroBeta plate counter (Perkin Elmer). As controls OT-1 splenocytes 
alone were pulsed with OVA peptide (250 μg/mL) or kept in culture media. All 
conditions were evaluated in triplicates.  
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Isolation of MDSCs from colorectal cancer (CRC) patients. The study was 
approved by the Institute Ethical Committee, and written informed consent was 
obtained from patients. 20 ml of peripheral blood were collected from healthy donors 
and T2 or T3 CRC patients. CRC patients did not receive radiation or chemotherapy 
before sample collection. Blood was stratified on Ficoll gradient to separate 
peripheral blood mononuclear cells (PBMC). All blood samples were analysed within 
3 hr after collection by FACS-analysis. Briefly, 1*106
 
cells were re-suspended in 
HBSS (Hank’s balanced salt solution, Lonza) supplemented with 0.5% BSA (Sigma). 
Staining was performed at 4°C for 30 minutes, with a cocktail of mAbs to HLA-DR-
Pacific Blue (clone L243); CD14-PE, -APC, -FITC (clone M5E2); CD33-PerCp-
Cy5.5 (clone WM53); iNOS/NOS Type II-FITC (Clone 6/iNOS/NOS Type II), from 
BD Bioscience or BioLegend. Further, we used unconjugated rabbit monoclonal anti 
human EP2R (clone EPR8030(B); Abcam) followed by incubation with secondary 
goat anti rabbit Alexa Fluor® 488 conjugated antibody (Life Technologies). For 
intra-cellular staining, Foxp3/Transcription Factor Staining Buffer Set (eBioscience) 
were used according to the manufacturer’s instruction. Cells were detected using the 
BD FACSCantoTM II or BD LSRFortessaTM and analyzed with BD FACSDiva and 
FlowJo (9.3.2) software. When needed, cells were stained, sorted using a BD 
FACSAriaTM-III cell sorter and subsequently analyzed by confocal microscopy.  
Bone marrow (BM) colony formation. BM cells were isolated from the tibias and 
femurs of WT or p50-/-
 
mice and the colony formation capacity was measured by 
detection and quantification using MethoCultTM GF M3434, that supports optimal 
growth of granulocyte-macrophage progenitors (CFU-GM, CFU-M, CFU-G), of 
erythroid progenitors (BFU-E) and and multi-potential granulocyte, erythroid, 
macrophage, megakaryocyte progenitors (CFU-GEMM). 12 days after seeded, 
colonies were counted independently by two separate operators. 
Histopathological analysis of mice BM. Sections of WT and p50-/-
 
BM were 
routinely stained with Haematoxylin and Eosin (H&E) and analyzed by an expert 
pathologist (CT) using a Leica DM2000 optical microscope (x400 and x630 
magnification) and microphotographs were collected with a Leica DFC320 digital 
camera using the Leica IM50 imaging software.  
Quantification of circulating granulocytes in peripheral blood smears. Cell 
counts were visually performed on five May-Grunwald Giemsa-stained smears on 
high-power microscopic fields (x400 magnification) and the average number of total 
and immature granulocytes was determined by averaging the counts.  
BM transfer. 5*106
 
CD45.1 WT and p50-/-
 
BM cells were injected intravenously in 
sub-lethally irradiated (900cGy) CD45.2 p50-/-
 
mice and littermate controls. BM 
reconstitution was evaluated 8 weeks after transplantation by flow cytometry on 
peripheral blood and was over 90%.  
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Flow cytometry and sorting. Splenocytes were collected from spleen after 
disaggregation and filtration through Falcon strainers (70 μm). Primary tumors were 
cut into small pieces, disaggregated with 0.5 mg ml-1
 
collagenase IV and 150 U ml-1
 
DNase I in RPMI-1640 for 30 min at 37°C and filtered through strainers. Cells (106) 
were re-suspended in HBSS (Hank’s balanced salt solution, Lonza) supplemented 
with 0.5% BSA (Sigma) and the staining was performed at 4°C for 20 minutes with 
specific antibodies. The following antibodies were used: CD45-FITC, -PerCP (Clone 
30-F11); CD11b-PerCp- Cy5.5, -APC, -PE-Cy7, -FITC (Clone M1/70); Gr1-PE 
(Clone RB6-8C5); Ly6G-PE, -APC, -FITC, BV570 (Clone 1A8); Ly6C-PE, -FITC,-
APC-Cy7, -PE-Cy7, -APC (Clone HK1.4); MHCII-PE (Clone M5/114.15.2); CD8-
APC, (Clone 53-6.7); CD3-PerCp, -PE, -BV650 (Clone 145-2C11); CD4-APC, PE-
Cy7 (Clone GK1.5); IFNγ-PE, -FITC (Clone XMG1.2); lineage markers (PE-CD3, - 
CD4, -CD8, –Mac-1, –Gr-1, -Ter119, and -B220); hematopoietic progenitor markers 
(Sca-1, c- Kit/CD117); CD44-FITC (Clone IM7); CD62L-APC, -BV570 (Clone 
MEL-14); TNFa-APC, -PE-Cy7 (Clone MP6-XT22); CD31-PE, (Clone MEC 13.3); 
PDL1-PE, (Clone 10F.9G2); Granzyme B-PE, -AF700 (Clone GB11); IRF8-PE, 
(Clone V3GYWCH), from BD Bioscience, eBioscience, BioLegend or Miltenyi 
Biotech. Further we used unconjugated we used unconjugated rabbit polyclonal anti-
mouse iNOS (ab 15323, Abcam) followed by incubation with secondary goat anti 
rabbit Alexa Fluor® 488 conjugated antibody (Life Technologies). Cell viability was 
determined by LIVE/DEADTM Fixable Violet Dead Cell Stain Kit (Thermo Fisher), 
negative cells were considered viable. For intra-cellular staining Foxp3/Transcription 
Factor Staining Buffer Set (eBioscience) were used according to the manufacturer’s 
instruction. Cells were detected using the BD FACSCantoTM II or BD LSRFortessaTM 
and analyzed with BD FACSDiva and FlowJo (9.3.2) software.  
mRNA Sequencing (mRNA-Seq). Total RNA was extracted from 1-5*106
 
M- 
MDSC (RNeasy kit, Qiagen), and 2-5 μg were used to generate sequencing libraries 
with a Truseq RNA Sample Prep Kit V2 (Illumina) according to the manufacturer’s 
instructions. Sequencing was performed on a HiSeq2000 (Illumina).  
Chromatin Immunoprecipitation (ChIP). ChIP was carried out with a previously 
described high-throughput protocol.37,56 Briefly, immunoprecipitation was performed 
by incubating the chromatin at 4°C overnight with Stat1 p84/p91 (M-22) antibody 
(Santa Cruz Biotechnology) or normal rabbit IgG (Millipore) as negative control. 
Then, ChIP DNA fragments and input DNA were analyzed by qPCR using the 
following NOS2 gene specific primers (Fw: tgagctaacttgcacacccaactgg; Rev: 
tgtaaagttgtgaccctggcagca). ChIP-enriched DNA was compared with input DNA, 
according to the formula 100 × 2(Input Ct – sample Ct). 
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In vivo treatments. MN/MCA1-bearing C57BL6 mice were injected daily with 10U 
of murine recombinant IFNg (Peprotech) or vehicle intramuscularly, from day 3 after 
tumor injection. When specified, starting from the day before tumor injection, mice 
received an intraperitoneal (i.p.) injection of 0,3 mg anti-mouse CD4 (Rat Anti-
Mouse CD4 Monoclonal Antibody, Unconjugated, Clone GK1.5, BioXcell) and 0,3 
mg anti-mouse CD8 (Rat Anti-Mouse CD8a Monoclonal Antibody, Unconjugated, 
Clone 2.43, BioXcell), once a week for the entire experimental period. FACS analysis 




cells depletion for 7 days. 
Murine recombinant IL-12 (Peprotech) were administrated i.p. twice a week 
(100ng/mouse), starting from day 7 after tumor injection. Anti-PD-1 antibody (clone 
RPM1-14, BioXcell) were administrated i.p. (200μg/mouse) twice a week, starting 
10 days after tumor cells injection. MN/MCA1- and B16-bearing C57BL6 mice were 
i.p. injected daily with 5mg/kg of the PGE2 receptor antagonist AH6809 (Tocris) or 
vehicle, starting from day 10 after tumor injection.  
Adoptive cell transfer. 8 weeks old C57BL/6 WT and p50-/-
 
mice were injected 
intramuscularly in the left leg with 105
 
cells of MN/MCA1 and treated with IFNg as 
described above. One week after tumor injection p50-/-
 
mice were adoptively 




M-MDSC, that were immune 
magnetically purified from the spleen of tumor-bearing mice.  
Enzyme-linked Immunosorbent Assay (ELISA). Murine GM-CSF, G-CSF, M-
CSF, IL6, IL-10, IL1β and TGF-β (R&D Systems) and PGE2 (Cayman) were tested 
by ELISA kits according to the manufacturers’ instruction.  
Silencing of p50 in human monocytes. Human monocytes were isolated from 
peripheral blood as previously described.8 3x106 cells were transfected with 30pmoli 
of p50-specific Stealth RNAi siRNA (NFKB1VHS40876) or scramble (Invitrogen) 
by Amaxa® Human Monocyte Nucleofector® Kit according with manufacturers’ 
instruction (Lonza). After 24h cells were left untreated or stimulated with 200ng/ml 
of human IFNγ (Peprotech) for 4h. Cell extracts were analyzed by SDS-PAGE (10% 
acrylamide) as described.27 Immunoblotting was performed with rabbit anti-p50 (no. 
1141) antisera57 and anti-vinculin antibody (Santa Cruz Biotechnologies). Real-time 
PCR was performed as previously described27 with the following gene-specific 
primers: NOS2 (Fw: aaagaccaggctgtcgttga; Rev: acgggaccggtattcattct), NFKB1/p50 
(Fw: gcttaggagggagagcccac; Rev: tctgccattctgaagccggg) and actin (Fw: 
cccaaggccaaccgcgagaagat; Rev: gtcccggccagccaggtccag). 
Confocal microscopy on tumor MDSC. Murine fibrosarcoma (MN/MCA1) were 
processed as previously described10 than, MDSC were enriched by positive selection 
with CD11b microbeads, according to manufacturer’s instruction (MACS, Miltenyi). 
CD11b+
 
cells were plated on poly-Lys 12 well and fixed with PFA 4%, than 
unspecific binding sites were blocked with Donkey Serum % + BSA 2% + Triton X-
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100 0,1% + NP-40 0,2% in PBS-Tween20 0,05% for 1h. Cells were stained with the 
following primary antibodies: rat monoclonal [ER-MP20] anti-Ly6C (#ab15627 
Abcam), rat anti- mouse Ly-6G (#551459 BD Bioscience), rabbit monoclonal anti-
p50 (clone E381, Abcam). After 1h of incubation at RT, goat anti-rabbit AlexaFluor-
647 and goat anti-rat AlexaFluor-488 conjugated were used as secondary antibodies. 
Nuclei were stained with DAPI (#D1306 Life Technologies) and then mounted with 
ProLong Antifade Gold Reagent (P-36931 Life Technologies). The slides were 
analyzed with an Olympus Fluoview FV1000 laser scanning confocal microscope. 
Confocal images were processed with a Gaussian filter and intracellular mean 
fluorescence intensity was quantified using FluoView software TV10-ASW 
application software for spectral analysis (version 3.1a; Olympus). 
Confocal microscopy on BM-MDSC and PEC. Cells were seeded on Poly-L-
Lysine (Sigma-Aldrich) coated sterile rounded glasses at 2x105
 
cells/ml in medium 
and fixed with 4% PFA for 10 minutes at room temperature. Cell permeabilization 
was obtained after 1 h incubation with PBS 0.1% Triton-X100 (Sigma-Aldrich) plus 
5% normal goat serum (Dako Cytomation, Carpinteria, CA USA) and 2% BSA, 
(Amersham Biosciences, Piscataway Township, NJ USA). Cells were then incubated 
with rabbit anti-mouse p50 NF-kB (NLS, sc-114; Santa Cruz) or rabbit anti-mouse 
p65 NF-kB (c-20, sc-372; Santa Cruz). After 1 h of incubation at RT, goat anti-rabbit 
AlexaFluor-647 or goat anti rabbit AlexaFluor-488 conjugated (Life Technologies) 
were used as secondary antibodies. Nuclei were counterstained with DAPI 
(Invitrogen, Molecular Probes). Samples were mounted with FluorPreserve Reagent 
(Calbiochem San Diego, CA USA) and analyzed with an Olympus Fluoview FV1000 
laser scanning confocal microscope using a fine focusing oil immersion lens (40X, 
N.A. 1.3) at 1 Airy Unit resolution and operating in channel mode with 405 and 633 
nm excitations. (40×1.30 NA Plan-Apochromat; Olympus). The mean fluorescence 
intensity of the nucleus was quantified after a freehand drawing considering the 
nucleus as regions of interest using FluoView software (version 3.1a; Olympus).  
NO detection in vivo. For in situ NO quantification, murine fibrosarcomas were 
harvested in PBS containing Glucose 1%, then included in Low Melting Point 
Agarose 6% and cut with the vibratome (LEICA) in slides 200mm wide. Next, slides 
were stained with Diaminorhodamine-4M AM (DAR- 4M- AM)58 solution (#D9194 
SIGMA-ALDRICH) 2,5mM for 2 h at 37°C in RPMI with FBS 10%, Gln 1% and 
Pen/Strep 1% then fixed with PFA 4%. Nuclei were stained with DAPI (4',6-
diamidino-2-phenylindole) (#D1306 Life Technologies) and then mounted with 
ProLong Antifade Gold Reagent (P-36931 Life Technologies). Analysis was 
performed with an Olympus Fluoview FV1000 laser scanning confocal microscope. 
Samples were acquired with fine focusing oil immersion lens (60X, N.A. 1.35) at 1 
Airy Unit resolution and operating in channel mode with 633 nm excitations. The 
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resulting fluorescence emissions were collected using 425-to-475 nm (for DAPI) and 
655-to-750 nm (for DAR-4M-AM) band-pass filters. Confocal images were 
processed with a Gaussian filter and intracellular mean fluorescence intensity was 
quantified using FluoView software TV10-ASW application software for spectral 
analysis (version 3.1a; Olympus).  
Statistics. Statistical significance between two groups was determined by two-tailed 
Student’s t test or two-way ANOVA corrected for multiple comparison by Sidak’s 
test and among more than two groups by one-way or two-way ANOVA corrected for 
multiple comparison by Tukey’s test (Prism 6). *p<0.05; **p<0.01; ***p<0.001.  
Computational Methods. 
RNA-SEQ. After quality filtering according to the Illumina pipeline, paired-end 
reads (76 bp for M-MDSC and 51 bp for PECs) were mapped to the mm9 reference 
genome and to the Mus musculus transcriptome (Illumina's iGenomes reference 
annotation downloaded from UCSC http://support.illumina.com/sequencing/ 
sequencing_software/igenome.html). We used TopHat v1.3.159 allowing up to two 
mismatches and specifying a mean distance between pairs (-r) of 150 bp for M-
MDSC and of 250 for PEC. Differential gene expression was evaluated with an exact 
test for the negative binomially distributed counts using edgeR v3.10.5 with limma 
v3.24.15 (Bioconductor package, https://bioconductor.org/packages/release/bioc/ 
html/edgeR.html)60–63. Read counts for edgeR analysis were obtained with the 
software htseq-count v. 0.5.3p964. Only genes with a sum of reads of at least 10 
between all 8 conditions were considered. To reduce the amount of bias in the 
experiments, we adjusted the standard Counts Per Million (CPM) for all 8 conditions 
with the Trimmed Mean of M-values (TMM) using the calcNormFactors function 
from the edgeR Bioconductor package. With respect to standard normalization, TMM 
normalization have the advantage to reduce deeply the false positive rate63.  We 
modelled the data variability estimating the dispersion of the negative binomial 
model using the quantile-adjusted Conditional Maximum Likelihood (qCML) 
method. We first used the (qCML) estimateCommonDisp function and then the 
(qCML) estimateTagwiseDisp function, both from the edgeR Bioconductor package. 
We finally computed exact p-values for the negative binomial distribution using the 
function exactTest making a pairwise comparisons between the following groups:  
 - WT samples stimulated with IFNγ versus WT untreated samples; 
 - p50-/-
 
samples stimulated with IFNγ versus WT samples stimulated with IFNγ. 
Only coding genes according to the Ensembl release-67 annotation 
(http://ftp.ensembl.org/pub/release-67/gtf/mus_musculus/) were considered. 
Inducible genes were selected according to the adjusted p-value (FDR<0.05, using 
the Benjamini-Hochberg (B-H) correction) and according to the intensity of signal 
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(2-fold). In order to compare expression between genes and to compensate for 
different gene lengths, also the Fragment Per Kilobase of exon Per Million 
(FPKM>1.5 in at least one replicate condition) were considered. We selected 
inducible genes also according to the adjusted counts (TMM-CPM>0.1), therefore, 
in the WT samples, we eliminated very low expressed genes which are, erroneously 
detected as induced or repressed because of bias in the experiment. Inducible genes 
whose intensity of expression either decreased or increased after IFNγ stimulus in 
absence of p50-/-
 
are respectively named down- or up-regulated p50-dependent genes 
(FDR<0.05, two-fold). The group of inducible genes whose intensity of expression 
is not affected by p50 is defined p50-indep genes. Selective gene expression 
alterations in both p50-/-
 
M-MDSC and PEC stimulated with IFNγ for 4 h (two 
biological replicates) are shown in heatmaps. Gene expression levels (log2-
transformed FPKM) are z-score scaled. Raw data sets are available at the Gene 
Expression Omnibus data repository (GSE84468): http://www.ncbi.nlm.nih.gov/ 
geo/query/acc.cgi?token=obkjowgcpbelrkx&acc=GSE84468.  
CHIP-SEQ. After quality filtering according to the Illumina pipeline, short reads (51 
bp), were mapped to the mm9 genome using Bowtie v0.12.7 (Langmead et al., 2009). 
Only uniquely mapping reads with two or fewer mismatches (-m1 –v2) were retained. 
STAT1 genomic occupancy in WT and p50-/-
 
PEC. Peak calling was performed 
using MACS v1.465 with default parameters and bw=100. Each ChIP was compared 
to input DNA derived from BM-derived macrophages (GEO accession: 
GSM499415). We defined “IFNg-inducible” the peaks that were 1) induced in treated 
vs untreated samples, 2) repressed in untreated vs treated samples (threshold of 1e−10 
for peak calling) and 3) enriched with respect to the input genomic DNA (threshold 
of 1e−5). We used a threshold of 1e−5 to define p50-dependent STAT1 peaks.  
p50 influences IFNg-induced STAT1 recruitment to a group of p50-dependent 
genes in PEC. Each induced gene was assigned to the nearest STAT1 peak according 
to the distance between the TSS (Transcription Start Site) of each gene and the 
summit of STAT1 induced peaks. The genomic distances (log2 base pair) between 
genes and the nearest Stat1 peak are represented with box plots. Box plots of the 
genomic distances (log2 base pair) between p50-dependent (or p50-independent) 
genes and p50-dependent (or p50-independent) Stat1 peaks are also shown. In order 
to evaluate significant differences between specific groups, a Wilcoxon signed-rank 
test was applied (p<0.01). 
Track visualization. Tracks for the UCSC genome browser66 were generated using 
the unique mapping reads and were linearly rescaled to the same sequencing depth. 
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Supplementary Fig.1. Related to Fig.1. (A) Confocal microscopy showing up- regulation of 
nuclear p50 NF-κB in tumor-infiltrating M-MDSC (***p<0.001 by two-tailed t- test n=49 nuclei 
of PMN-MDSCs n=65 nuclei of M-MDSC). (B) M-MDSCs (Ly6Chi Ly6G- cells) isolated from 
the spleen of WT MN-MCA1 tumor-bearing mice were plated in 96 wells at a final concentration 
of 24% and 12% of total cells and co-cultured with splenocytes from naive C57Bl6 mice, labelled 
with 1uM CFSE, in the presence of anti- CD3/CD28. After 3 days of co-colture, cells were stained 
and CFSE signal of gated lymphocytes was used to analyse cell proliferation. (D) The scatterplot 
shows the purity of the monocytic (M-) and granulocytic (PMN-) MDSC subsets, following 
purification by magnetic cell sorting from the spleen of tumor-bearing mice. (C) Gating strategy 
used to analyse murine spleen MDSCs of tumor bearing mice. (E) NO production in tumor tissues 
from WT and p50-/-
 
mice. NO was detected with Diaminorhodamine-4M AM (DAR-4M-AM). 





Supplementary Fig.2. Related to Fig.2. (A) Representative gating strategy of NOS2 expressing 
M-MDSCs in PBMC from CRC patients. (B) p50 siRNA-mediated silencing of p50 NF-κB in 
circulating CD14+HLA-DR+ mononuclear cells from healthy donors. (C) Effects of p50 silencing 
on IFNγ-induced NOS2 mRNA expression levels (mean±SD of one out of two independent 
experiments with similar results. *p<0.05 by two-tailed t-test n=3 technical replicates for each 





Supplementary Fig.3. Related to Fig.3. (A) Gating strategy used to analyze murine tumor 
infiltrating MDSCs. (B) B16 tumor growth in p50flox and p50Tie2 mice (*p<0.05 by two-tailed two-
way ANOVA, n=7 p50flox and n=7 p50Tie2 mice). (C) Increased number of spleen and tumor-
infiltrating M-MDSCs (CD11b+Ly6G-Ly6C+) in p50Tie2 tumor-bearing mice (*p<0.05 by two-
tailed t-test spleen, n=6 p50flox mice and n=8 p50Tie2 mice; tumor, n=8 p50flox mice and n=8 p50Tie2 
mice). (D) Flow cytometry analysis of NOS2 and TNFα expression in splenic M-MDSC, from 
p50flox and p50Tie2 tumor bearing mice. (*p<0.05, **p<0.01, ***p<0.001 by two-tailed t-test, spleen 
NOS2 n=6 p50flox mice and n=8 p50Tie2 mice, tumor NOS2 n=3 p50flox mice and n=3 p50Tie2 mice; 
spleen TNFα n=5 p50flox mice and n=4 p50Tie2 mice, tumor TNFα n=8 p50flox mice and n=8 p50Tie2 
mice). (E) Flow cytometry analysis of IFNγ and GzmB in CD4+ and CD8+ T cells, from p50flox and 
p50Tie2 tumor bearing mice (*p<0.05, **p<0.01, ***p<0.001 by two-tailed t-test, spleen IFNγ n=8 
p50flox mice and n=8 p50Tie2 mice; tumor IFNγ n=8 p50flox mice and n=8 p50Tie2 mice; GzmB n=8 





Supplementary Fig.4. Related to Fig.4. Effects of p50 deficiency on gene expression and Stat1 binding 
in macrophages treated with IFNγ. (A) Decreased Nos2 mRNA expression (left) and NO production 
(right) by IFNγ-treated p50-/- PEC. (**p<0.01, ***p<0.001 by two-tailed t-test, mRNA expression data 
shown are mean±SD n=2 WT and n=2 p50-/- biological replicates; NO production data are from one 
representative experiment, data shown are mean±SD n=3 WT and n=2 p50-/- technical replicates). (B) 
TSN primes IFNγ-treated PEC for enhanced NO production. (**p<0.01, by two-tailed one- way 
ANOVA, data are from one representative experiment, data shown are mean±SD n=2 WT and n=2 p50-
/- technical replicates). (C) Stat1 phosphorylation in WT vs p50-/- PEC in response to IFNγ treatment. 
Data are from one representative experiment. (D) Heatmap showing selective gene expression defects 
in p50-/- macrophages (PEC) stimulated with IFNγ for 4 hours (n=2 biological replicates). Data obtained 
with two biological replicates were highly correlated (r2>0.96). For each gene, the expression level 
(log2-transformed FPKM) is z-score scaled (red: highly expressed; blue: lowly expressed). In the 
vertical bar, colors indicate six groups of inducible genes, according to the response to p50-/- (red: IFNγ-
induced genes up-regulated in p50-/- vs WT PEC; orange: IFNγ-induced genes down- regulated in p50-
/- vs WT PEC; light grey: IFNγ-induced genes not affected by p50; blue: IFNγ-repressed genes down-
regulated in p50-/- vs WT PEC; light blue: IFNγ-repressed genes up-regulated in p50-/- vs WT PEC; grey: 
IFNγ-repressed genes not affected by p50). The number of genes belonging to each of the six clusters is 
indicated on the left. (E) Box plot shows the genomic distances (log2 bp) between genes induced and 
repressed by IFNγ and the nearest induced Stat1 peak. (F) A representative snapshot of Nos2 gene with 
impaired mRNA induction and Stat1 recruitment at their regulatory elements in p50-/- PEC stimulated 
with IFNγ. Arrows and black bars indicate sites of defective Stat1 occupancy. (G) Box plot of the 
genomic distances (log2 bp) between p50-dependent (or p50-independent) inducible genes and p50-
dependent (or p50-independent) Stat1 induced peaks, showing a direct correlation between 
transcriptional defects and reduced Stat1 binding in p50-/- macrophages treated with IFNγ. Wilcoxon 
signed-rank test was used to calculate p values in E and G (p<0.01).  
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Supplementary Fig.5. Related to Fig.5. Ablation of p50 NF-κB restores IL-12-mediated antitumor 
activity in vivo. Left, tumor growth (MN/MCA1) in WT vs p50-/- mice (data shown are ±SEM P 
value was calculated by two-way ANOVA Vehicle n=5 WT mice, Vehicle n=5 p50-/- mice, IL-12 
n=4 WT mice, IL-12 n=5 p50-/- mice). Right, metastasis formation in WT vs p50-/- tumor bearing 
mice. (data shown are ±SEM ***p<0.001 **p<0.01, *p<0.05 by two-tailed one-way ANOVA 


















Supplementary Fig.6. Related to Fig.6. Tumor supernatant (TSN) induces nuclear p50 NF-κB in BM-
MDSCs. (A) Left, confocal microscopy of p50 and p65/RelA NF-κB in BM-derived M-MDSCs 
conditioned with either TSN, M-CSF, G-CSF or M-CSF plus G-CSF (M/G-CSF). Right, mean 
fluorescence intensity (M.F.I.) of nuclear p50 and p65 in BM- derived M-MDSCs conditioned with 
either TSN, M-CSF, G-CSF, M-CSF plus G-CSF (M/G- CSF), as indicated. PEC stimulated for 2h with 
LPS were used as positive controls. (**p<0.01 ***p<0.001 by two-tailed one-way ANOVA n=29 p50 
nuclei and n=36 p65 nuclei medium, n= 119 p50 nuclei and n=71 p65 nuclei TSN, n=64 p50 nuclei and 
n=71 p65 nuclei G-CSF, n=38 p50 nuclei and n=56 p65 nuclei M-CSF, n=67 p50 nuclei and n=101 p65 
nuclei M/G-CSF, n=28 p50 nuclei and n=31 p65 nuclei LPS). (B) The EP2 antagonist AH6809 and anti-
PD1 antibody similarly reduce fibrosarcoma growth (data shown are mean±SEM *p<0.05 by two-tailed 
two-way ANOVA n=7 Vehicle treated mice, n=8 AH6809 treated mice, n=8 anti-PD1 treated mice) and 
lung metastasis formation in WT mice (p value was calculated by two-tailed one-way ANOVA; n=7 
Vehicle treated mice, n=8 AH6809 treated mice, n=8 anti-PD1 treated mice). (C) AH6809 inhibits 
NOS2 expression by splenic M-MDSCs from fibrosarcoma (MN/MCA1) bearing WT mice (data shown 
are mean±SEM *p<0.05, **p<0.01 by two-tailed one-way ANOVA n=3 pools of WT Vehicle treated 
mice, n=3 pools of p50-/- Vehicle treated mice, n=3 pools of WT AH6809 treated mice, n=3 pools of 
p50-/- AH6809 treated mice). (D) Left, the EP2 antagonist AH6809 inhibits melanoma B16 growth only 
in tumor bearing WT mice, but not in the p50- deficient counterpart (*p<0.05 by two-tailed two-way 
ANOVA n=7). Right, AH6809 inhibits NOS2 expression by splenic M-MDSCs from melanoma B16 
bearing WT mice, but not in the p50-deficient counterpart (data shown are mean±SEM *p<0.05 by two-
tailed one-way ANOVA n=4 pools of WT Vehicle treated mice, n=4 pools p50-/- Vehicle treated mice, 
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Hypercholesterolemia induces RORγ up-regulation in both monocytic-MDSCs 
and TAMs. Disruption of RORγ expression prevents hypercholesterolemia-
induced myelopoiesis disabling cancer dissemination and metastasis formation.  
Abstract 
Cancers induce "emergency" hematopoiesis and expansion of tumor-
associated myeloid cells (TAMCs), including myeloid-derived suppressor 
cells (MDSCs) and tumor-associated macrophages (TAMs). These are 
heterogeneous cell populations that suppress antitumor adaptive immune 
responses, while promoting angiogenesis and tissue remodelling, as well as 
resistance to chemo-immunotherapy. Hence, the identification of 
mechanisms driving the tumor-promoting reprogramming of cancer-
associated myeloid cells is a crucial step for the development of new 
effective therapies. Recently, we identified RORC1/RORγ as master inducer 
of emergency myelopoiesis during cancer disease. RORγ is a member of 
the nuclear receptor family of intracellular transcription factors that is co-
activated by cholesterol-related molecules (i.e. desmosterol, oxysterols). Of 
note, hypercholesterolemia predisposes to cancer and induces expansion of 
Ly6Chi immature monocytes. Based on this, we hypothesized a direct 
correlation between cholesterol metabolism and RORγ-driven TAMCs 
expansion and differentiation. Interestingly, tumor bearing-mice and 
colorectal cancer patients displayed increased blood levels of LDL-
cholesterol. Moreover, diet-induced hypercholesterolemia in tumor-bearing 
mice increased the metastatic rate, RORg expression in myeloid cells, 
expansion of immunosuppressive monocytic-MDSCs and tumor infiltration 
by the F4/80high TAMs subset. Expansion of these myeloid subsets produced 
systemic immunosuppression, resulting in impaired effector memory T cells 
frequency in favour of quiescent naïve T lymphocytes. Our results indicate 
that cholesterol-related molecules guide the differentiation of suppressor 
myeloid cells in cancer bearers, enhancing RORγ transcriptional activity, 
and indicate cholesterol levels as potential markers of tumor progression. 
The interplay between cholesterol, activation of myeloid-specific RORγ and 
cancer-related myelopoiesis highlights a new immunometabolic pathway 
susceptible of new therapeutic developments. 
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Introduction 
The expansion of relatively immature myeloid-derived suppressor cells 
(MDSCs) (emergency myelopoiesis), as well as the skewing of tumor-
associated macrophages (TAMs) toward an M2-like polarization are key 
immune alterations of tumor bearers.1–3 Hallmarks of MDSCs are their 
ability to suppress T- and NK-cells cytotoxicity and to modulate TAM 
functions, by conferring them anti-inflammatory/suppressive properties.4 
Further, MDSCs support tumor progression by promoting tumor cell 
survival, angiogenesis and metastasis.5 Their clinical relevance has been 
reported in various cancers, in which frequency of circulating MDSCs 
correlates with cancer stage, and negatively affects cancer therapy.6 
MDSCs are heterogeneous in terms of morphology, differentiation, 
distribution and functions. They are mainly subdivided into two subsets: 
monocytic (M-MDSCs) and granulocytic (PMN-MDSCs) identified by 
surface markers as CD11b+Ly6ChiLy6G- and CD11b+Ly6CloLy6G+, 
respectively.3,7 Recently, our lab identified the isoform 1 of retinoic acid-
related orphan receptor gamma (RORC1/RORg) as one of the lead 
orchestrator of cancer-driven MDSCs expansion. Indeed, MDSCs from 
cancer patients and tumor-bearing mice had a myeloid-specific up-regulation 
of RORg. By side, Rorc-deficient mice showed a reduced tumor progression 
and an impaired expansion of MDSCs.8  
RORγ is a nuclear receptor which, by definition, acts as a ligand-activated 
transcription factor.9 The recently identified natural ligands for RORγ are 
cholesterol precursors10,11 and derivatives (i.e. oxysterols)12,13, which 
enhance the RORg intrinsic activity.14,15 Oxysterols are a wide range of 
biologically active end-products of cholesterol12,16, produced enzymatically12 
or non-enzymatically after reaction with oxidative stress species (e.g. 
ROS)17,18 aberrantly expressed in several cancers.19   
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Obesity is an established risk factor for the onset of many cancer types and a 
poor prognostic indicator in patients with established disease.20–22 However, 
the multifactorial nature of obesity has made it difficult to characterize cause 
and effect relationships in cancer pathophysiology. A prevalent and 
clinically relevant factor linking cancer disease and obesity is inflammation.  
Indeed, obesity is associated with a systemic chronic inflammation, resulting 
in altered immune cell composition in different tissues.23–26  Obesity is 
generally characterized by elevated cholesterol levels and to changes in 
oxysterols production and metabolism.27–29  Epidemiologic data regarding 
cholesterol and cancer onset are controversial and it is unclear whether total, 
LDL or HDL cholesterols impart risk.30–32 Studies investigating the 
correlation between patients taking lowering cholesterol drugs and risk of 
cancer onset are conflicting.33–35 
In addition, oxysterols are among the main components of oxidized Low 
Density Lipoproteins (oxLDLs),18 which raise in dyslipidemic and 
hypercholesterolemic conditions, and are directly involved in the atherogenic 
process.36 It has been also shown that the lectin-type oxidized LDL receptor-
1 (LOX-1), one of the major scavenger receptors for oxLDLs highly 
expressed by macrophages and endothelial cells,36 is mainly associated with 
the immunosuppressive subset of PMN-MDSCs in cancer patients.37 Of 
note, whereas in liver RORγ regulates lipid metabolism by inducing the 
transcription of enzymes involved in oxysterols production (e.g. CYP27A1, 
CYP7A1),38 dyslipidemias as well hypercholesterolemia induce an 
expansion of immature Ly6Chi monocytes39 and represent a risk factor for 
cancers.40 The cholesterol metabolite 27-hydroxycholesterol has been 
described to induce expansion of polymorphonuclear cells facilitating breast 
cancer metastatic process.41  
Moreover, additional studies have described that the cholesterol/oxysterols 
efflux transporters ABCA1 and ABCG1 are strictly associated with the 
expansion and the immunosuppressive properties of both MDSCs and 
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TAMs.42–45 In agreement, macrophages, which are the main scavenger cells 
of LDL cholesterol in hypercholesterolemic conditions, have been described 
to be influenced in their inflammatory activity by a wide range of oxysterols 
(i.e. 27- and 25-hydroxycholesterol).46,47 
Together, these evidences suggest that cholesterol metabolism and its 
interaction with RORg nuclear receptor could mediate changes in myeloid 
cell differentiation during cancer development. Here, this thesis describes 
that a hypercholesterogenic Western-like diet influences the monocytic 




Cancer progression alters circulating cholesterol levels 
Previous observations in both cancer patients and murine models highlighted 
a positive correlation between hypercholesterolemia and carcinogenesis, 
with the major concept that high LDL cholesterol levels correlate with a poor 
clinical outcome in many cancer types, in contrast to the protective role of 
high HDL cholesterol.48–53 In contrast, other studies suggest that no 
association exists between cholesterol and cancer progression34, or even that 
lowering cholesterol levels with statins exacerbates disease progression.35,54 
To clarify the significance of cholesterol levels in cancer bearers, we 
collected blood serum samples from wild-type mice bearing the 
transplantable MN/MCA1 fibrosarcoma and measured the levels of total, 
HDL and LDL cholesterols, in comparison with tumor-free wild-type mice. 
After 24-26 days of tumor growth, when mice are in advanced stages of 
disease, with tumor volume (MN/MCA1 fibrosarcoma) of about 2.00 cm3 
(Supplementary Fig.1A), we detected enhanced levels (mg/dl) of total and 
LDL cholesterols as compared to tumor-free mice, whereas the HDL levels 
decreased (Fig.1A). To assess the entity of this imbalance, we calculated the 
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ratios of total and LDL cholesterol levels upon HDL levels. Both total/HDL 
and LDL/HDL ratios increased in tumor-bearing mice (2-fold and 3-fold, 
respectively), as compared to tumor-free mice (Supplementary Fig.1B). 
Next, we repeated the same analysis in mice bearing the transplantable 
melanoma model B16/F10 (Supplementary Fig.1C) and detected a similar 
imbalance in serum cholesterol levels, in comparison with to tumor-free 
mice (Fig.1B), as observed in fibrosarcoma-bearing mice, although to a 
lesser extent (total/HDL ratio=1.5; LDL/HDL ratio=2) (Supplementary 
Fig.1D). 
We next  monitored the changes of cholesterol levels during disease 
progression: before  tumor cells transplantation, 12-14 days after tumor cells 
inoculation (early disease stage) and after 24-26 days (late disease stage)8. 
Alteration of serum cholesterol levels was much evident 24-26 days after 
tumor implantation (Fig.1C), suggesting that alterations of lipid metabolism 
occur drastically in late stages of disease progression. 
To validate this observation in cancer patients, we analysed the serum levels 
of total, HDL and LDL cholesterols in: healthy donors as controls (HC; 
n=10), colorectal cancer patients with non-metastatic disease (NM; n=10), 
colorectal cancer patients with a metastatic advanced disease (MTS; n=10). 
Noteworthy, colorectal cancer (CRC) patients showed a significant increase 
of total and LDL cholesterols in advanced disease, that was paralleled by 
decreased HDL cholesterol levels (Fig.1D). Tot/HDL and LDL/HDL ratios 




Figure 1. Cancer progression induces increased serum levels of total and LDL cholesterol and 
decreased HDL cholesterol. Serum levels of total, HDL and LDL cholesterols (mg/dl) in wild-
type mice bearing the MN/MCA1 fibrosarcoma (A) or B16/F10 melanoma models (B) in late 
stage disease (26 days and 19 days of tumor growth, respectively) in comparison with tumor-free 
control mice. C) Serum levels of total, HDL and LDL cholesterol levels before MN/MCA1 cells 
transplantation, after 12 days (early disease) and 25 days (advanced disease) of tumor growth, in 
comparison with tumor-free control mice. D) Serum cholesterol levels of total (left panel), HDL 
(central panel) and LDL (right panel) cholesterols in colorectal cancer patients (CRC) in non-
metastatic (NM) and metastatic disease stages (MTS), compared to healthy donors (HC). E) 
Values of total and LDL cholesterols in mg/dl from (D) were respectively normalized to HDL 
levels. Then, the ratios obtained were graphed as fold change relative to healthy donor ratios. 
Graphs from mice experiments are representative of 4 independent experiments. Data are 









Hypercholesterogenic Western-like diet exacerbates cancer metastasis in 
a RORg-dependent manner 
There is compelling evidence that hypercholesterolemia, and more generally 
obesity, enhances tumor progression.30,55 The nuclear receptor RORg is 
activated by binding with cholesterol derivatives (i.e. oxysterols)12,14, which 
are dramatically increased in obesity conditions29. To determine whether the 
anti-tumoral effect of RORg-deficiency8 is correlated to the 
hypercholesterolemia-associated cancer promotion, and to imbalance of 
serum cholesterol levels, we fed Rorc-/- mice and wild-type control mice 
with a hypercholesterogenic Western-like diet (WD), containing 0,2% w/w 
cholesterol and 20% w/w fat, or with a standard chow diet (CD) (containing 
0,006% w/w cholesterol and 5% w/w fat). After 6 weeks of pre-conditioning 
with the Western diet, we transplanted obese mice with MN/MCA1 
fibrosarcoma cells, keeping mice in the same dietary regimen (Fig.2A). 
After 6 weeks of WD-diet pre-conditioning, we observed increased levels of 
total and LDL cholesterols, as well as reduced HDL, in both wild-type and 
Rorc-/- tumor free mice (Fig.2B). Surprisingly, after MN/MCA1 cells 
transplantation, we detected an exacerbated increase of total and LDL 
cholesterols in WD fed mice (Fig.2B, Supplementary Fig.2), as compared to 
chow diet-fed mice (Fig.1A,C and Fig.2B). Of note, no differences in 
cholesterol levels were observed between wild-type and Rorc-/- mice 
(Fig.2B). Moreover, while confirming tumor growth reduction in RORg-
deficient conditions (Fig.2C, D), WD-diet increased the metastasis number 
and bulk only in RORg-proficient (wt) mice (Fig.2E-G). These data 




Figure 2. Hypercholesterogenic Western-diet exacerbates cancer metastasis in a RORg-
dependent manner. A) Scheme showing the experimental design: wild-type and Rorc-/- mice 
were pre-conditioned with hypercholesterogenic Wester-like diet (WD) or with a standard chow 
diet starting at 6 weeks of age. After 6 weeks of Western diet, mice were transplanted with the 
MN/MCA1 fibrosarcoma. Mice were kept in their respective dietary regimens until 24 days after 
tumor cells implantation. B) Variations of total (left panel), HDL (central panel) and LDL (right 
panel) cholesterol levels during the experimental period. C) Tumor volume growth curve 
obtained by measurements three times per week, starting from day 14 after tumor cells injection. 
D) Weight of tumors explanted after the sacrifice of mice at day 24 of growth. E) Number of 
lung metastatic lesions in  tumor-bearing mice. F) Representative lung sections of 4 experimental 
groups underling the presence of metastatic lesions (arrows) and the differential area of lesions. 
G) Percentage of lung metastatic lesions. Each dot value represents the mean area of 3 serial 
longitudinal sections from a single lung. Graphs are representative of at least 3 independent 
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RORg mediates the Western diet-dependent expansion of monocytic 
MDSCs and pro-tumoral macrophages. 
Myeloid-derived cells are key regulators of the metastatic process56, not only 
in the primary tumor, but also on the distal metastatic site, where they 
facilitate the establishment and subsequent growth of metastatic lesions57,58. 
Since hypercholesterolemia is a condition driving the expansion of the 
Ly6Chigh monocytes, precursors of both monocytic myeloid-derived 
suppressor cells (M-MDSCs) and tumor-associated macrophages (TAMs) 
39,59, we speculated that the RORg-dependent metastatic phenotype observed 
in Western diet-fed mice may involve cells of myeloid lineage. In order to 
test this hypothesis, we analysed by FACS the MDSC and TAM subsets in 
our experimental groups. In blood, as well as in the spleen, we detected an 
increased number of Cd11b+Ly6Chi M-MDSCs in wild-type mice under WD 
feeding as compared to chow diet-fed control mice, which was dampened in 
Rorc-/- mice (Fig.3A-B, left panels). In contrast, the Cd11b+Ly6G+ PMN-
MDSC subset was not affected by WD (Fig.3A-B, central panels). 
Interestingly, Western diet feeding induced an increase in the expression of 
RORg in M-MDSC from wild-type mice, which resulted in higher levels as 
compared to the expression in PMN-MDSCs (Fig.3A-B, right panels; 
Supplementary Fig.3A). 
Intratumoral analysis of infiltrating myeloid cells confirmed the WD-
dependent increase of monocytic MDSCs in wild-type mice, which was 
impaired in RORg deficient mice (Fig.3C, left panel), along with a higher 
number of Ly6Chi RORg+ cells expressing increased RORg protein (Fig.3D). 
Regarding the intratumoral PMN-MDSC subset, we confirmed the increased 
frequency of Ly6G+ cells in Rorc-/- mice, which was not affected by different 
diet regimens (Fig.3C, right panel, and Ref. 8).  Interestingly, intratumoral 
Rorc-deficient PMN-MDSCs displayed a more mature (CD16/CD32high) 
inflammatory phenotype8 (data not shown).  
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Figure 3. RORg drives the Western diet-dependent increase of monocytic-MDSCs and TAMs. 
Flow cytometry analysis of CD45+CD11b+Ly6Chi (M-MDSC) and CD45+CD11b+Ly6G+ (PMN-
MDSC) cells and mean fluorescent intensity (MFI) of RORg in blood (A) and spleen (B) of 
MN/MCA1-bearing mice at day 24 of growth. C) M-MDSC and PMN-MDSC percentages were 
evaluated in tumor tissues explanted at day 24. D) Percentage of RORg+ cells (left panel) and 
RORg MFI (central panel) in intra-tumoral Ly6Chi M-MDSCs from wild-type mice; right panel 
represents the differential RORg expression between chow and Western diet conditions. E) 
FACS analysis of total CD45+CD11b+F4/80+ TAMs and (F) RORg MFI in TAMs. G) TAMs 
expression of TNFa. Graphs are representative of at least 3 independent experiments. Data are 
represented as mean +/- SEM. Statistical analysis:  *p<0,05; **p<0,01; ***p<0,001; 
****p<0,0001. 
 
TAMs are composed by heterogeneous macrophage populations.60–62 
Interestingly, FACS analysis of bulk TAMs, obtained from wild-type mice 
under Western diet feeding, showed significant increased number of both 
















































































compared to chow diet condition. In analogy with M-MDSCs, this 
heightened presence of TAMs was absent in Rorc-/- mice fed with Western 
diet (Fig. 3E).  
Intriguingly, TNFa+ TAMs significantly increased in Rorc-/- mice, 
independently from the dietary regimens (Fig.3G, right). These data 
suggested that the pro-metastatic effects of hypercholesterogenic diet could 
be due to RORg-mediated increase of immunosuppressive myeloid cells. 
To assess the direct effect of the Western diet on the immune cells infiltrate 
into metastatic sites, we analysed metastatic lung lesions by flow cytometry, 
combined with an unsupervised visual implementation of t-distributed 
stochastic neighbour embedding (tSNE [viSNE]) analysis (Fig.4A). The 
generated tSNE plot highlighted a marked heterogeneity in myeloid cells 
among the different four experimental groups (Fig.4A). Notably, major 
changes were observed on the Ly6Chi M-MDSC subset. M-MDSCs resulted 
increased in metastatic lungs from wild-type mice fed with the Western diet, 
as compared to chow diet control mice, and this increase was dampened in 
Rorc-/- WD-fed mice (Fig.4A-B). Moreover, we confirmed an increased 
expression of RORg by M-MDSCs (Fig.4C). Further, lung M-MDSCs from 
tumor-bearing Rorc-/- mice displayed a reduced expression of iNOS and 
increased TNFa levels in both dietary conditions (Fig.4D). 
Analysis of lung PMN-MDSCs showed a significant increase in the RORg-
deficient groups, independent of the dietary regimens (Fig.4A, green cluster 
and Supplementary Fig.3B). No differences were observed also in the 
number of dendritic cells infiltrating metastatic lungs (Suppl. Fig.3C). 
Recent work has highlighted the contribution of tissue-resident 
macrophages, including pulmonary alveolar macrophages (AM) 
(Cd11blowCD11c+F480dim) (Fig.4E), in the promotion of cancer development 
and metastasis formation63,64. Interestingly, Western diet feeding increased 
the number of RORg+ AM (Fig.4F) only in tumor-bearing wild-type mice. 
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Figure 4. Western diet alters myeloid cells landscape in metastatic lungs in a RORg-dependent 
manner. A) Representative tSNE plot of CD45+ cells in metastatic lungs using the markers Cd11b, 
Ly6C, Ly6G, Cd11c and F480. Cell populations defined by gating strategy (E) were projected onto t-
SNE space and assigned with specific colors. B) Percentage of Ly6Chi M-MDSCs in metastatic lungs. 
(C, left) RORg MFI and percentage of RORg+Ly6Chi cells (central panel) in wild-type M-MDSCs; 
right panel represents the differential RORg expression between chow and Western diet conditions. D) 
FACS analysis of iNOS (left panel) and TNFa (right panel) in lung M-MDSCs. E) Representative 
gating strategy of Cd11bloCD11chiF4/80+ alveolar macrophages (AMs). F) Percentage of alveolar 
macrophages in metastatic lungs (left panel) and relative RORg MFI (right panel). G) Percentage of 
interstitial (non-alveolar) CD11bhiF4/80+ macrophages (left panel) and relative TNFa expression 
(right panel). Graphs are representative of at least 3 independent experiments. Data are represented as 
mean +/- SEM. Statistical analysis:  *p<0,05; **p<0,01; ***p<0,001; ****p<0,0001. 
 
Moreover, we observed a reduced number of CD11bhiF4/80+ interstitial 
macrophages (IM) in WD-fed wild-type mice (Fig.4G, left panel and 
Supplementary Fig.3D), expressing higher levels of TNFa (Fig.4G, right 





































0&&&&&&&&&50K& 100K&& 150K& 200K& 250K 0&&&&&&&&&50K& 100K&& 150K& 200K& 250K 0&&&&&&&&&50K& 100K&& 150K& 200K& 250K 0&&&&&&&&&50K& 100K&& 150K& 200K& 250K



































PMN$MDSC Other LeukocytesM$MDSC Dendritic cellsInterstitial Macrophages Alveolar Macrophages
wild$type Rorc$/$
chow@diet chow@dietWestern@diet Western@diet


















































































































































which, however, expressed higher levels of TNFa (Fig.4G, right panel). This 
evidence suggests that the frequency of TNFa+ IMs is decreased by 
hypercholesterogenic diet in a RORg-dependent manner, hence favouring a 
pro-metastatic lung microenvironment. 
Influence of RORg/Western diet on T cells 
To assess how RORg and Western diet-conditioned myeloid cells influence 
adaptive immunity, we analysed by FACS the percentage of various T 
lymphocyte subsets. We identified an increase in primary tumor of CD3+ 
(Fig.5A) and CD4+ (Fig.5B) T cells in Rorc-/- mice in CD, (Supplementary 
Fig.4A,B). Western diet regimen and RORg deficiency further increased 
their accumulation in the lungs. Surprisingly, an increased expression of the 
immune checkpoint PD-1, a marker of T cell exhaustion and inactivation65,66, 
was observed in CD4+ T cells from Rorc-/- and was dampened by Western 
diet (Fig.5C, left panel). In addition, CD4+ T cells from Rorc-/- under WD 
feeding showed increased production of IFNg (Fig.5C, right panel and 
Supplementary Fig.4C). To further characterize CD4+ cells, we analysed 
naïve and effector memory T cell populations, defined by differential 
expression of CD44 and CD62L67. RORg deficiency dramatically reduced 
the number of CD44+CD62L- naïve T cells (Tn) in favour of CD44-CD62L+ 
effector memory T cells (Tem) (Fig.5D). Further, both wild-type and Rorc-/- 
WD-fed mice showed a statistically significant increase in the number of 
naïve T cells, as compared to the chow diet-fed mice (Fig.5D, right panel).  
Analysis of CD8+ T cells in metastatic lungs did not show differences in 
terms of number and IFNg expression (Fig.5E, F), despite an increase in PD-
1 expression was detected in wild-type mice (Fig.5G). Similarly, with CD4+ 
T cells, we observed strong expansion of effector memory CD8+ T cells in 
Rorc deficiency (Fig.5H).  Together, these results indicate that a significant 
reshaping of the T cell compartment parallels the observed myeloid cell 
modifications controlled by diet regimen and RORg. 
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Figure 5. T lymphocytes rearrangement accompanies the RORg/Western diet-dependent 
myeloid alterations. FACS analysis of CD3+ (A) and CD4+ T cells in metastatic lungs from wild-
type and Rorc-/- mice under Western or chow diet. C) PD-1 expression levels in CD4+ cells (left) 
and IFNg (right panel). D) Representative gates of CD44-CD62L+ naïve CD4+ T cells (Tn) and 
CD44+CD62L- effector memory CD4+ T cells (Tem) from metastatic lungs of wild-type and Rorc-
/- mice, regardless of dietary conditions, which are represented as percentages in the right panel. 
The statistical values reported represent differences in T naïve subset (green sub-bar). E) 
Analysis by FACS of CD8+ T cells in metastatic lungs, F) their IFNg expression and G) 
percentage for PD-1 positivity. H) Representative gates of CD44-CD62L+ naïve CD8+ T cells 
(Tn), CD44+CD62L+ central memory CD8+ T cells (Tcem), and CD44+CD62L- effector memory 
CD8+ T cells (Tem) from metastatic lungs of wild-type and Rorc-/- mice, regardless of dietary 
conditions, and represented as percentages in the right panel. The statistical values reported 
represent differences in both T naïve and T effector memory subsets (green and orange sub-bars, 
respectively). No statistical differences were observed in Tcem subset among groups. Graphs are 
representative of at least 3 independent experiments. Data are represented as mean +/- SEM. 










































































































































Western diet increases the highly pro-tumoral TAM F4/80high subset in a 
RORg-dependent manner. 
We and others have recently identified two distinct subsets of TAMs on the 
basis of the differential  expression levels of F4/80 (F4/80high and 
F4/80low)68–70. TAM F4/80high are characterized by higher in situ 
proliferation70, MHC-II expression69, M2-like polarization (higher 
production of Arg1, Il10, Tgfb, and lower Il1b, Il6, Il12), and inhibition of T 
cell activity69. Hence, we decided to monitor these two subsets of F4/80high 
and F4/80low in our experimental conditions.  
As shown (Fig.6A-B), Western diet induced a selective increase of F4/80high 
TAMs in wild-type mice, which was prevented in Rorc-deficiency 
conditions. Lack of RORg reduced the F4/80high TAM population also in 
chow diet feeding (Fig.6A, and 6B-left panel). Moreover, in Rorc-/- mice a 
reduction of TAM F4/80low was observed in both dietary regimens (Fig.6A, 
and 6B-right panel). F4/80high TAMs displayed higher RORg positivity 
(Fig.6C and Supplementary Fig.5A) than F4/80low cells, that was enhanced 
by Western diet (Fig.6C, Supplementary Fig.5A). In addition, F4/80high 
TAMs expressed higher RORg in response to WD feeding (Supplementary 
Fig.5C). 
F4/80high cells, despite any change in the iNOS expression (Supplementary 
Fig.5C), in wild-type mice under Western diet feeding, produced lower 
TNFa,  which is restored in lack of RORg (Supplementary Fig.5C). 
Interestingly, Western diet enhanced PD-L1 expression by both F4/80high and 
F4/80low TAMs from wild-type mice (Fig. 6D, Supplementary Fig.5D), 




Figure 6. Western diet promotes expansion of F4/80high TAMs in a RORg-dependent manner. A) 
Representative gating strategy of F4/80high and F4/80low TAMs in wild-type and Rorc-/- mice bearing 
the MN/CA1 fibrosarcoma, during different dietary regimens. B) Quantification of F4/80high and 
F4/80low subset percentages in CD45+ cells. C) Percentages of RORg+ F4/80high and F4/80low TAMs. 
D) FACS analysis of PD-L1+ F4/80high and F4/80low TAMs. Graphs are representative of at least 3 
independent experiments. Data are represented as mean +/- SEM. Statistical analysis:  *p<0,05; 
**p<0,01; ***p<0,001; ****p<0,0001. 
 
TAM F4/80high and F4/80low subsets possess different expression profiles 
of cholesterol metabolism-related genes 
To better define the possible differential roles of F4/80high and F4/80low 
TAMs in cholesterol metabolism we performed genome wide analysis 
through the Agilent DNA microarray platform, comparing global gene 
profiling of F4/80high TAMs, F4/80low TAMs and control peritoneal 
macrophages (PEC). The results showed that F4/80high and F4/80low TAMs 
are profoundly distinct in terms of global gene expression profile (not 
shown, under publication). Focus on genes involved in the cholesterol 
metabolism regulation, synthesis, uptake, efflux and lipoprotein packaging, 
and downstream managing and enzymatic modifications, revealed strong 
differences among the different populations (Fig.7A). In particular, the 
expression profiles of cholesterol-related genes from F4/80high subset showed 
distinctive signatures in each cholesterol ‘sub-pathway’, as compared to 

















































































































By qPCR we validated the expression of two additional cholesterol-related 
genes not included in the analysis: Ldlr, which encodes for the ubiquitously 
expressed LDL receptor, the main mediator of the uptake of exogenous 
cholesterol and unmodified LDL, directly involved in pro-inflammatory 
response of macrophages71; Cyp27a1 gene encoding an enzyme converting 
cholesterol into 27-hycroxycholesterol, known as a RORg activating 
ligand12,15 and directly involved in several activities exerted by tumor-
associated myeloid cells41,47,72. While Ldlr did not show differential 
expression (Fig.7B, right), Cyp27a1 was significantly more expressed by 
F4/80high TAMs, as compared to F4/80low TAMs (Fig.7B, left panel). 
Next, we monitored the protein expression of genes differentially expressed 
by F4/80high and F4/80low TAMs (Fig.7A). In particular, the macrophage 
scavenger receptor 1 (Msr1/MSR1), also known as CD204 or Scavenger 
receptor A-1 (SR-A1), that acts by binding and internalizing a number of 
ligands that predominantly include modified LDL particles73. Of note, 
CD204 is considered a marker of M2-polarized macrophages74,75 and its 
expression in TAMs correlated with poor prognosis in patients75,76. 
As compared to PEC, MSR1 gene expression was up-regulated in F4/80high 
cells and inhibited in F4/80low TAMs (Fig.7A, red arrow). This trend was 
confirmed at protein level (FACS) (Fig.7C). Of note, lack of RORg reduced 
the induced expression of MSR1 by WD feeding (Fig.7C).  
The Ch25h gene encodes the enzyme cholesterol 25-hydroxylase (CH25H), 
which converts cholesterol in oxysterol 25-hydroxycholesterol (25-OHC), 
identified as RORg ligand13. In the context of immune response CH25H and 
its product showed contradictory pro- and anti-inflammatory functions77. In 
macrophages CH25H is highly induced by short term stimulation with LPS, 
and strongly down-regulated in tolerogenic conditions.46 We identified a 
higher expression of Ch25h mRNA in F4/80high cells in comparison with 
F4/80low cells and PEC control (Fig.7A, blue arrow). This differential 
expression was confirmed by FACS (Fig.7D). Notably, both F4/80high and 
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F4/80low cells from wild-type CD-fed mice showed higher CH25H 
expression in comparison with Western diet regimen (Fig.7D).  
 
 
Figure 7. TAM F4/80high and F4/80lo subsets possess different expression profiles of 
cholesterol metabolism-related genes. A) Heatmap showing the differential expression of genes 
related to 5 sub-pathways of the cholesterol metabolism, among PEC, F4/80high and F4/80low 
TAMs. Coloured arrows indicate genes investigated for protein expression in our experimental 
groups (Fig.2A). B) RT-qPCR gene expression of Ldlr and Cyp27a1 in PEC, F4/80high and 
F4/80low TAMs. Data are represented as mean +/- SEM of three biological replicates. FACS 
analysis of MSR1 (C), CH25H (D), CYP27A1 (E) and SREC-II (F) in F4/80high and F4/80low 
TAMs from wild-type and Rorc-/- mice, fed with Western or chow diet. Right panels in C), D), E) 
and F) are representative of the differential protein expression between the F4/80high and F4/80low 
subsets. Graphs are representative of 2 independent experiments. Data are represented as mean 
















































































































































































































CYP27A1 is a key enzyme in cholesterol metabolism which, produces 27-
hydroxycholesterol (27-OHC), a RORg ligand12 and key intermediate in bile 
acid production and in steroid hormone synthesis.78 27-OHC has direct 
activity on immune cells in cancer: Cyp27a1 is highly expressed in TAMs 
and its product 27-OHC increases the number of inflammatory monocytes in 
breast cancer models.41,72 Moreover, 27-OHC drives the M2 polarization of 
human monocyte-derived macrophages.47 We observed higher expression of 
Cyp27a1 mRNA in F4/80high TAMs (10-fold), as compared to in F4/80low 
TAMs (Fig.7B, green arrow), which was corroborated by its higher protein 
levels (Fig.7E) and decreased by Western diet in wild-type mice. F4/80high 
from Rorc-/- mice in CD feeding showed higher levels of CYP27A1 as 
compared to wild-type control (Fig.7E). 
We also found a marked differential expression of Scarf2 gene. Scarf2 
(scavenger receptor class F-2) encodes for SREC-II protein whose function 
and activity is poorly investigated. SREC-II is known to functionally interact 
with its isoform SREC-I79, which acts as a receptor for modified LDL 
(primarily acetylated) and is emerging for its role in innate immunity and 
regulation of cell signalling through Toll-Like Receptors (TLR)80. We 
revealed up-regulation of Scarf2 mRNA in F4/80high TAMs, as compared to 
both F4/80low cells and PEC (Fig.7A, brown arrow), which was confirmed by 
FACS (Fig.7F). Noteworthy, SREC-II was induced by Western diet feeding 
(Fig.7F).  
In summary, these data indicate that different TAM populations express 
distinct signatures of genes involved in cholesterol metabolism and that this 
class of genes is significantly modulated by diet regimens, in a RORg-
dependent manner.  The impact of this metabolic-immune network in cancer 





Increasing evidences are underlining obesity as a strong risk factor for the 
onset of several cancers.20–22 This association reflects the established link 
between inflammation and cancer, since obesity generates chronic 
inflammatory conditions.21,81 Here, we investigated the influence of 
Western-like diet-induced hypercholesterolemia on cancer development and, 
in particular, its impact on RORg-driven differentiation of tumor-associated 
myeloid cells. 
We demonstrate in both preclinical and clinical settings that cancer 
progression itself induces alterations in serum cholesterol, indicating cancer 
as a cause (not a consequence27,30) of dyslipidemias. We describe that 
alterations of total and LDL cholesterols, as opposed to reduced HDL levels, 
is a hallmark of advanced cancer stages, which coincides with the expansion 
of myeloid suppressor cells. 
Exacerbation of these events by hypercholesterogenic Western-like diet 
amplifies the RORg-driven, cancer-related myelopoietic alterations8. In 
agreement with previous reports25,41, by using a murine fibrosarcoma model, 
we observed that obesity-induced hypercholesterolemia alters the 
myelopoietic output, enhancing metastasis formation. This process is RORg-
dependent, as Rorc deficiency impairs cancer-driven myeloid cell expansion 
and dampens the metastatic burden. Indeed, tumor progression towards 
advanced stages increased the frequency of Ly6Chi RORg+ monocytic-
MDSCs in blood, spleen, as well as in the metastatic lung. These events were 
further magnified by Western diet and paralleled by elevation of infiltrating 
RORg+ CD11b+F4/80+ TAMs. Consistently, RORg deficiency significantly 
prevented these events and resulted in enhanced production of TNFa by 
TAMs.  
Previous observations25,41 also showed that the Western diet promotes 
changes in the neutrophilic subsets that accumulate in metastatic lungs. In 
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our tumor model (MN/MCA1) the cell types primarily affected by Western 
diet stemmed, in a RORg-dependent manner, from the monocytic/ 
macrophage lineage and were identified as the RORg+ M-MDSCs 
population.  
Interestingly, in diet-induced hypercholesterolemia, we observed a RORg-
dependent increase of RORg+ alveolar macrophages, which were described 
to directly impact the formation of the pre-metastatic niche in the lungs64. Of 
note, this event correlated negatively with the number of interstitial (non-
alveolar) macrophages. It needs to be established whether the balance 
between alveolar and non-alveolar macrophages may determine metastasis 
formation. This evidence highlights the key role of RORg activity in 
metastatic lung, since its ablation resulted in higher production of TNFa by 
lung macrophages and reduces metastasis formation.   
T cell functions were affected along with these events. Indeed, absence of 
RORg augmented the number of CD4+ T cells, which in Western diet 
conditions showed pronounced activation, characterized by low PD-1 and 
high IFNg expression levels.  
In parallel, CD8+ T cells displayed higher levels of PD-1, which were 
reduced by RORg deficiency. Of interest, while lack of RORg restrained the 
CD4 and CD8 naïve T cell compartment and expanded the pool of anticancer 
effector memory T cells82,83, Western diet elicited an opposite effect. 
Western diet-induced RORg activity strongly influenced the functions of 
distinct TAM subsets. In particular, WD reduced TNFa production, while 
increasing frequency, RORg and PD-L1 expression by pro-tumoral F4/80high 
TAMs69,70. Minor effects were elicited on F4/80low TAMs. This evidence 
was corroborated by the expression profile of cholesterol metabolism-related 
genes in the two TAMs subsets. F4/80high TAMs highly expressed different 
scavenger receptors with the capacity to uptake modified LDL cholesterol 
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(i.e. Msr1, Stab-1, Scarf2), as well as two major enzymes promoting 
oxysterols production (CYP27A1 and CH25H) and the cholesterol efflux 
transporter ABCA1, which has been directly correlated with the pro-tumor 
activity of TAMs42,44,45. Additional genes controlling inflammatory pathways 
(MSR1, CYP27A1, CH25H, SREC-II), were also influenced to different 
extents by Western diet and by RORg expression. 
Overall, our work demonstrates that hypercholesterolemia induces profound 
changes in the myeloid cells expansion, as well as in their inflammatory and 
metabolic traits, which are controlled by RORg. We conclude that the 
network hypercholesterolemia–RORg activity promotes myeloid alterations 
and consequent disarmament of adaptive immunity in target organs,  which 












Material and Methods 
Ethics statement. The study was designed in compliance with: Italian Governing 
Law (Legislative Decree 116 of Jan. 27, 1992); EU directives and guidelines (EEC 
Council Directive 86/609, OJ L 358, 12/12/1986); Legislative Decree September 
19, 1994, n. 626 (89/391/CEE, 89/654/CEE, 89/655/CEE, 89/656/CEE, 
90/269/CEE, 90/270/CEE, 90/394/CEE, 90/679/CEE); the NIH Guide for the Care 
and Use of Laboratory Animals (1996 edition); Authorization n. 11/2006-A issued 
January 23, 2006 by Ministry of Health. The study was approved by the scientific 
board of Humanitas Clinical and Research Center. Mice have been monitored daily 
and euthanized when displaying excessive discomfort. Septic patients were enrolled 
in the study after signing Cancer Research Center Humanitas IRB-approved 
consent. 
Animals. C57BL/6 mice were purchased from Charles River (Calco, Italy). 
Homozygous RORC mutant mice (B6.129P2(Cg)-Rorctm1Litt/J) (Sun et al., 2000) 
were donated by Prof. Dr. Dan Littman (New York University). Starting from 6 
weeks of age mice were fed with a high cholesterol/high fat Western-like diet 
(ssniff ® EF D12079 mod. with 21% butterfat & cholesterol -1% corn oil) or with 
standard chow diet for further weeks in an IACUC-approved animal facility.  
Patients. Peripheral blood was collected from healthy donors (n=10), from non-
metastatic colorectal cancer patient (n=10; £Stage 2) and metastatic patients (n=10; 
³Stage 3). All the subjects were sex and aged mixed. 
MN/MCA1 tumor model. After 6 weeks of hypercholesterogenic diet, 12 weeks 
old mice were injected intramuscularly in the left leg with 105
 
cells of murine 
fibrosarcoma (MN/MCA1). Tumor growth was monitored three times a week, and 
it was measured with a caliper when become palpable, starting around from day 14. 
B16 tumor model. 8 weeks old wild-type mice were injected subcutaneously with 
5*105 cells of melanoma (B16/F10) in 200 ul of saline solution into the right flank. 
Tumor growth was monitored 3 times a week with a caliper, starting from day 10. 
Blood cholesterol measurement. Blood samples were taken by patients and 
healthy donor and collected in serum tube gel separating serum from the cells. They 
were let to clot for 20 minutes at RT and then centrifuged for 15 min at 2000 RPM, 
RT. Mouse blood samples were collected via puncture of facial vein in Eppendorf 
tube and kept on ice for 20 min. They were centrifuged for 20 min at 13000 RPM, 
4°C. Serum samples were measured for the content of total, LDL and HDL 
cholesterol by the Clinical Analysis Laboratory of Humanitas Hospital. Test assay 
kit used were purchased from Abbott (Cholesterol 7D62; Direct LDL 1E31-20; 
Ultra HDL 3K33-21). 
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Lung Histology. Histology was performed on three longitudinal serial sections 
(150 µm apart, 8 µm in thickness) from each left lung, formalin-fixed, paraffin-
embedded, stained with hematoxylin and eosin (H&E), and scanned by VS120 
DotSlide BX61 virtual slide microscope (Olympus Optical). The total number and 
area of lung lesions were obtained by manually tracing the perimeter of lesions 
using the Image Pro-Premiere software (Media Cybernetics). 
Flow cytometry. Splenocytes were collected from spleen after disaggregation and 
filtration through Falcon strainers (70 μm). Primary tumors and right metastatic 
lungs were cut into small pieces, disaggregated with 0.5 mg/ml
 
collagenase IV and 
150 U/ml
 
DNase I in RPMI-1640 for 30 min at 37 °C and filtered through strainers. 
Cells (106) were re-suspended in HBSS (Hank’s balanced salt solution, Lonza) 
supplemented with 0.5% BSA (Sigma) and the staining was performed at 4°C for 
20 minutes with specific antibodies. The following antibodies were used: CD45-
FITC, -PerCP (Clone 30-F11); CD11b-PerCp- Cy5.5, -APC, -PE-Cy7, -FITC 
(Clone M1/70); Ly6G-PE, -APC, -FITC, BV570 (Clone 1A8); Ly6C-PE, -FITC,-
APC-Cy7, -PE-Cy7, -APC (Clone HK1.4); F4/80-PE, -PE-Cy7, -APC (Clone 
BM8); CD11c-PE, -FITC, -APC (Clone N418); RORγ-APC, -PE (Clone AFKJS); 
CD204 (MSR1)-APC-Cy7, -PE-Cy7 (Clone RE148); CD8-APC, (Clone 53-6.7); 
CD3-PerCP, -PE, -BV650 (Clone 145-2C11); CD4-APC, PE-Cy7 (Clone GK1.5); 
IFNγ-PE, -FITC (Clone XMG1.2); CD44-FITC (Clone IM7); CD62L-APC, -
BV570 (Clone MEL-14); TNFa-APC, -PE-Cy7 (Clone MP6-XT22); PDL1-PE, 
(Clone 10F.9G2); from BD Bioscience, eBioscience, BioLegend or Miltenyi Biotec. 
Antibody targeting mouse CH25H-FITC conjugated (bs-6480R-FITC) were 
purchased from Bioss. Further, we used unconjugated rabbit polyclonal anti-mouse 
iNOS (ab 15323, Abcam), anti-CYP27A1 (Abcam, Clone EPR7529), anti SREC-II 
(Invitrogen, SA101027AW) followed by incubation with secondary goat anti-rabbit 
Alexa Fluor® 488- or 647-conjugated antibody (Life Technologies). Cell viability 
was determined by LIVE/DEADTM Fixable Violet Dead Cell Stain Kit (Thermo 
Fisher), negative cells were considered viable. For intracellular staining 
Foxp3/Transcription Factor Staining Buffer Set (eBioscience) were used according 
to the manufacturer’s instruction. Cells were detected using the BD FACSCantoTM 






TAMs sorting. TAMs were isolated from tumor as 
previously described and were enriched by positive selection with CD11b 
microbeads, according to manufacturer's instructions (MACS, Miltenyi). CD11b+
 
cells were stained with CD45 and F4/80 antibodies, and sorted with cell sorter BD 






Microarray expression profiling. Thioglycollate-elicited peritoneal exudate cells 





TAMs were sorted from three biological replicates. The RNA 
was purified from PEC and TAMs using the RNeasy Plus Mini Kit, following 
standard RNA isolation protocol (Qiagen, Italy), and quantified with ND-1000 UV–
Vis Spectrophotometer (NanoDrop Technologies, USA). All the cRNA 
synthesis/sample-labelling, hybridization, washing, and scanning steps were 
conducted following the manufacturer’s specifications (Agilent Technologies Inc., 
Italy). After hybridization, the slides were washed and then scanned with the 
Agilent G2565BA Microarray Scanner. The fluorescence intensities of scanned 
images were extracted and pre-processed by Agilent Feature Extraction Software 
(v10.5.1.1). Expression measures were computed using the robust multiarray 
average. 
Real-Time PCR. Total RNA was extracted with TRIzol (Invitrogen) according to 
the manufacturer’s instructions. 1 μg of total RNA was reverse-transcribed by the 
High Capacity cDNA Reverse Transcription kit (Applied Biosystems), amplified 
using Fast Sybr Green Master Mix (Applied Biosystems), and detected by the 
7900HT Fast Real-Time System (Applied Biosystems). The primers used are: Ldlr 
(fw, 5’-agtggccccgaatcattgac-3’; rev, 5’-ctaactaaacaccagacagaggc-3’); Cyp27a1 
(fw, 5’-ggaccggaacgctacaattt-3’; rev, 5’-tggtcttgttcagcacctgg-3’); Gapdh (fw, 5’-
gcaaagtggagattgttgccat-3’; rev, 5’-ccttgactgtgccgttgaattt-3’). Data were processed 
using SDS2.2.2 software (Applied Biosystems). Results were normalized to the 
expression of the housekeeping gene Gapdh and then expressed as fold up-
regulation with respect to the control cell population.  
Statistics. Statistical significance was determined by two-tailed Student’s t test, 
one-way or two-away ANOVA, depending on the experimental conditions and 
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Supplementary Figure 1. Related to Figure 1. A) Representative growth curve of 
MN/MCA1 fibrosarcoma in wild-type mice. Measures are represented as mean +/- SEM. B) 
Values of total and LDL cholesterol in mg/dl from tumor-bearing mice (A, and Fig.1A) 
were respectively normalized to HDL levels. Then, the ratios obtained were graphed as fold 
change relative to tumor-free ratios. C) Representative growth curve of B16/F10 melanoma 
in wild-type mice. Measures are represented as mean +/- SEM. D) Total/HDL and 
LDL/HDL ratios from B16/F10-bearing mice were graphed as fold change relative to 
tumor-free ratios. Graphs are representative of 4 independent experiments. Data are 





Supplementary Figure 2. Related to Figure 2. Serum levels of total (left panel), HDL 
(central panel) and LDL (right panel) cholesterol in wild-type and Rorc-/- mice under 
Western or chow diet after 25 days of MN/MCA1 fibrosarcoma growth (tum-bearing), 
in comparison with respective tumor-free (tum-free) control mice. Graphs are 
representative of 3 independent experiments. Data are represented as mean +/- SEM. 
Statistical analysis: *p<0,05; **p<0,01; ***p<0,001; ****p<0,0001.  
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Supplementary Figure 3. Related to Figure 3 and 4. A) FACS analysis of RORg+ cell 
percentages in M-MDSC (CD11b+Ly6Chi) and PMN-MDSC (CD11b+Ly6G+) subsets in 
blood (left panel) and spleen (right panel) of wild-type and Rorc-/- MN/MCA1 fibrosarcoma-
bearing mice after 25 days of tumor growth, and under Western or chow diet feeding. 
Quantification of (B) PMN-MDSCs and of (C) non-resident CD11b+Cd11c+MHC-II+ 
dendritic cells (DCs) into metastatic lungs. D) FACS analysis of RORg expression in non-
alveolar interstitial macrophages (CD11bhiF4/80+) indicated as RORg+ cells and MFI of 
RORg protein. Graphs are representative of at least 2 independent experiments. Data are 
































































































































Supplementary Figure 4. Related to Figure 5. FACS analysis of (A) CD3+ and (B) 
CD4+ cells into tumor microenvironment of wild-type and Rorc-/- MN/MCA1 
fibrosarcoma-bearing mice after 25 days of tumor growth, and under Western or chow 
diet feeding. C) IFNg expression in tumor-infiltrated CD4+ T cells. D) Quantification of 
IFNg+ (left panel) and PD-1+ (right panel) CD8+ T cells in metastatic lungs. Graphs are 
representative of at least 2 independent experiments. Data are represented as mean +/- 

















































































Supplementary Figure 5. Related to Figure 6. A) RORg expression in TAM F4/80high 
and F4/80low from wild-type mice bearing the MN/MCA1 fibrosarcoma, under Western 
or chow diet. FACS analysis of iNOS (left panels) and TNFa (right panels) expression 
in (B) TAM F4/80low and (C) F4/80high subsets in wild-type and Rorc-/- MN/MCA1-
bearing mice under Western or chow diet. D) Quantification of PD-L1 expression in 
F4/80high and F4/80low TAMs. Graphs are representative of at least 2 independent 
experiments. Data are represented as mean +/- SEM. Statistical analysis: *p<0,05; 














































































































































The last decade has seen a revolution in cancer treatments, with a definite 
integration of conventional therapies (e.g. chemotherapy and radiation) with 
new immunomodulatory drugs, which improve specific immune responses 
against tumors. In particular, the identification of immunological 
checkpoints (e.g. CTLA-4, PD-1)1,2 led to a radical paradigm shift in 
fundamental immunology, making cancer immunotherapy effective. First 
generation of immunotherapeutic agents include blocking antibodies of 
CTLA-4 (ipilimumab) and PD-L1/PD-1 (atezolizumab/nivolumab, 
pembrolizumab), able to reactivate T cell specific responses against tumor 
cells.3 Unfortunately, such immune checkpoint blockade therapy (ICB) today 
it is effective only in a minority of patients.4 
Retrospective analyses of patients treated with immunotherapeutic agents 
have revealed that individual patients may be classified by distinct immune-
profiles, which largely predict their clinical responses 5–7.  
To clarify the mechanisms that guide the immunological set-up of the 
individual patient during disease progression, our laboratory is trying to 
decipher the molecular determinants that tumors use to impose this 
immunological reprogramming, paying particular attention to the myeloid 
compartment. Myeloid cells represent the most abundant cell lineage that 
expand in response to cancer-related inflammation8. This event, defined as 
‘emergency’ myelopoiesis, generates distinct subsets of tumor-promoting 
and suppressive myeloid cells, including tumor-associated macrophages 
(TAMs) and myeloid-derived suppressor cells (MDSCs)9. MDSCs are 
further subdivided in two subsets: granulocytic and monocytic (PMN-MDSC 
and M-MDSC, respectively).10 The high frequency of immunosuppressive 
myeloid cells into tumor microenvironment has emerged as negative 
prognostic indicator, in terms of survival and clinical response to 
therapies.11,12 
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To study the molecular determinants of "emergency myelopoiesis", we 
hypothesized that tumors release factors that act locally, in the tumor 
microenvironment, and distally, in the bone marrow, acting on both more 
mature myeloid cells and on medullary progenitors. We then focused on 
transcriptional and epigenetic events, as potential determinants of these 
phenomena, hypothesizing that the correction of such transcriptional and 
epigenetic aberrations could reprogram the MDSCs and TAMs towards an 
antitumor modality, improving the outcome of cancer immunotherapies. 
In this scenario, our lab has previously identified that p50 NF-kB 
transcription factor accumulates into the nucleus of tolerogenic macrophages 
and TAMs, and regulates the transcription of genes mediating 
immunosuppressive and anti-inflammatory functions.13,14 Macrophages arise 
from the same common myeloid progenitor of monocytic MDSCs. 
Moreover, TAMs and MDSCs have a similar M2-like immunosuppressive 
gene signature. Therefore, we investigated the potential role of p50 NF-kB 
in the expansion, recruitment and functional properties of M-MDSCs. 
Accumulation of nuclear p50 NF-kB in both mouse and human drive the 
expansion of M-MDSCs and induced the production of immunosuppressive 
molecule NO in response to IFNg. Indeed, the ablation of p50 NF-kB 
reactivated specific antitumor immunity and reinstated the in vivo antitumor 
activity of IL-12 and IFNg cytokines. The accumulation of p50 NF-kB in 
myeloid cells promotes the IFNg-mediated binding of STAT1 onto specific 
gene regulatory elements of IFNg-responsive genes, including Nos2. We also 
observed that lack of p50 results in increased monocytic myeloid cells in the 
spleen of tumor-bearing mice, with low NO production and suppressive 
activity.  
COX2-stimulated production of PGE2 enhances the expansion of MDSCs 
and promotes suppression of adaptive immunity15. We show that antagonists 
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of the PGE2 receptors reprogram M-MDSC functions in response to IFNg 
towards an anti-tumor inflammatory phenotype. COX inhibitors (e.g. 
aspirin) were suggested for prevention and treatment of cancer16. 
Nevertheless, due to their severe side effects, targeting specific prostanoid 
receptors endowed with immunosuppressive properties, such as EP2 17–19, 
might provide an alternative selective and safer approach to burst specific 
immunity in cancer patients. 
Overall, our work on p50 NF-kB indicates that its nuclear accumulation 
corrupts the differentiation and activation of M-MDSCs leading to 
immunosuppressive pro-tumoral properties. In addition, during cancer 
disease the chronic inflammatory status and the subsequent constant 
production of PGE2 mediate the corruption of M-MDSCs at the epigenetic 
level, establishing a pattern of gene expression which exerts their 
immunosuppressive phenotype. Thus, this study suggests the use of PGE2 
receptor antagonists as potential adjuvants for anticancer immunotherapy. 
We have previously shown that the transcription factor RORC1/RORg is up-
regulated in myeloid cell precursors during cancer progression, driving the 
expansion and the immunosuppressive properties of MDSCs and TAMs.20  
Of interest, RORg intrinsic activity is enhanced by cholesterol-related 
molecules, including its precursors and oxysterols.21 Further, 
hypercholesterolemia and cholesterol-derived oxysterols can shape the 
myeloid cells during cancer and obesity22–25. This evidence suggested a 
possible link between cholesterol metabolism and myeloid cells fate in 
cancer bearers. 
Interestingly, we observed that cancer progression influences lipid 
metabolism, altering serum cholesterol levels in a way that mimics 
hypercholesterolemia (elevation of total and LDL, and decreased levels of 
HDL). In addition, administration of high cholesterol-content Western-like 
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diet to mice exacerbated metastasis formation. These effects were associated 
with increased numbers of both RORg+ M-MDSCs and RORg+ TAMs.  
Consistently, RORg ablation reduced the expansion and the 
immunosuppressive phenotype of both M-MDSCs and TAMs, impairing the 
pro-metastatic effects of Western diet, but with no influence on the 
cholesterol levels.  
Noteworthy, RORg, with a participation of Western diet-mediated expansion 
of RORg+ M-MDSCs and RORg+ TAMs, dramatically dampened the 
frequency of antitumor effector memory cells (both CD4 and CD8), in 
favour of quiescent naïve T cells, indicating a possible link between 
obesity/hypercholesterolemia, immunosuppression and tumor progression.  
New evidence indicates that TAMs are characterized by significant 
heterogeneity. Indeed, TAMs display different expression levels of various 
macrophage markers, including of F4/80 and others (e.g. MHC-II), that 
allow distinction among different TAM subsets. The F4/80high TAM subset 
was established to have a pronounced pro-tumoral activity, as compared to 
F4/80low TAMs. We observed that F4/80high TAMs are induced by Western 
diet in a RORg-dependent manner. Moreover, genomic analysis revealed that 
this subset expresses a cluster of genes related to cholesterol metabolism, 
with the capacity to ‘sense’ and metabolize exogenous cholesterol (oxysterol 
formation and efflux).  
Our results underline new intricate pathways of immune-metabolic 
interactions, conferring to RORg the status of key player in cancer-driven 
dysmetabolism (namely hypercholesterolemia) and alterations of myeloid 
immune functions. Our observation suggests that RORγ inhibitors and/or of 
cholesterol-lowering drugs (e.g. statins, ezetimibe) may act as potential 
immunomodulators, alone or in combination with standard immunotherapy, 
and supports its potential relevance in cancer patients affected by obesity or 
hypercholesterolemia. 
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In summary, this study highlights the relevance of the crosstalk between 
immunity and metabolism and places myeloid cells at the crossroads of this 
intricate system. The characterization of the metabolic state and the impact 
on the patient's immunophenotype appears increasingly relevant for the 
design of personalized therapies, aimed at correcting dysmetabolic 
conditions and immune dysfunctions that favour disease progression. 
 
Collectively, our data identify p50 NF-kB as key driver of 
immunosuppressive M-MDSCs in response to tumor-derived PGE2 and 
potentiate the evidence that RORg orchestrates the pathological 
differentiation of suppressor myeloid cells, with a remarkable action in 
dyslipidemic conditions. Hence, inhibitors of PGE2/p50 NF-kB and of 
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